ACIDOSIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Acidosis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00013-X 1. Acidosis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on acidosis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON ACIDOSIS ................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Acidosis ......................................................................................... 7 E-Journals: PubMed Central ....................................................................................................... 62 The National Library of Medicine: PubMed ................................................................................ 69 CHAPTER 2. NUTRITION AND ACIDOSIS ....................................................................................... 115 Overview.................................................................................................................................... 115 Finding Nutrition Studies on Acidosis...................................................................................... 115 Federal Resources on Nutrition ................................................................................................. 119 Additional Web Resources ......................................................................................................... 119 CHAPTER 3. ALTERNATIVE MEDICINE AND ACIDOSIS ................................................................. 121 Overview.................................................................................................................................... 121 National Center for Complementary and Alternative Medicine................................................ 121 Additional Web Resources ......................................................................................................... 131 General References ..................................................................................................................... 132 CHAPTER 4. DISSERTATIONS ON ACIDOSIS................................................................................... 133 Overview.................................................................................................................................... 133 Dissertations on Acidosis........................................................................................................... 133 Keeping Current ........................................................................................................................ 133 CHAPTER 5. PATENTS ON ACIDOSIS ............................................................................................. 135 Overview.................................................................................................................................... 135 Patents on Acidosis.................................................................................................................... 135 Patent Applications on Acidosis ................................................................................................ 161 Keeping Current ........................................................................................................................ 172 CHAPTER 6. BOOKS ON ACIDOSIS ................................................................................................. 173 Overview.................................................................................................................................... 173 Book Summaries: Federal Agencies............................................................................................ 173 Book Summaries: Online Booksellers......................................................................................... 181 Chapters on Acidosis.................................................................................................................. 181 CHAPTER 7. MULTIMEDIA ON ACIDOSIS ...................................................................................... 183 Overview.................................................................................................................................... 183 Video Recordings ....................................................................................................................... 183 CHAPTER 8. PERIODICALS AND NEWS ON ACIDOSIS ................................................................... 185 Overview.................................................................................................................................... 185 News Services and Press Releases.............................................................................................. 185 Newsletter Articles .................................................................................................................... 187 Academic Periodicals covering Acidosis .................................................................................... 189 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 191 Overview.................................................................................................................................... 191 U.S. Pharmacopeia..................................................................................................................... 191 Commercial Databases ............................................................................................................... 192 Researching Orphan Drugs ....................................................................................................... 192 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 197 Overview.................................................................................................................................... 197 NIH Guidelines.......................................................................................................................... 197 NIH Databases........................................................................................................................... 199 Other Commercial Databases..................................................................................................... 201 APPENDIX B. PATIENT RESOURCES ............................................................................................... 203 Overview.................................................................................................................................... 203
viii Contents
Patient Guideline Sources.......................................................................................................... 203 Associations and Acidosis .......................................................................................................... 206 Finding Associations.................................................................................................................. 206 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 209 Overview.................................................................................................................................... 209 Preparation................................................................................................................................. 209 Finding a Local Medical Library................................................................................................ 209 Medical Libraries in the U.S. and Canada ................................................................................. 209 ONLINE GLOSSARIES................................................................................................................ 215 Online Dictionary Directories ................................................................................................... 216 ACIDOSIS DICTIONARY........................................................................................................... 217 INDEX .............................................................................................................................................. 309
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with acidosis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about acidosis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to acidosis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on acidosis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to acidosis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on acidosis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON ACIDOSIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on acidosis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and acidosis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “acidosis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B Source: New England Journal of Medicine. 333(17): 1099-1105. October 26, 1995. Summary: In this article, the authors describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (FIAU) as therapy for chronic hepatitis B virus infection. Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks. They were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. During the 13th week, lactic acidosis and liver failure suddenly developed in 1 patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe
4
Acidosis
hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function, despite the discontinuation of fialuridine. Of these seven patients, five died and two survived after liver transplantation. The authors conclude that the toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues. 5 figures. 1 table. 43 references. (AA-M). •
Renal Tubular Acidosis: Pathophysiology and Diagnosis Source: Archives of Internal Medicine. 156(15): 1629-1636. August 12-26, 1996. Summary: In this article, the authors review the pathophysiology and diagnosis of renal tubular acidosis (RTA). They review the literature on this topic and then present a case that illustrates the diagnostic difficulties that may be encountered in a patient with suspected RTA. The principles of renal acid excretion are then discussed. The diagnostic tests available are covered in regard to both their general principles and to interpretation of the results in the context of the various RTA subtypes. Finally, a schematic approach to the diagnosis of RTA is presented to illustrate that only a few relatively simple tests are required to diagnose RTA and to differentiate the pathophysiological subtypes.
•
Alkali Therapy in Renal Tubular Acidosis: Who Needs it? Source: JASN. Journal of the American Society of Nephrology. 13 (8): 2186-2188. August 2002. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-6423. Summary: Renal tubular acidosis (RTA) is a renal (kidney) tubule disorder that causes acidosis by restricting the reduction of urinary pH and thereby the titration of urinary buffers and the excretion of acid. The acidosis of type 1 RTA (classic) results in osteoporosis and other disorders of bone demineralization. Alkali (base pH) therapy has been given to children with RTA to heal osteopenia and to encourage normal growth. This article considers the use and indications of alkali therapy in adults with RTA. The authors review recent studies in this area, including studies investigating the impact of high net acid dietary load. The authors also consider the therapeutic potential of alkali in the increasingly large number of elderly people who are likely to be impaired by RTA. The authors conclude that with the scope of its recognized expression so expanded, the frequency of its consequent occurrence so increasing, and the potential societal benefits of its treatment so enormous (and so inexpensively achieved), RTA may be coming of age as a disorder of public health importance. 41 references.
•
Inherited Renal Tubular Acidosis Source: Current Opinion in Nephrology and Hypertension. 9(5): 541-546. September 2000. Contact: Available from Lippincott Williams and Wilkins. P.O. Box 1600, Hagerstown, MD 21741. (800) 638-3030 or (301) 223-2300. Fax (301) 223-2400. Website: www.currentopinion.com. Summary: The past few years have witnessed great progress in determining the molecular basis of inherited renal tubular acidosis (RTA). This article summarizes the current understanding of the genetic causes of primary inherited RTA. The authors also evaluated the ability of known functional and biochemical properties of the mutant
Studies
5
proteins to explain the pathophysiology of associated renal acidification defects. Molecular genetic study has demonstrated that inherited RTA is associated with mutations in genes, with expression restricted almost uniquely to the kidney. Consistent with the physiologically defined importance of multiple gene products in urinary acidification, heritable renal tubular acidosis is genetically heterogeneous. Autosomal dominant distal renal tubular acidosis has been association with a small number of mutations, although the pathophysiologic mechanisms behind these mutations remains unclear. Rarely, autosomal recessive distal RTA is caused by homozygosity or compound heterozygosity for the loss of function mutation. A larger proportion, often accompanied by hearing loss, is associated with a different gene mutation. Another gene mutation has been recently identified in proximal renal tubular acidosis with corneal calcification. The authors conclude that although these mutations have been discovered during investigation of the genetic causes of inherited renal acidification defects, studies of these naturally occurring mutations will advance the understanding of the normal urinary acidification process, as well as of acid base transport processes in other organ systems. 2 figures. 1 table. 33 references. •
Hereditary Distal Renal Tubular Acidosis: New Understandings Source: in Coggins, C.H.; Hancock, E.W., Eds. Annual Review of Medicine: Selected Topics in the Clinical Sciences, Volume 52. Palo Alto, CA: Annual Reviews Inc. 2001. p. 471-484. Contact: Available from Annual Reviews Inc. 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139. (800) 523-8635. Fax: (415) 855-9815. PRICE: $47. ISBN: 0824305450. Summary: The primary or hereditary form of distal renal tubular acidosis (dRTA), although rare, has received increased attention recently because of dramatic advances in the understanding of its genetic basis. This review article discusses several recent important studies that have begun to unravel the genetic defects causing different types of primary or hereditary dRTA (the authors do not discuss acquired dRTA). The final regulation of renal acid excretion is effected by various acid and base transporters localized in specialized cells in the cortical collecting and outer medullary collecting tubules. Inherited defects in two of the key acid or base transporters involved in distal acidification, as well as mutation in the cytosolic carbonic anhydrase gene, can cause dRTA. The syndrome is inherited in both autosomal dominant and recessive patterns; patients with recessive dRTA present with either acute illness or growth failure at a young age, sometimes accompanied by deafness, whereas dominant dRTA is usually a milder disease and involves no hearing loss. Hypokalemia (low levels of potassium in the blood), metabolic acidosis, nephrocalcinosis (calcium phosphate in the tubules of the kidney, resulting in kidney insufficiency), and renal calculi (kidney stones) are seen in both autosomal recessiave and dominant dRTA but tend to be more severe and more common in autosomal recessive dRTA. Growth retardation is also much more common and severe in recessive dRTA, probably because the recessive form occurs earlier in life and causes severe metabolic acidosis. The severity of the acidosis manifesting at an early age is the key determinant of delayed growth. 2 figures. 1 table. 64 references.
•
Diabetic Ketoacidosis Source: Practical Diabetology. 10(3): 1-5, 8. May-June 1991. Summary: This article describes the pathophysiology and therapy of diabetic ketoacidosis (DKA), from initial presentation to discharge. Topics covered include the role of insulin, increased production of free fatty acids, increased hepatic production of
6
Acidosis
glucose and ketoacids, dehydration, the diagnosis of DKA, interpretation of the diagnostic tests used to confirm DKA, treating DKA (replacing fluids, insulin, and potassium), monitoring the patient during therapy, and other clinical and laboratory considerations. The author also mentions potential complications of DKA, including hypoglycemia, hypokalemia, insulin resistance and prolonged DKA, hypoxemia, obtundation and brain edema, lactic acidosis, and hypercholermic acidosis. 1 figure. 3 tables. •
Value of Calcium Carbonate in Treating Acidosis, Phosphate Retention, and Hypocalcemia Source: Nephrology News and Issues. 5(7): 16, 18-19, 32. July 1991. Summary: This article discusses the value of calcium carbonate in treating acidosis, phosphate retention, and hypocalcemia. The author notes that calcium carbonate is easily available in high and varied dosage forms and is inexpensive. Topics include indications for calcium carbonate in the renal patient, guidelines for the use of calcium carbonate, and complications arising from the use of calcium carbonate, including hypercalcemia and constipation. The author suggests that continued problems with high serum calcium and phosphorus in some patients using calcium salts may necessitate the intermittent use of aluminum binders. 43 references.
•
Treatment Strategies for Diabetic Ketoacidosis in Children and Adolescents With Insulin-Dependent Diabetes Mellitus Source: Clinical Diabetes. 11(5): 102-106. September-October 1993. Summary: This article reviews the current thinking on treatment strategies for diabetic ketoacidosis (DKA) in children and adolescents with insulin-dependent diabetes mellitus (IDDM). Topics include a brief review of DKA and how it happens; rehydrating patients; replenishing potassium; lowering the glucose level; correcting acidosis; treating other DKA symptoms; avoiding cerebral edema; continuing insulin therapy; and monitoring patients. 2 tables. 11 references.
•
Diabetic Ketoacidosis and Hyperosmolar Nonketotic State: Gaining Control Over Extreme Hyperglycemic Complications Source: Postgraduate Medicine. 99(6): 143-148, 150, 152. June 1996. Summary: This continuing education article focuses on the evaluation and management of diabetic ketoacidosis and hyperosmolar nonketotic state in adults. The distinctions between these conditions are clearly defined, and the authors stress that accurate recognition is important for proper treatment. Topics include the differences between insulin-dependent and noninsulin-dependent diabetes (IDDM and NIDDM, respectively); assessment considerations; factors related to decompensated hyperglycemic states; characteristic findings in diabetic ketoacidosis and in hyperosmolar nonketotic state; treatment modalities; and recommendations for followup of treatment. The authors contend that the two conditions may represent variants of decompensated hyperglycemia that differ only by the magnitude of dehydration and the severity of acidosis. 4 tables. 21 references. (AA-M).
Studies
7
Federally Funded Research on Acidosis The U.S. Government supports a variety of research studies relating to acidosis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to acidosis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore acidosis. The following is typical of the type of information found when searching the CRISP database for acidosis: •
Project Title: A CHEMICALLY SYNTHETIC ANTI-TOXIC VACCINE AGAINST MALARI Principal Investigator & Institution: Schofield, Louis; Walter and Eliza Hall Inst Medical Res of Medical Research Victoria, Timing: Fiscal Year 2002; Project Start 15-SEP-2000; Project End 31-AUG-2003 Summary: (Adapted from the Applicant's Abstract): Plasmodium falciparum is a global health problem because of the morbidity and mortality associated with infection. Much of this morbidity and mortality is believed to arise from the actions of a malaria toxin. The toxin initiates a systemic inflammatory cascade involving cytokine excess, which may result in disseminated intravascular coagulation, hepatic dysfunction, acute renal failure, multi-organ inflammation, hypoglycemia, lactic acidosis and death. The toxin may further contribute to organ-specific and cerebral disease syndromes by hyperactivation of the vascular endothelium. Clinical immunity to malaria is acquired considerably earlier than anti-parasite immunity, and it is possible that this is mediated by anti-toxin mechanisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A ROLE OF ACID-SENSING ION CHANNELS IN ISCHEMIA Principal Investigator & Institution: Simon, Roger P.; Director, Neurobiology Research; Emanuel Hospital and Health Center Portland, or 972083950 Timing: Fiscal Year 2002; Project Start 01-JAN-2002; Project End 31-DEC-2003 Summary: (provided by applicant): Ischemic injury causes an immediate and marked fall in brain pH, the consequences of which are multiple and complex and incompletely understood. The recent discovery of proton-gated cation channels (acid-sensing ion channels, ASIC) in the brain offers a novel opportunity to explore hitherto unknown aspects of biology relevant to understanding the response of the brain to ischemia. The ASIC system does respond during ischemia. Our preliminary data show up-regulation of the brain-specific ASIC2a subunit following ischemia and co-localization of another
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
8
Acidosis
ASIC subunit to brain mitochondria, a major site of perturbation during ischemic necrosis and apoptosis. In patch-clamping experiments, cultured neocortical cells showed an acid-evoked current matching that of ASIC1a, whose properties changed after in vitro ischemia, and neuronal (PC12) cells displayed an acid-evoked current that was blocked with an ASIC subunit-specific antagonist. We therefore propose to 1) characterize the expression of all ASIC subunits after focal and global ischemia; 2) identify and compare ASIC subunit-protein interactions in normal and ischemic brain; 3) describe the sub-cellular location of the ASIC subunits; and 4) assess electrophysiologically the effect of ischemia on ASIC function and the effect of ASIC activity on the outcome of ischemic injury. These novel studies are likely to offer new understanding of the biology of brain ischemia and offer new targets for therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALDOLASE-MEDIATED REGULATION OF V-ATPASE Principal Investigator & Institution: Lu, Ming; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2005 Summary: (provided by applicant): Vacuolar H+ATPases (V-ATPases or H+ATPases) are highly conserved proton pumps that couple hydrolysis of ATP to proton transport out of the cytosol. They are essential for renal acid-base homeostasis, for sorting of newly synthesized proteins in the Golgi, and for acidification and normal function of the yeast vacuole. Although a central question in the field is how V-ATPase is regulated under physiological conditions, until recently little was known about the underlying mechanisms. The glycolytic enzyme aldolase has been identified to interact with three subunits of V-ATPase by our lab. This represents the first example of physical association between the ATP-generating glycolytic pathway and an ATP-hydrolyzing ion pump. Deletion of the aldolase gene in yeast cells results in complete disassembly of and a dramatic reduction in V-ATPase. These abnormalities can be fully restored by aldolase complementation. Our data suggest that disruption of the interaction between aldolase and V-ATPase results in malfunction of V-ATPase, which leads to renal tubular acidosis found in patients with hereditary fructose intolerance, an autosomal recessive disorder caused by mutations in an isoform of aldolase. In this proposal, we will carry out molecular genetic analysis in yeast cells to examine the structural basis and regulation of the interaction between aldolase and V-ATPase, and test the hypothesis that aldolase mediates V-ATPase assembly, function and stability. The specific aims of this proposal are: 1) to generate aldolase and V-ATPase subunit mutants that lack binding for a specific interaction but retain aldolase enzymatic activity and/or binding to other V-ATPase subunits; 2) to express the aldolase and V-ATPase subunit mutants in yeast deletion mutant strains lacking either aldolase or a single subunit of V-ATPase, and examine the effects on V-ATPase assembly, function and stability; 3) to examine the parameters required for aldolase to bind intact V-ATPase and disassembled V-ATPase sectors. These studies will provide important insight into the molecular basis for metabolic control of proton transport. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ATP SYNTHESIS IN MITOCHONDRIAL DISORDERS Principal Investigator & Institution: Manfredi, Giovanni; Assistant Professor of Neuroscience; Neurology and Neuroscience; Weill Medical College of Cornell Univ New York, Ny 10021
Studies
9
Timing: Fiscal Year 2002; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: Mitochondria are the main sources of energy in the cell. They contain their own DNA (mtDNA), whose genes encode components of the respiratory chain/oxidative phosphorylation system. They are essential for the normal functioning of all cells in the body, and are absolutely critical for the function of those tissues that are highly dependent on aerobic metabolism, especially muscle and brain. Since 1988, both mtDNA point mutations and mtDNA rearrangements (i.e. large-scale deletions and duplications) have been associated with a heterogeneous group of sporadic, mendelian, and maternally-inherited mitochondrial encephalomyopathies. These mutations generally cause an impairment of the respiratory chain, with a reduction in ATP synthesis. However, very little is known about how affected cells cope with the reduced ATP production: for example, which ATP-dependent cellular functions are preserved and which are down-regulated or abolished. Understanding ATP distribution inside mutant, as well as normal, cells would be extremely important for the interpretation of the biochemical and clinical phenotype of mitochondrial disorders. This Career Development Award Application proposes to investigate the effect of mtDNA abnormalities, on the intracellular ATP pool in different cell compartments, with particular emphasis on the mitochondria, the cytoplasmic membrane, and the nucleus. We plan to study the ATP content in cytoplasmic hybrids of human mtDNAless cyss ( rho o cells ) repopulated with mitochondria derived from patients tissues, by targeting a recombinant firefly luciferase to different cell compartments. Utilizing a similar experimental approach, we will also attempt a novel genetic strategy for treatment of point mutations in the mtDNA ATPase6 gene, that are responsible for a maternally- inherited form of Leigh syndrome (MILS): to recode the ATPase 6 gene to contain the universal genetic code by in vitro mutagenesis, to fuse a mitochondrial targeting sequence to the recoded sequence, and then to transfer this construct into the nucleus, in order to express the gene from nuclear DNA and target it back to mitochondrial ( allotopic expression). Allotopic expression of the recoded wild-type genes should partially restore the APT synthetic function in mutant cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ATPASES IN MICROVASCULAR ENDOTHELIAL CELLS AND DIABETES Principal Investigator & Institution: Martinez-Zaguilan, Raul; Physiology; Texas Tech University Health Scis Center Health Sciences Center Lubbock, Tx 79430 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-JUL-2004 Summary: Angiogenesis is important for vascular remodeling and is strictly controlled under normal conditions. In pathological states such as cancer and diabetes, angiogenesis is altered. The process of angiogenesis requires growth and invasion/migration of endothelial cells through extracellular matrix proteins. Microvascular endothelial cells are exposed to an acid and anoxic environment, conditions that are unfavorable for growth and survival. Thus it is paradoxical that microvascular endothelial cells grow under these conditions. It is known that the extracellular environment of tumors is acidic and anoxic, yet these cells grow and survive in this hostile environment. A vacuolar type proton ATPase (pmV-ATPase) has been identified in highly invasive and metastatic tumor cells. The cells utilize pmVATPase to maintain an aalkaline cytosolic pH permissive for growth. Because microvascular endothelial cells also invade and migrate through extracellular matrix proteins, it is hypothesized that microvascular endothelial cells exhibit pmV-ATPase that is greater at the invading/leading edge of the cells, and that pmV-ATPase activity is
10
Acidosis
exacerbated by chronic acidosis. It is also hypothesized that pmV-ATPase is decreased in microvascular endothelial cells from diabetic models where angiogenesis is impaired. To test these hypothesis, pmV-ATPase will first be analyzed in microvascular endothelial cells by evaluating the role of pmV-ATPase for pHcyt regulation using timeresolved fluorescence spectroscopy and ion substituion/pharmacological approaches. The presence of this pump's activity at the plams membrane will be analyzed by immunocytochemistry, immunogold electron microscopy and Western blot analyses of subcellular fractions. The relevance of pmV-ATPase at the leading edge of the cell will be understood by studying pHcyt regulation in single cells from leading to lagging edge using line scanning laser confocal resolution respectively. The physiological relevance of pmV-ATPase will be evaluated using in vitro invations mibration assays, in vitro angiogenesis models and the wounded monolayer model. This will be done in the presence and absence of V-ATPse inhibitors. The relevance of pmV-ATPase in angiogenesis and diabetes will be understood by using microvascular endothelial cells from a spontaneous model of diabetes with inborn defects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BICARBONATE TRANSPORT BY THE MATURING RENAL TUBULE Principal Investigator & Institution: Schwartz, George J.; Professor; Pediatrics; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 01-JUL-1990; Project End 30-JUN-2004 Summary: (Adapted from the Applicant's Abstract): Membrane-bound carbonic anhydrase (CA) is essential for HCO transport in the proximal tubule and collecting duct. Clinically, problems in neonatal renal acidification may be due to delayed membrane CA expression. Membrane CA includes CA isoform IV, which is anchored to the luminal membrane via a glycosylphosphatidylinositol (GPI) linkage. However, two anti-CA IV peptide antibodies show that CA IV is expressed on both apical and basolateral membranes of the proximal tubule, the latter not expected for a GPIanchored protein. Other membrane CA isoforms (CA XII, and XIV), could reside on the basolateral membrane and cross-react with these antibodies. The identity of the basolateral CA, the mechanisms for its targeting, and its regulation during acidosis and development will be examined in rabbit kidney. Aim 1 is to determine which CA isoform resides in the basolateral membrane of the proximal tubule. A PCR-based approach will be used to obtain cDNA probes for CAs XII, and XIV in rabbit. Peptides will be prepared from these sequences to test specificity of the CA IV antibodies and to generate CA XII- and XIV-specific antibodies. Another anti-CA IV peptide antibody (with no homology to CAs XII or XIV) will be made. The apical basolateral CAs will be compared and characterized. Aim 2 examines the targeting of membrane CAs. Membrane CA cDNAs will be FLAG-tagged and transiently transfected into immortalized mouse proximal tubule cells. The polarity of expressed membrane CAs will be examined and compared with the targeting of the C-terminus. This will establish whether GPI-linkage confers apical polarity and the C-terminal hydrophilic segment confers basolateral polarity to the membrane CA. The regulation of these CAs in response to metabolic acidosis and maturation will also be examined. Aim 3 investigates physiologic correlations. The presence of basolateral CA activity on HCO transport and cell pH will be examined in perfused proximal tubules. The regulation of basolateral CAs in response to acidosis and development will be studied. Finally, the mechanisms by which acidosis causes resistance to CA inhibition will be studied in outer medullary collecting ducts, which absorb HCO despite a luminal disequilibrium
Studies
11
pH. The objective is to better understand the role of membrane carbonic anhydrases (CAs) in mediating renal acid-base transport. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOCHEMICAL DEFICIENCIES
GENETICS
OF
CARBONIC
ANHYDRASE
Principal Investigator & Institution: Sly, William S.; Chairman and Professor; Biochem and Molecular Biology; St. Louis University St. Louis, Mo 63110 Timing: Fiscal Year 2002; Project Start 01-APR-1988; Project End 30-NOV-2003 Summary: The twelve known carbonic anhydrases (CAs) and CA-related proteins (CARPs) play important roles in diverse physiological processes including respiration, bone resorption, renal acidification, gluconeogenesis, signal transduction, and formation of cerebrospinal fluid and gastric acid. The recently discovered CA IX and CA XII are related to oncogenesis and are over-expressed in certain cancers. The broad goal of this research is to study the functional genomics of this gene family to determine the importance of individual members to health and disease. We have five specific aims: 1. Complete studies characterizing the biochemical and molecular genetics of CA II deficiency. CA II deficiency is the basis for the human inborn error of metabolism producing osteopetrosis, renal tubular acidosis, and brain calcification, novel studies are also proposed on the CA II-deficient mouse. 2. Characterize the mouse doubly deficient for CA II and CA IV and determine what other CA in kidney compensates for CA IV deficiency. CA IV is the GPI-anchored membrane CA on surfaces of epithelial cells in kidney and gut and of capillary endothelial cells. The CA IV null mouse lacks the expected renal defect. 3. Characterize the CA VA gene knockout mouse, the newly discovered CA Vb, and candidates for CA V deficiency. CA VA is the mitochondrial CA thought to be involved in gluconeogenesis and ureagenesis. 4. Characterize CA IX and define its role in the regulation of cell proliferation and in oncogenesis. CA IX is a tumor-associated CA that is over-expressed in several cancers and expressed in normal stomach. 5. Characterize the properties and the functional genomics of CA XII. CA XII is a newly discovered, transmembrane CA that is over-expressed in several cancers and expressed in normal kidney and intestine. These studies should enhance our understanding of how thee individual carbonic anyhydrases contribute to normal physiology, how single CA deficiencies produce disease, and why the newly discovered CAs IX and XII are over-expressed in certain cancers, and should also suggest new targets for isozyme-specific CA inhibitors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL ADHESION MOLECULES IN CEREBRAL MALARIA. Principal Investigator & Institution: Van Der Heyde, Henri C.; Microbiology and Immunology; Louisiana State Univ Hsc Shreveport P. O. Box 33932 Shreveport, La 71103 Timing: Fiscal Year 2002; Project Start 01-JUL-1997; Project End 31-AUG-2002 Summary: (provided by the applicant): Despite decades of effort to conquer malaria, it remains a leading cause of death due to a single infectious agent. The advent of drugresistance by Plasmodium falciparum and insecticide resistance by the mosquito vector jointly makes development of therapy against malaria highly desirable. While a vaccine to prevent infection is a laudable goal, the development of therapy to control the pathological consequences of malaria may represent a more achievable solution. To develop such a therapy, we need a detailed understanding of the pathophysiology of malaria. Results from clinical studies of P. falciparum patients indicate that these
12
Acidosis
individuals develop impaired consciousness with posturing (cerebral malaria), respiratory distress with lactic acidosis, anemia and (rarely) acute nephritis. Development of shock is, according to the WHO, a prognostic indicator of poor outcome. In addition, patients with P. falciparum have activated endothelium with increased expression on endothelium of a number of cell adhesion molecules (CAMs). Collectively these findings indicate that the processes of circulatory shock are occurring in patients with P. falciparum malaria. Recent work from our laboratory indicates that P. berghei-infected mice, a well-recognized model of cerebral malaria, also develop circulatory shock and respiratory distress with lactic acidosis. This model is therefore useful to mechanistically dissect the role of CAMs in the development of cerebral malaria and respiratory distress. We will use the recently developed dual radiolabel technique to assess CAM expression on endothelium and flow cytometry to assess CAM expression on T cells during P. berghei malaria. CAMs with increased expression during P. berghei malaria will be tested for their role in cerebral malaria and respiratory distress by using CAM0/0 and anti-CAM mAb-treated mice. Pro-inflammatory cytokines are often needed to increase CAM expression, so we will determine whether selected pro-inflammatory cytokines function in pathogenesis of malaria by regulating CAM expression. Our preliminary data indicate that both CAMs and pro-inflammatory cytokines are indeed required for pathogenesis of P. berghei malaria. We will test whether inhibition of an intracellular signaling pathway (specifically NF-?B) abrogates cerebral malaria and respiratory distress by preventing increased CAM expression and T cell adherence to endothelium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL CYCLE PROTEINS IN RENAL GROWTH, INJURY, AND REPAIR Principal Investigator & Institution: Preisig, Patricia A.; Professor; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 15-AUG-2000; Project End 31-JUL-2005 Summary: Renal epithelial cells are normally quiescent, but can increase their growth rate. In some situations, such as following an acute renal injury, the cell growth is essential to repairing the damaged epithelium, and appears tightly regulated. In contrast, unregulated, and ultimately destructive, growth occurs in renal cancer, polycystic kidney disease, and the progressive loss of renal function associated with loss of renal mass, diabetes mellitus, and most forms of glomerular injury. The growth changes that occur involve both hyperplasia (resulting in an increase in cell number) and hypertrophy (resulting in an increase in cell size). Using in vitro systems, two mechanisms of renal epithelial cell hypertrophy have been characterized; One involves regulation of the cell cycle process (referred to as being cell cycle-dependent) and is mediated by growth factors and cytokines, and the other is independent of cell cycle processes and mediated by agents that alkalinize intravesicular compartments, such as NH4C1. Using in vivo renal growth models, we have shown that: 1) Compensatory renal growth following uninephrectomy is a hypertrophic growth process that involves primarily activation of cyclin D kinase, without an increase in BrdU incorporation, and is not affected by inhibiting ammoniagenesis, suggesting that a cell cycle-dependent mechanism is involved; 2) Diabetes-induced renal growth involves an initial hyperplastic growth phase associated with activation of both G, kinase and an increase in BrdU incorporation, followed by a hypertrophic growth phase associated with continued activation of cyclin D kinase, inhibition of cyclin E kinase, and inhibition of BrdU incorporation; 3) The renal growth associated with chronic hypokalemia can be
Studies
13
reversed when ammoniagenesis is inhibition by an alkaline diet, suggesting a cell cycleindependent mechanism of growth; and 4) In transgenic mice in which the endothelin B receptor has been knocked out, uninephrectomy does not lead to hypertrophy. Aim 1 will continue to characterize the role of cell cycle proteins in compensatory renal growth. Aim 2 will focus of diabetes-induced hypertrophy. Studies will examine the regulation of the cell cycle proteins in the switch between a hyperplastic and hypertrophic growth pattern. Studies will be done in 3 models of diabetes mellitus: streptozotocin-induced type I, in Nod mice (type I), and in db/db mice (type II). Studies will also be done to determine the role of the endothelin B receptor in diabetes-induced renal growth. Aim 3 will determine the mechanisms involved in the activation of cyclin D kinase and inhibition of cyclin E kinase in cell cycle-dependent hypertrophy. Aim 4 will determine if the endothelin B receptor plays a role in chronic metabolic acidosis and chronic potassium deficiency, models of renal hypertrophy thought to be mediated by the cell cycle-independent mechanism. Together these studies will afford us the opportunity to determine if direct regulation of cell cycle processes provides an avenue for therapeutic advances that will either improve upon the beneficial effects or reduce the detrimental sequelae of renal injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR MECHANISMS OF MEDULLARY SEROTONERGIC NEURONS DURING DEVELOPMENT Principal Investigator & Institution: Richerson, George B.; Associate Professor; Children's Hospital (Boston) Boston, Ma 021155737 Timing: Fiscal Year 2003; Project Start 07-JUL-2003; Project End 31-MAR-2008 Summary: The overall goal of this program is to define the cause of SIDS. With the recent discovery of abnormal LSD binding in the medulla of SIDS infants, we have focused our efforts on the medullary serotonergic system, to define what specifically happens to serotonergic neurons to cause them to malfunction. The goal of Project 5 is to define the cellular properties of serotonergic neurons, as a means of providing a neurobiological explanation for the link between serotonin and SIDS. We have previously demonstrated that serotenergic neurons closely apposed to large arteries in the rat ventral medulla increase their firing rate in response to acidosis, and we have proposed that they are chemoreceptors that stimulete breathing, arousal and other CNS changes to restore pH homeostasis: We now plan to use a rat model to determine whether the cellular properties of serotonergic neurons can explain the three risk factors in the Triple Risk Model for SIDS. We wiil use a combination of multielectrode arrays and patch clamp recordings from serotonergic neurons in culture and in brain slices. We will: 1) Study how different subsets of serotonergic neuron respond to acidosis, hypoxia, temperature and glucose. 2) Examine how muscarinic receptor activation leads to enhancement of chemoreception. 3) Define the changes in chemosensitity of serotonergic neurons as they undergo development. 4) Determine the effects of acute and chronic (during pregnancy) nicotine exposure on the function of serotonergic neurons. 5) Compare the cellular properties of serotonergic neurons from rats with those of piglets and mice, and determine whether serotonergic neurons from these species, as well as human infants, are closely associated with large arteries of the ventral medulla. These experiments will provide information critical to a full understanding of the role of serotonergic neurons in brain function, and will lead to specific testable hypotheses about how their malfunction or maldevelopment could lead to death during sleep. URimately, the results of these experiments may provide important insights that could lead to diagnostic and therapeutic tests for those infants at highest risk of SIDS.
14
Acidosis
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CEREBRAL ISCHEMIA IN THE FEMALE Principal Investigator & Institution: Hurn, Patricia D.; Professor and Vice Chairman for Research; Anesthesiology/Crit Care Med; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 01-FEB-1995; Project End 31-JAN-2004 Summary: In this animal research protocol, the investigators propose to ascertain the cerebral blood flow and metabolic effects of the presumed neuroprotective female hormones during and following global cerebral ischemia. Specifically, the proposed study will determine the effect of global cerebral ischemia on cerebral blood flow (CBF), energy metabolism, and pial vessel reactivity in female animals compared to their male counterparts. The investigators also will evaluate whether or not the female hormone, beta- estradiol, plays an important role in recovery mechanisms from ischemia. Unneutered males also will be studied to determine if there are important gender-specific recovery responses during ischemia/reperfusion and if any therapeutic benefit from reproductive steroid administration is limited to females. The proposed experiments will explore two specific mechanisms of ischemic injury in vivo; specifically, 1) acidosis leading to depressed recovery of energy metabolism, loss of pH regulation, and related iron- catalyzed oxidant injury; and 2) microvascular endothelial dysfunction. To study these variables, the investigators will use magnetic resonance (MR) spectroscopy and intravital microscopy to determine if estradiol acts via specific cellular mechanisms. Four Specific Aims are presented. In Specific Aim #1, the investigators will test the hypothesis that ischemic acidosis is less in females, with consequently more complete recovery of brain energy phosphates compared to males; and that chronic estrogen therapy further improves post-ischemic recovery of energy metabolism and intracellular pH. Specific Aim #2 will examine the effect of pre-ischemic hyperglycemia and its consequent exaggerated tissue acidosis on metabolic recovery, testing the hypothesis that the anti- oxidant activity of estradiol decreases vulnerability to hyperglycemiamediated reperfusion injury. Intravital microscopy will be employed in Specific Aim #3 to determine if post-ischemic pial vessel reactivity to endothelium-dependent pharmacologic agents is impaired in females and estradiol-treated animals. Finally, Specific Aim #4 will test the hypothesis that chronic estradiol therapy increases brain cGMP, nitric oxide synthase activity and pial vessel responsivity to NO-mediated agents in a dose-dependent manner. The information derived from these experiments should contribute to our understanding of vascular function in females at decreased risk for cerebrovascular disease relative to males and of the role of estrogen as potential neuroprotective therapy for patients of either sex. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHARACTERIZATION OF A NEW FAMILY OF PROTEIN KINASES Principal Investigator & Institution: Popov, Kirill M.; Assistant Professor; Molecular Biology and Biochem; University of Missouri Kansas City Kansas City, Mo 64110 Timing: Fiscal Year 2002; Project Start 01-JUL-1995; Project End 30-JUN-2004 Summary: (From the application abstract:) The mitochondrial pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate, the reaction that determines the metabolic fate of carbohydrates. The enzymatic activity of the mammalian PDC is regulated by reversible phosphorylation. The specific kinase (pyruvate dehydrogenase kinase or PDK) converts it to an inactive form that can be
Studies
15
reactivated only by a specific phosphatase. The hyperphosphorylation of PDC observed in diabetes, ischemia, and metabolic acidosis directly contributes to the morbidity and mortality associated with these conditions. It is generally believed that the hyperphosphorylation is due, in part, to enhanced kinase activity. Recently this laboratory provided the first data indicating that, in humans and other mammals there are multiple isoenzymes of PDK. The physiological significance of multiple isoenzymes is currently unknown. The results available thus far strongly suggest that the isoenzymes are functionally different. The isoenzyme PDK2 is likely to be responsible for the * short-term regulation of PDC activity. The inducible isoenzyme PDK4, in contrast, may be mainly responsible for long-term control. Its over-expression in diabetes is likely a leading cause of the hyperphosphorylation of PDC that, in turn, contributes to hyperglycemia. This proposal is aimed to further elucidate the structure, function, regulation and physiological significance of the multiple isoenzymes of PDK. Its major goals are: 1) to determine the three dimensional structure of pyruvate dehydrogenase kinase; 2) to elucidate the molecular basis for catalysis and substrate recognition by pyruvate dehydrogenase kinase; 3) to further define the molecular mechanisms responsible for regulation of pyruvate dehydrogenase kinase activity; 4) to characterize the molecular interactions between isozymes, as well as between isozymes and pyruvate dehydrogenase complex under normal conditions, as well as under starvation and diabetes. These goals will be achieved though a combination of structure/functional analysis, biochemical characterization, as well as more physiologically oriented studies of isozymes under conditions such as starvation and diabetes. This will allow us to understand how this structurally unique protein kinase functions. It will also allow us to take the first step towards the design of isoenzymespecific drugs that may alleviate some of the symptoms and prevent complications associated with diabetes, ischemia and acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SYNDROME
CLONIDINE
TREATMENT
FOR
NEONATAL
ABSTINENCE
Principal Investigator & Institution: Gauda, Estelle B.; Associate Professor; Pediatrics; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2006 Summary: (provided by applicant): In the United States, as many as 20,000 babies a year are born to opioid ("narcotic") addicted mothers. Like their mothers, these infants are opioid dependent. Following birth, the infant is removed from its opioid source, inducing a withdrawal syndrome in these infants. Withdrawal symptoms in newborns include vomiting, diarrhea, poor feeding, tachycardia, hypertension, diaphoresis, restlessness, insomnia, irritability, tremors, clonus, hyperphagia with poor growth and acidosis, reversible neurologic abnormalities, and even seizures. This complex of signs and symptoms is referred to as neonatal abstinence syndrome (NAS). Reinstitution of opioids followed by a slow tapering protocol is currently the standard of care, necessitating prolonged hospitalization from weeks to months. Clonidine is a nonnarcotic central alpha2-adrenergic receptor agonist that blocks the effects of overexcitation of the sympathetic nervous system and is an approved treatment for opioid withdrawal in adults. We currently have a physician sponsored IND (#63,781) to study the effect of clonidine as adjunct therapy to opioids for the treatment of NAS. This proposal will test the hypothesis that combination therapy of clonidine and opioids is 1) safe and efficacious, 2) allows reduced amount of opioid drug use, and 3) results in shorter time of treatment and hospitalization. This will be accomplished in a
16
Acidosis
randomized, placebo controlled double blind clinical trial comparing diluted tincture of opium (DTO) combined with a placebo (control) vs. DTO combined with clonidine. Additional sub-studies include determination of 1) pharmacokinetics and pharmacodynamics of DTO and clonidine in the enrolled cohort and 2) further safety evaluation by evaluating developmental outcome on the Bayley Scale of Infant Development (BSID) at 6 and 12 months of age. Pharmacokinetics will be determined by measuring serum concentrations of clonidine and morphine and analyzing volume of distribution, elimination half-life and clearance. These results will have important clinical implications and may change the standards of care not only for management of infants with severe NAS, but also for the management of infants and children, after long-term iatrogenic opioid exposure for instance following prolonged analgesia for mechanical ventilation or multiple operations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF BREATHING DURING PHYSIOLOGIC CONDITIONS Principal Investigator & Institution: Forster, Hubert V.; Professor; Physiology; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2002; Project Start 01-JUN-1986; Project End 31-MAY-2005 Summary: Several theories on the neural control of breathing that were based on data from reduced preparations were not supported by our recent findings in awake and asleep goats on the effects of rostral medullary neuronal dysfunction and/or carotid body denervation (CBD). Some findings mimicked the altered breathing found in obstructive sleep apnea (OSA) and congenital central hypoventilation syndrome (CCHS). The mechanisms that mediated these effects are not established, but one likely mechanism is through intracranial chemoreceptors for years thought to exist only near the ventral medullary surface (including the retrotrapezoid nucleus RTN)). However, findings in reduced preparations of chemoreceptors at widespread brain sites have raised questions related to the location and role of chemoreceptors that affect breathing in awake and asleep states and whether brain chemoreceptor sensitivity is altered by CBD. One recently identified site of chemoreception is the medullary raphe nuclei (MRN) whose role in the control of breathing during awake and asleep states remains speculative. Accordingly, to study chemosensitivity and the role of the RTN and MRN in the control of breathing, we will implant microtubules into these nuclei of goats to: a) create a focal acidosis by dialysis of mock cerebrospinal fluid with different PCO2's, or b) induce neuronal dysfunction through injection of glutamate or serotonin receptor antagonists or agonists, or a neurotoxin. Major hypotheses are: 1) focal acidosis (equivalent to that breathing 7 percent inspired CO2, delta brain pH approximately -.05) in the RTN will increase breathing in awake, but not asleep states, while acidosis in the MRN will increase breathing in asleep, but not awake states, 2) at RTN sites where focal acidosis increases breathing, neuronal dysfunction will attenuate whole body CO2 sensitivity, but not alter rest and exercise breathing, 3) neuronal dysfunction in the MRN will attenuate CO2 sensitivity and rest and exercise breathing, 4) during the first 10 days after CBD, the effect of RTN and MRN focal acidosis will be attenuated but 15 plus days after CBD, the effect of focal acidosis will be accentuated. and 5) at most RTN and MRN sites, the acute effects of neurotoxic lesions will be hypoventilation (rest and exercise) and attenuated CO2 sensitivity; the acute effects of these lesions will be greater in CBD than in intact goats, but recovery after lesioning will be greater in intact than in CBD goats. Our unique studies are important because hypotheses generated largely from reduced preparations will be tested in awake and asleep states to enhance the understanding of medullary chemoreceptor contribution to the control of breathing and
Studies
17
how abnormalities in this contribution may underlie diseases such as OSA, CCHS, and the Sudden Infant Death Syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF RENAL GLUTAMINASE INDUCTION DURING ACIDOSIS Principal Investigator & Institution: Curthoys, Norman P.; Professor and Chairman; Biochem and Molecular Biology; Colorado State University-Fort Collins Fort Collins, Co 80523 Timing: Fiscal Year 2002; Project Start 01-OCT-1989; Project End 31-MAR-2006 Summary: During chronic metabolic acidosis, increased renal ammoniagenesis and gluconeogenesis from glutamine are sustained, in part, by a cell specific increase in expression of the mitochondrial glutaminase (GA) that results from the selective stabilization of the GA mRNA. Previous experiments identified an 8-base AU- sequence within the 3'- non-translated region of the GA mRNA that functions as a pH-response element (pHRE) when introduced into a chimeric reporter mRNA. This sequence was used as an affinity ligand to purify and identify zeta-crystallin/NADPH; quinone reductase as the pHRE-binding protein. The functional characterization of the pHRE was carried out in LLC-PK1-FBPase+ cells, a porcine proximal tubule-like cell line that expresses multiple forms of GA mRNAs. The corresponding porcine GA cDNAs were cloned and sequenced. Only the 4.5-kb GA mRNA contains pHREs that are identical to the sequence identified in the rat GA mRNA and only this form of GA mRNA is stabilized and increased by incubating the cells in acidic medium (Ph=6.9, 10 mM HCO3). Thus this cell lines provides a system to further characterized the molecular mechanism of GA mRNA stabilization and the associated signal transduction pathway. Finally, the 4.50kb GA mRNA is the ortholog of a newly identified isoform of the human kidney-type GA that is generated by alternative splicing of exons within the GA gene. This isoform contains a unique C-terminal domain of unknown function. The specific aims of the proposed research are: to express and characterize the isoforms of the kidney-type GA; to characterize the mechanism of GA mRNA turnover; to characterize the role of zeta-crystallin/NADPH; quinone reductase in the stabilization of the GA mRNA; and to identify the signal transduction pathway that leads to enhanced binding of zeta-crystallin/NADPH; quinone reductase to the pHRE. The results of the proposed experiments should significantly increase the understanding of the molecular mechanism that regulates this essential adaptive response and may provide insight to improve the clinical treatment of chronic acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--LABORATORY OF INTEGRATED KIDNEY FUNCTION Principal Investigator & Institution: Wang, Tong; Research Scientist; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2003; Project Start 01-DEC-2003; Project End 30-NOV-2008 Summary: Recently, the use of genetically altered animal models became an important tool to examine the contributions of individual channels, transporters and proteins to the maintenance of physiological function and pathophysiology of disease. We are now able to perform renal clearances and in vivo and in vitro tubular microperfusion studies in mice. These techniques will be used to gain insight into the physiological role of specific transporter proteins to tubule and overall renal function. To facilitate the goal of the Program Project to extend our fundamental knowledge about cellular and molecular
18
Acidosis
mechanisms regulating renal tubular function in normal and diseased states, we propose to continue the Small Animal Physiology Core, with the following specific aims: (1) Provide a variety of rat and mouse animal models, such as adrenalectomy and hormone replacement, metabolic or respiratory acidosis and chronic diuretic treatment (furosemide, thiazide). (2) Provide a metabolic measurement of plasma and urine electrolytes and examine the dietary modulations in different animal models, including knockout and mutant mice provided by each PI. (3) Perform renal clearance experiments in rats and mice to examine renal phenotypes in mutant animals and to assess the physiological roles of ion channels, proteins and transporters, such as ENaC, ROMK, CFTR and NKCC2. (4) Measure arterial blood pH, pCO2 and HCO3- and urine pH and HCO3- to evaluate the acid-base status in these animals. (5) Perform in situ microperfusion of the proximal tubule and loop of Henle of rat and mouse to assess segmental tubular function and measure electrolyte content of nanoliter sized samples (Na+, K+, Cl-, total CO2, Ca2+ and Mg2+) of tubular fluid collected from these different sites. (6) Perform in vitro microperfusion of isolated proximal tubule and collecting tubule to examine the electrolyte transport in these segments. (7) Measure tubular absorption of proteins such as albumin to investigate endocytosis-related tubular functions. This core will be utilized by most of the PPG projects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CSF AND THE CENTRAL CHEMICAL CONTROL OF BREATHING Principal Investigator & Institution: Nattie, Eugene E.; Professor of Physiology; Physiology; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2002; Project Start 01-DEC-1981; Project End 31-MAY-2004 Summary: Appropriate breathing requires 1) feedback concerning the level of CO2 from central chemoreceptors, and 2) a tonic 'drive', partly from CO2, and partly from other sources including the rostral ventrolateral medulla (RVLM). Recent work established that 1) central chemoreception is present at many brainstem locations, and 2) the retrotrapezoid nucleus (RTN) is a key RVLM site that provides both chemoreception and a tonic drive to breathe. We ask: Why are there so many central chemoreceptor sites? How do they work? What is the physiological role of the RTN in the control of breathing? We will evaluate chemoreceptor and RTN function during sleep and wakefulness in a chronic unanesthetized rat model using a microdialysis probe to deliver substances to the RTN (or other site). The probe tip is 1 mm in length and 240 mum in diameter, a volume of 45 nl. It allows repeated application of neuroactive substances at the same site in the same animal with continuous measurement of ventilation and oxygen consumption (whole body plethysmograph), arousal state (EEG, nuchal EMG), body temperature and blood pressure (telemetry), and, in some cases, blood gases and pH. Approximately 2/3 of the experiments use this model; 1/3 an anesthetized, ventilated rat with phrenic activity as the measure of respiratory output. For studies of chemoreception physiology, we produce focal tissue acidosis by CO2 microdialysis in both models. For studies of mechanism, we alter neural function by injection/dialysis within the focal region of acidosis in the anesthetized rat. For studies of the RTN, we inhibit neurons reversibly by dialysis with muscimol, a GABA-A receptor agonist, in the chronic model. Central chemoreceptor physiology is significant; CO2 is a key component of the respiratory control system and CO2 retention in disease causes morbidity. Chemoreception and RTN function vary with arousal state, and thus are likely to be important in sleep disordered breathing, and the RTN is hypothesized to be an animal homologue for the arcuate nucleus, described as abnormal in SIDS victims. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
19
Project Title: EFFECTS OF ACID ON BONE Principal Investigator & Institution: Bushinsky, David A.; Professor of Medicine and Physiology; Medicine; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: Metabolic acidosis, present during many clinical disorders, has significant effects on bone. The proposed studies are designed to test hypotheses relating to the effects of increases in proton concentration ([H+]), acidosis, on the ionic composition of bone mineral and on bone cell function. We propose to study how acidosis affects mass spectroscopy and to study how acidosis alters signal transduction pathways and bone cell expression. With the microprobe we obtain sensitive, mass resolved images and spectra of the ionic composition of bone mineral. We propose three Specific Aims: 1) To test the hypothesis that there are specific changes in bone ion composition with respect to time and location after exposure to acidosis. To pursue this aim we will test the hypothesis that in vivo acidosis initially causes a preferential loss of mid-cortical bicarbonate, Na and K due to physicochemical dissolution, with subsequent additional loss of phosphate due to cell-mediated resorption. We will test the hypothesis that the magnitude of H+ buffering by bone increases with age as the carbonate content increase and the phosphate content decreases and that there are labile pools of Ca and K preferentially released during in vivo acidosis. We will test the hypothesis that mice deficient in osteopontin (OP), matrix gla protein (MGP) or c-src have altered basal bone ion composition and an altered osseous response (Jca and JH) to acidosis. 2) To test the hypothesis that the mechanism of acid-induced cell-mediated bone resorption involves activation of signal transduction pathways such as protein kinase A (PKA), protein kinase C (PKC) and/or mitogen-activated protein kinase (MAPK) by using specific inhibitors of PKA and PKC and measurements of PKA, PKC and MAPK during acidosis. 3) To test the hypothesis that metabolic acidosis selectively inhibits osteoblastic extracellular matrix gene expression via distinct transcriptional mechanisms, by testing acidosis effects on OP and MGP RNA transcription initiation. We will identify sequences in the mouse OP and MGP genes which are capable of conferring pH dependence to a reporter gene. These Specific Aims are interrelated as the effects of acidosis at the level of the gene lead to alterations in bone cell function which subsequently alter bone mineral. Our long term goal is to develop a model to describe how acidosis affects bone in order to devise therapy to preserve mineral while maintaining the H+ buffering properties of bone. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF ACIDOSIS ON EXERCISE INDUCED MUSCLE PROTEIN SYNTHESIS Principal Investigator & Institution: Johansen, Kirsten L.; Assistant Professor; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF BIER BLOCK W/ BRETYLIUM ON RHYTHMIC FOREARM EXERCISE Principal Investigator & Institution: Sinoway, Lawrence I.; Professor of Medicine; Pennsylvania State Univ Hershey Med Ctr 500 University Drive Hershey, Pa 170332390
20
Acidosis
Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: The goals of this study are to determine if the withdrawal of sympathetic tone leads to greater blood flow to exercising muscle. We will also determine if this greater flow leads to less muscle acidosis and less sympathetic discharge. We will also determine if in subjects with heart failure, the effects of sympathetic withdrawal are greater than they are in age matched controls. We hypothesize that in heart failure, sympathetic blockade will increase limb flow, reduce muscle acidosis, and attenuate the muscle reflex response to exercise. During the last GCRC period, we have perfected the bretylium bier block procedure. We have studied the effect of this block on limb blood flow during forearm exercise sympathetic discharge, and muscle metabolism. Sympathetic blockade produced a two-fold increase in forearm blood flow and vascular conductance. (P<0.05) both at rest and during hand grip contractions. Hemoglobin saturation was increased 30% at rest following sympathetic blockade but was not different from the control trial during contractions. Similarly, exercise venous plasma lactate, potassium and hydrogen ion concentration were not different following sympathetic blockade. Separate nuclear magnetiic resonance studies indicated that intracellular acidosis was not affected by sympathetic blockade. The data suggest that forearm oxygen uptake and lactate production were both increased two-fold during the bretylium trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXPRESSION OF TRPV1 AND VARIANT TRPV1 IN THE KIDNEY Principal Investigator & Institution: Cohen, David M.; Associate Professor of Medicine; Medicine; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): TRPV1 is a cation channel that was originally cloned as the capsaicin (or "hot pepper") receptor. TRPV1 is expressed in the peripheral nervous system where it serves to sense and integrate a large number of noxious stimuli such as heat, protons, and lipid mediators. Very recent data indicate that TRPV1 is also expressed in some epithelial cells (e.g., those of the colon, lung, and bladder) and plays a vital role in sensing noxious stressors including wall tension and cellular acidosis. Based upon Northern analysis and RNase protection assays, others have postulated the existence of novel splice variants of TRPV1 expressed only in the kidney. To date, convincing splice variants have not been described in any tissue. In the course of identifying a rat kidney TRPV1 clone, we discovered several novel splice variants of TRPV1 predicted to encode proteins with either small or large C-terminal deletions. These variants were not found in central or peripheral nervous system. In other models, including the related TRPC4 channel, splice variants have encoded dominant negativeacting channel subunits. In addition, we noted anti-TRPV1 immunoreactivity in lysates prepared from renal epithelial MDCK cells; furthermore, this immunoreactivity could be downregulated by protracted treatment with the TRPV1 agonist, capsaicin. Moreover, MDCK cells exhibited robust calcium transients in response to TRPV1 agonists. In aggregate, these data suggested an intact TRPV1 system in kidney tubule cells with unique regulatory features (i.e., splice variants). As such, the first objective is to identify the anatomic and subcellular localization of TRPV1 and of the novel kidneyspecific TRPV1 splice variants in the mammalian kidney, through a combination of immunoblotting, immunohistochemistry, RNase protection, and in situ hybridization techniques. The second objective is to describe the functional significance of variant TRPV1 expression in the kidney, via fura-2-based calcium imaging, protein interaction strategies, and electrophysiological methods. The long-term objectives are to establish
Studies
21
the sensory role of TRPV1 in the kidney (through a combination of anatomic and functional studies), and to determine whether one of these unique kidney-specific splice products encodes either a channel with unique properties, or an inhibitor or modulator of TRPV1 function. In addition, such a reagent might have potential therapeutic utility with respect to this important pathway mediating nociception. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC CONTROL OF VACUOLAR H+-ATPASE EXPRESSION Principal Investigator & Institution: Lee, Beth S.; Assistant Professor; Physiology and Cell Biology; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2002; Project Start 01-JAN-1997; Project End 30-JUN-2006 Summary: (provided by applicant): The vacuolar proton-translocating ATPase, or VATPase, is a multi-subunit complex that uses energy from ATP hydrolysis to transport protons across cellular membranes. In most eukaryotes, V-ATPases reside solely in membranes of the endocytic network, where they serve to acidify endosomes, lysosomes, the trans-Golgi, and other vacuolar compartments. However, some specialized cell types, including kidney epithelia, osteoclasts, macrophages, and neurons, express the V-ATPase at high levels and in specialized subcellular compartments, where the enzyme is critical for such diverse functions as urinary acidification, bone resorption, regulation of intracellular pH, and regulated vesicular uptake of neurotransmitters. The variety of functions performed by V-ATPases among mammalian cells is attributable to expression of multiple subunit isoforms, differences in overall expression levels, and the capacity for regulated targeting to specialized membrane compartments. Inappropriate expression of V-ATPase in humans has been shown to lead to serious disease states, including renal tubular acidosis, deafness, and osteopetrosis. The genetic controls that regulate V-ATPase expression must be varied and diverse to meet the specific proton-transport needs of many specialized cell types, as well as its constitutive role in the endocytic network. These include both transcriptional and post-transcriptonal mechansims, as well as intracellular targeting of both V-ATPase mRNA and proteins. The long-term goal of this project is to understand the mechanisms by which V-ATPases are expressed at appropriate levels and in appropriate membrane compartments. To this end, the specific aims are directed toward (1) examining mechanisms by which V-ATPase mRNA stability is regulated in protonsecreting cells such as macrophages and kidney epithelia; (2) examining determinants within V-ATPase mRNAs that mediate intracellular trafficking in specialized cell types; and (3) defining genetic elements that control expression of a uniquely regulated VATPase subunit involved in intracellular trafficking. These aims will be achieved through experiments in which V-ATPase mRNAs are genetically manipulated in cell culture models; the effects of these manipulations of V-ATPase expression and cell function will be determined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC CORRECTION OF MATERNALLY INHERITED DISEASES Principal Investigator & Institution: Guan, Min-Xin; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 452293039 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): The objective of this proposed research is to define the role of mitochondrial leucyl-tRNA synthetase and elongation factor TU (EFTU) in the pathogenesis of mutations in the tRNALeu (UUR) that are commonly related to
22
Acidosis
human diseases. This second goal of this study is to explore a way to therapeutically intervene for maternally inherited disease by over-expression of these two proteins in the cybrids carrying pathogenic mutations in the tRNA Leu (UUR). A variety of mitochondrial DNA (mtDNA) mutation have been found to be associated with many clinical abnormalities, including neuromuscular disorders. Of the 100 pathogenic point mutations in mtDNA, >70 occur in tRNA genes. Of these, the most common mutation is the A to G transition at position 3243 (A3243G) in the tRNALeu (UUR) gene, which causes mitochondrial encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS) and other disorders. Mitochondria with this mutated tRNA exhibited a reduced ATP production, which results from quantitative deficiencies in mitochondrial protein synthesis. We hypothesize that the over-expression of human mitochondrial leucyl-tRNA synthetase and EFTU in the disease cell model of the A3243G mutation in the tRNALeu (UUR) gene will correct the mitochondrial translational defects, consequently increasing the level of ATP production. This application proposes two specific aims: 1). Construction of the stably transfected cell lines through transferring human mitochondrial leucyl-tRNA synthetase and EFTU cDNAs into the cybrid cell lines carrying the A3243G mutation and wild type mtDNA. 2). These stably transfected cell lines will be evaluated for the correction of mitochondrial dysfunction by using biochemical and metabolic assays. Success of this protection will define the role of the mitochondrial leucyl-tRNA synthetase and EFTU in the pathogenesis of mutations in the tRNALeu(UUR) gene associated with human diseases. This should provide new insights into the molecular mechanism of maternally inherited disorders. In particular, success in the aim of correcting the biochemical defect associated with A3243G mutation in the tRNA Leu (UUR) gene by overexpressing mitochondrial leucyl-tRNA synthetase, will open the way to therapeutic interventions for maternally inherited diseases. In the long term, fundamental experimental approaches and knowledge, which results from this proposed work would be applicable to many other tRNA gene mutations, associated diseases in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUTARYL-COA DEHYDROGENASE AND NEUROLOGIC DISEASE Principal Investigator & Institution: Frerman, Frank E.; Professor of Pediatrics and Of; Pediatrics; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 10-DEC-1999; Project End 30-NOV-2003 Summary: Defects in the flavoprotein, glutaryl-CoA dehydrogenase (GCD), cause glutaric aciduria type I (GA1), an autosomal recessively inherited neurometabolic disorder. GCD catalyzes the alpha, beta dehydrogenation of glutaryl-CoA by a mechanism which is common along acyl-CoA dehydrogenases. GCD also catalyzes the decarboxylation of the enzyme- bound intermediate, glutaconyl-CoA, to crotonyl-CoA and CO2. Decarboxylation of glutaconyl-CoA requires oxidation of the dehydrogenase flavin and protonation of the proposed crotonyl-CoA anion (-CH2=-CH=-CH=COSCoA). In patients with defects in GCD, the onset of neurological symptoms in GA1 patients usually follows a viral injection early in life. Over 50 missense mutations have been identified that may affect oxidation and decarboxylation of glutaryl-CoA. These mutations may also affect assembly or stability of the tetramer, the oxidation-reduction potential of the dehydrogenase flavin or reoxidation of the dehydrogenase flavin by electron transfer flavoprotein (ETF). The proposed research has the following specific aims. [1] A number of mutant alleles will be expressed and the defective proteins characterized by kinetic and redox methods to access the basis of the enzymatic defects.
Studies
23
[2] We will investigate the coupling of glutaryl-CoA oxidation with decarboxylation/protonation of the enzyme bound intermediate, glutaconyl-CoA, using site directed mutations hypothesized to uncouple these steps in catalysis. The crystal structure of GCD with a bound glutaryl-CoA analog and with the reaction intermediate, glutaconyl-CoA, will be determined to provide insight into the decarboxylation reaction. [3] We will investigate the decarboxylation of glutaconyl-CoA directly and define the roles of specific amino acids in the reaction. The participation of the 2'-hydroxyl of the ribityl side chain of the FAD prosthetic group in stabilization of decarboxylation/protonation intermediates will also be determined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: H,K,ATPASE FUNCTION IN POTASSIUM HOMEOSTASIS Principal Investigator & Institution: Wingo, Charles S.; Professor of Medicine and Physiology; Medicine; University of Florida Gainesville, Fl 32611 Timing: Fiscal Year 2002; Project Start 01-AUG-1996; Project End 31-JUL-2004 Summary: The long-range goal of this research is to examine the role of H,K-ATPases in potassium homeostasis and to determine how these ion-motive pumps are regulated by ion channels. H,K-ATPases are important for renal potassium conservation, but it is now apparent that the kidney possesses several different H,K-ATPase enzymatic activities which likely reflect the presence of multiple gene products. Experiments in Specific Aim 1 will determine the molecular identities of the H,K-ATPase subunit isoforms that are responsible for specific enzymatic activities, and for potassium and proton flux in discrete nephron segments, by the study of animals with targeted gene disruption of the H,K-ATPase HK-alpha-1, HK-alpha-2, or HK-beta genes. Experiments in Specific Aim 2 will examine whether knockout of HK-alpha-1, HK-alpha-2, or HK-beta subunits affects the normal anatomy of the kidney or the morphological response to potassium depletion. Experiments in Specific Aim 3 will characterize fully the newly discovered potassium-permeable ion channels that are present at the apical membrane of the inner stripe of the outer medullary collecting duct (OMCD), and the cell types that contain these channels. These channels exhibit novel properties since they appear to be stimulated by cellular acidification whereas most potassium channels are inhibited by acidosis. The proposed experiments are intended to establish the contribution of each of these genes to an important adaptive response (potassium depletion), the compensatory renal response to the disruption of these genes, and whether these genes are involved in the normal morphology of the kidney or its response to potassium depletion. Since accruing evidence indicates that modest potassium depletion causes or contributes to systemic arterial hypertension, and may contribute to chronic renal insufficiency, these studies area expected to contribute to our understanding of the role of potassium depletion as a risk factor for both renal and cardiovascular disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: H/HCO3 TRANSPORT IN THE COLLECTING DUCT Principal Investigator & Institution: Weiner, I. David.; Associate Professor; Medicine; University of Florida Gainesville, Fl 32611 Timing: Fiscal Year 2003; Project Start 01-AUG-1993; Project End 31-MAY-2007 Summary: (provided by applicant): Ammonia metabolism is critical for normal health. Inappropriate ammonia metabolism in the kidney leads to metabolic acidosis and in the liver leads to ammonia encephalopathy. In the central nervous system increased extracellular ammonia alters neuronal function and can lead to encephalopathy.
24
Acidosis
Accordingly, understanding the cellular and molecular mechanisms of ammonia metabolism, which includes ammonia transport, is important. Recent studies have identified a novel family of ammonium ion (NH4+)-specific transporters. These proteins were first identified in yeast and in plants, and homologues are present throughout nature. In model systems, such as yeast, plants and bacteria, these are intrinsic membrane proteins that mediate high-affinity, ammonium-specific transport and whose expression is physiologically regulated. Two of these proteins, RhBG and RhCG are expressed in the connecting segment and the collecting duct of the kidney, and exhibit polarized expression. These observations lead us to postulate that RhBG and RhCG are integral membrane, physiologically-regulated ammonium-ion transporters that play critical roles in renal ammonia metabolism. The broad, long-term objectives of this project are to define the roles of RhBG and RhCG in mammalian renal physiology. To do so, the Specific Aims of the current proposal are to: (1) Define the regulation of mouse renal RhBG and RhCG expression and vesicular trafficking in response to specific clinical conditions associated with altered renal ammonia metabolism; (2) Determine the mechanism of extracellular ammonia-stimulated changes in RhBG- and RhCG-mediated ion transport; and, (3) identify the specific ion-transport characteristics of RhBG and RhCG. We will utilize in vivo animal models of altered renal ammonia metabolism, metabolic acidosis and alkalosis and hypokalemia, to define the regulation of RhBG and RhCG expression and cellular localization, a cultured collecting duct cell line, mIMCD-3, for in vitro studies examining the cellular mechanisms underlying regulation of RhBG and RhCG-mediated transport, and heterologous expression systems in which to define the specific ion transport characteristics of RhBG and RhCG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HMG-COA CYCLE CONTROL IN NORMAL AND DIABETIC LIVER Principal Investigator & Institution: Miziorko, Henry M.; Professor; Biochemistry; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2002; Project Start 01-APR-1978; Project End 30-JUN-2005 Summary: This program's long term objective is an understanding, at the molecular level, of the mechanisms which control metabolic flux through ketogenesis and the related early steps in cholesterogenesis. Disturbances in the ketogenic pathway can lead to developmental abnormalities as well as ketoacidosis; two inborn errors of metabolism, that have serious medical consequences, mapped within the ketogenic pathway. Likewise, impaired control of cholesterogenesis can produce hypercholesterolemia and the array of problems derived from vascular deposition of excess cholesterol. Enzymes under investigation include hydroxymethylglutaryl-CoA (HMG-CoA) synthase and HMG-CoA lyase will be investigated to elucidate structure/function correlations that account for the catalytic activity and regulatory properties. For each of these, the investigators have developed recombinant proteins and initiated extensive steps in characterizing these proteins. For HMG-CoA synthase, site directed mutagenesis has implicated several active site amino aids in catalysis. Several aims address functional assignments for these and any other residues identified as important to the reaction chemistry. The assignments of roles for these residues will be pursued using mechanistic and physical biochemistry approaches. Expression and functional assignment of prokaryotic proteins that are homologous to animal HMG-CoA synthase will also be explored. Any suitable candidates will be screened in crystallization trials aimed at securing the first diffraction quality crystals for this protein. In the case of HMG-CoA lyase, directed mutagenesis work has implicated amino acids involved in regulation and catalysis. Specific aims to be pursued include
Studies
25
extension of this approach to new targets implicated by protein chemistry, sequence homology, or mapping of point mutations that result in human HMG-CoA lyase deficiency. The mutants which appear to be a mechanistically informative will be characterized using mechanistic and physical approaches similar to those previously employed in this laboratory to identify catalytic or regulatory residues. The significance of thiol/disulfide exchange, in vitro regulation of peroxisomal HMG-CoA lyase, and in vivo regulation of mitochondrial HMG-CoA lyase will be tested. Crystalization trials will be extended in an attempt to secure diffraction quality crystals of prokaryotic or eukaryotic HMG-CoA lyase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERDISCIPLINARY STUDY OF ACID-MEDITATED TUMOR INVASION Principal Investigator & Institution: Gatenby, Robert A.; Radiology; University of Arizona P O Box 3308 Tucson, Az 857223308 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2006 Summary: (provided by applicant): The proposed study investigates a novel, conceptually simple mechanism for cancer invasion developed by the investigators. Its goal is a fuller understanding of the structure and dynamics of the tumor-host interface through an interdisciplinary approach with continuous interaction between laboratory experiments and the formulation and analysis of mathematical models. This work was initiated by extensive evidence that tumor metabolism is consistently different from normal tissue with increased reliance on glycolytic pathways for energy production. The investigators hypothesized that excess H+ ions excreted by tumor cells would diffuse into the tumor-host interface and adjacent normal tissue creating an acidic microenvironment favorable for tumor invasion because: 1. Normal cells are significantly less tolerant to acidic pile than are tumor cells 2.acidic pHe promotes release of proteolytic enzymes breaking down extracellular matrix facilitating tumor invasion 3. acid pHe increases release of IL8 and VEGF promoting angiogenesis. This hypothesis is formalized through mathematical models using both coupled partial differential equations and a modified cellular automata approach. Critical parameter values in these models such as H+ production and diffusion coefficient have been determine experimentally. This has allowed the mathematical models to produce detailed predictions of the peritumoral acid gradient and the resulting morphology of the tumor-host interface. These predictions have been investigated using a dorsal skin fold chamber technique. Preliminary data measuring pHe using fluorescence ratio imaging (FRIM) has confirmed a gradient of H+ ions extending from the tumor edge into adjacent normal tissue. Using dye exclusion techniques loss of viability has been demonstrated in peritumoral normal cells exposed to the acidic environment - a key component of the hypothesis. The proposed study will extend the experimental observations by comparing the peritumoral pHe gradients and the resulting changes in the peritumoral normal tissue and tumor growth dynamics in the MCF7/s and MDAmb-435 tumor lines which have markedly different acid production rates and in-vivo behavior. The mathematical models will be further refined as additional parameter values can be determined. Perturbations that produce slowing or reversal of the traveling wave solution to the state equations (ie tumor growth) will be explored to predict possible new treatment strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Acidosis
Project Title: INTRACELLULAR CHEMORECEPTORS
PH
RESPONSES
OF
CENTRAL
Principal Investigator & Institution: Putnam, Robert W.; Professor; Physiology and Biophysics; Wright State University Colonel Glenn Hwy Dayton, Oh 45435 Timing: Fiscal Year 2002; Project Start 01-JUL-1997; Project End 31-JUL-2005 Summary: Increased CO2 (hypercapnia) is a major stimulus for increased respiration and blood pressure. This pathway for cardiorespiratory control involves specialized central neurons, called chemosensitive neurons, that sense hypercapnia, but the cellular mechanisms that transduce hypercapnia into an increased neuronal firing rate are not well understood. Our work will involve the study of individual neurons from at least two chemosensitive brainstem areas (locus coeruleus and either nucleus tractus solitarius or ventrolateral medulla) and at least one nonchemosensitive area (either inferior olive or hypoglossal nucleus) using slices from neonatal rat brains. Simultaneous measurements of neuronal membrane potential (Vm) and intracellular pH (pHi) will be achieved using perforated patch recordings or whole cell recordings (WCR) combined with pH- sensitive fluorescent dyes and fluorescence imaging microscopy. Our first aim is to identify the signal pathways that transduce hypercapnia into an increased firing rate. It will consist of 4 separate aims: i) study the roles of molecular CO2, external pH (pHO) and pHi as the proximate signal of chemoreception by exposing neurons to solutions that vary in each of these parameters; ii) examine the phenomenon of "washout", whereby the Vm response to hypercapnia is lost during WCR measurements, to see if additional signal molecules (e.g. Cai, polyamines or carbonic anhydrase) are also involved in chemoreception; iii) study the "hypoxia paradox" (hypoxia-induced acidification does not appear to increase firing rate in chemosensitive neurons) to see if it is due to the lack of additional signal molecules; and iv) study the changes in the Vm and pHi response to hypercapnia in chemosensitive neurons from rats with reduced chemosensitivity (induced by chronic exposure to hypercapnia). Our second aim is to study the effects of the signals, identified in Aim 1, on various K+ channels and determine the role of each of these channels in modifying the shape of the action potential and neuronal firing rate. Three K+ channels will be studied: i) inward rectifying K+ channels, important in determining the slope of the interspike depolarization and thereby the firing rate of the neuron; ii) Ca2+-activated K+ channels, important in determining the shape of the action potential and the magnitude of the after hyperpolarization; and iii) TWIK-related acid sensitive K+ channels (TASK), important in determining the resting Vm. This work should indicate the precise nature of the proximate signal of chemosensitivity, elucidate the way in which hypercapnic stimuli affect various K+ channels and give insight into how these effects are integrated to result in the final neuronal response. Further, by comparing the findings in neurons from 2 chemosensitive areas, our findings should help clarify why there are numerous chemosensitive regions in the brainstem. These studies will contribute to our understanding of respiratory diseases thought to be due in part to central chemoreceptor dysfunction, such as sudden infant death syndrome (SIDS) and central alveolar hypoventilation syndromes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAP DYSFUNCTION
KINASES
AND
H202
INDUCED
MYOCARDIAL
Principal Investigator & Institution: Lucchesi, Pamela A.; Professor; Physiology and Biophysics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-JUL-1999; Project End 30-JUN-2003
Studies
27
Summary: Reperfusion of the myocardium following an ischemic episode is associated with profound contractile and metabolic dysfunction, referred to as myocardial stunning. Reperfusion also increases the activity of the Na+/H+ exchanger (NHE), which restores intracellular pH (pHi) towards normal following ischemia-induced acidosis. However, activation of NHE also produces undesirable secondary effects leading to the exacerbation of tissue injury, a phenomenon termed the "pH paradox". Increased generation of oxygen free radicals (OFR) plays an important role in reperfusion-induced myocardial stunning and NHE activation. An in vitro model for studying the effects of OFRs on cultured neonatal rat ventricular myocytes (NRVM) has been defined, in which low concentrations of H2O2 (similar to those generated during reperfusion) cause contractile dysfunction, Ca2+ overload, and NHE activation. There is considerable interest in identifying signaling events that link H2O2 to myocardial dysfunction. H2O2 and hypoxia activate members of the mitogen activated protein kinase (MAPK) family, including p38, c-jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinases (ERK1/2). Low doses of H2O2 decrease myocyte contractility and stimulate NHE activity in an ERK1/2-dependent manner. Preliminary data indicate that exposure of cardiac myocytes to H2O2 induces myofilament disassembly, Ca2+ overload, and the activation of the nonreceptor tyrosine kinase src. The hypothesis of this proposal is that the MAPK family modulates NHE activity, Ca2+ overload and contractile dysfunction induced by H2O2. In Aim 1, experiments with synthetic inhibitors and antisense oligonucleotides will determine whether MAP kinase inhibition blocks H2O2-induced phosphorylation of NHE, since phosphorylation of the exchanger protein is associated with its activation. NHE activation will be measured by fluorimetric imaging of intracellular pH and by examining the phosphorylation state of the NHE protein in vitro and in vivo. In Aim 2, the link between H2O2-induced contractile dysfunction, Ca2+ overload and MAPK activation will be investigated using pharmacological inhibitors and antisense oligonucleotides against p38, JNK, and ERK MAPKs. Contractile dysfunction will be defined as a decrease in myocyte contractility (using video edge detection), and by immunocytochemistry to measure myofibrillar assembly. In Aim 3, a studies using immunecomplex kinase assays, immunoprecipitation and Western blot analysis will identify regulatory components upstream of MAPKs that are activated by H2O2. This aim will focus on src, protein kinase C, and the Ras superfamily of monomeric GTP-binding proteins. The proposed investigations are fundamentally important to the development of therapeutic strategies targeted to signaling pathways involved in oxidant-induced injury and may have important clinical implications in the treatment myocardial ischemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF RENAL ACID/BASE HOMEOSTASIS Principal Investigator & Institution: Dubose, Thomas D.; Chief, Division of Nephrology; Internal Medicine; University of Kansas Medical Center Msn 1039 Kansas City, Ks 66160 Timing: Fiscal Year 2002; Project Start 01-JUL-1981; Project End 31-AUG-2002 Summary: Abundant evidence has established a pivotal role for an H+, K+- ATPase in renal K+ homeostasis and acid-base balance. The regulatory response of the H+, K+ATPases to chronic hypokalemia and chronic acidosis has been localized to the outer medullary and inner medullary collecting ducts (OMCD and IMCD). Two, and perhaps more, alpha-subunit isoforms have been localized to the mammalian kidney, but uncertainties remain with respect to participation of specific alpha isoforms in segmental K+ and acid-base homeostasis. Transport studies have been forced to rely on the effect of "specific" inhibitors of the H+, K+-ATPase (such as Sch 28080) to identify
28
Acidosis
that component of bicarbonate and/or K+ absorption attributable to this transporter. Since the H+, K+-ATPases exhibit differing sensitivities to ouabain and Sch 28080, it is not known with certainty if modulations in transport and the well established response to chronic metabolic acidosis and hypokalemia are the result of modulation in function of HKalpha1, HKalpha2, HKalpha4, or yet to be identified isoforms. This study is designed to elucidate the pathophysiologic factors which regulate at both molecular and functional levels, at H+, K+-ATPases in collecting duct segments, and in medullary collecting cells in culture. By transfecting mOMCD1, and mIMCD-3 cells with anti-sense HKalpah1, HKalpha2, and HKalpha4, we will define which isoform is responsible for the well-accepted adaptive response to chronic hypokalemia. We will then define the molecular equivalent of the H+, K+-ATPase enzymatic activity characterized as type III, which is upregulated by chronic K+ depletion. This approach will required the synthesis and screening of a subtraction cDNA library. Thirdly, we will determine if aldosterone or endothelin regulate H+, K+-ATPase function in mOMCD1 and mIMCD-3 cells in culture, and if so, we will delineate the alpha, H+, K+-ATPase iosoform responsible. Finally, we will define the contribution of the H+, K+-ATPases to net acid secretion in the OMCDis perfused in vitro during metabolic alkalosis without K+ depletion. Metabolic alkalosis with and without hypokalemia will then be simulated in mOMCD1, cells in culture to delineate whether hypokalemia or alkalemia per se upregulates the alpha H+, K+-ATPase, and if so, which alpha H+, K+-ATPase isoform responds specifically to each condition. These studies will help to elucidate the means by which K+ depletion can maintain metabolic alkalosis. The H+, K+- ATPase remains a candidate gene for abnormal structure and function in inherited and acquired forms of distal renal tubular acidosis. To understand this group of disorders more completely, fundamental studies which elucidate the molecular regulation of this family of transporters will be necessary to further our understanding of the pathophysiology of this disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF RENAL TUBULAR ANION TRANSPORT Principal Investigator & Institution: Aronson, Peter S.; Professor; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: The principal focus of this project continues to be the mechanisms of anion transport in the proximal tubule. Studies during the past decade have supported a model by which transcellular CI-absorption in the proximal tubule involves uphill CIuptake across the luminal membrane by exchange with formate and oxalate. Recycling of formate occurs by H/+- couple formate transport in parallel with Na/+-H/+ exchange, whereas next project period we propose to investigate two aspects of proximal tubule anion transport. First, we plan to complete the cDNA cloning and carry out the physiological characterization of a novel transporter that is likely to play a role in mediating apical membrane anion transport. Specifically, we will isolate, clone and sequence cDNAs encoding the transporter, determine anion specificity and transport modes by functional expression in Xenopus oocytes; general specific antibodies, and determine cell and membrane sites of expression; determine whether different isoforms of the transporter exist; examine structure-function relationships by use of chimeric constructs; and estimate the contribution of the transporter to integrated tubule function in microperfusion studies in mice with targeted disruption of the transporter gene. Second, in collaboration with Gerhard Giebisch (project#1), we propose to continue studies of the mechanisms of regulation of transcellular NaHCO/3 and NaCI
Studies
29
reabsorption in the proximal tubule. Specifically, we will measure the activities of both anion exchanges (CI-formate and CI-oxalate) and recycling pathways (H+-coupled formate transport, Na/+- sulfate co-transport, oxalate-sulfate exchange) in renal brush border vesicles isolated from rats subjects to conditions that regulate proximal NaHCO/3 and NaCI reabsorption (eg. metabolic acidosis, hypokalemic alkalosis, furosemide-induced volume contraction). Activities of these pathways in membrane vesicles will be correlated with rates of transtubular HCO/3- and CI- reabsorption in the intact tubule under similar conditions. We will thereby test the hypothesis that activities of luminal membrane anion transporters are appropriate altered tot permit independent regulation of proximal tubule NaHCO/3 and NaCI reabsorption. The proposed project will provide new information on the molecular mechanisms and regulation of renal CItransport, and is therefore of relevance for understanding clinical disorders of NaCI balance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF CELL DEATH IN LIVER CELLS Principal Investigator & Institution: Herman, Brian A.; Professor and Chair; Cellular & Structural Biology; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2002; Project Start 01-JUL-1999; Project End 30-JUN-2004 Summary: Basic information concerning the mechanisms responsible for hypoxic cell death is lacking. The overall goal of the proposed project is to define the cellular mechanisms which are responsible for the onset of irreversible injury and cell death using isolated rat hepatocytes as a model system. Cell viability, cytosolic free calcium and pH, mitochondrial membrane potential, lysosomal distribution and integrity, cytoskeletal status, plasma membrane distribution and integrity, and cell surface morphology will be evaluated in single individual hepatocytes during hypoxia by quantitative digitized video microscopy (DVM). DVM will allow the direct observation of the dynamics of organelles and molecules in living cells, providing new information about the roles of these components in cellular function. The onset of irreversible cell injury and cell death and the progression or recovery from injury during reoxygenation will be determined with respect to these cellular functions. Since increased cytosolic free calcium, cell swelling, decreased energy supply, proteolysis and reactive oxygen species have all been hypothesized to play a role in cell death during hypoxia or following reoxygenation, pharmacologic stabilization regimes utilizing calcium antagonists, anaerobic substrates, osmotic agents, protease inhibitors, and scavengers of free oxygen radicals will be assessed with regard to their ability to delay or prevent the onset of irreversible injury and cell death. The role of the cytoskeleton in hypoxic injury will be examined using agents which modulate cytoskeletal structure and function. Additionally, cytoskeletal structure during hypoxia will be visualized using immunocytochemistry in combination with light and electron microscopy. Parallel experiments with suspensions of hepatocytes will also be carried out using conventional biochemical techniques. This project will provide fundamental, new information regarding mechanisms responsible for the onset of hypoxic cell death. This information will be important for the development of treatment modalities effective in the preservation of cells and tissue during hypoxic episodes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
30
•
Acidosis
Project Title: MECHANISMS OF CELL INJURY IN BURN COMPLICATED BY SEPSIS Principal Investigator & Institution: Horton, Jureta W.; Professor; Surgery; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-JUL-2003 Summary: (adapted from applicant's abstract): Despite aggressive fluid resuscitation and topical antimicrobial therapy after burn trauma, sepsis frequently results from the loss of dermis; thus sepsis and resultant multiorgan failure are a major cause of death in the burn unit. Studies from the PI's lab and others' have shown that burn trauma and sepsis independently alter cardiocirculatory performance, and recent studies suggest that myocardial abnormalities after burn, trauma or sepsis are related to intracellular accumulation of calcium with subsequent cellular injury and dysfunction. Although this field has grown rapidly, much is still unknown about the cellular mechanisms underlying cardiac dysfunction after either trauma or sepsis. The PI's group have focused their attention on a clinically relevant model of burn injury complicated by sepsis (intratracheal administration of S. pneumoniae administered 24 hours postburn) and have shown progressive cardiocirculatory dysfunction in this two-hit model. Specific Aim 1a will determine if burn/sepsis exacerbates the increased [Ca2+] and [Na2+] shown to occur after burn alone and will determine the contribution of altered Na+/Ca2+ to cardiac contractile dysfunction. Specific aim 1b will determine the contribution of transient cellular acidosis and altered H+/Na+ exchange to increased [Na2+], and whether increased [Na+] in turn promotes Na+/Ca2+ exchange in [Ca2+] overload. Specific Aim 2 will determine the contribution of burn/ sepsis-mediated alterations in SR Ca2+ handling (SR Ca2+ efflux, Ca2+-ATPase activity, SERCA, and SR Ca content) to cellular Ca2+ and cardiac contractile deficits and determine the contribution of burn/sepsis induced myofilament Ca2+ insensitivity to cardiac contractile dysfunction. Studies in Specific Aim 3 will examine the role of PKC activation in intracellular Na+/Ca2+ accumulation and cardiac contractile dysfunction in burn sepsis. Studies in Specific Aim 4 will determine the contribution of increased [Ca2+] and reactive oxygen species to apoptosis in burn/sepsis and further determine the contribution of apoptosis to burn/sepsis-induced ionic derangements as well as cardiac contractile dysfunction. Only by understanding the cellular events involved in the postburn inflammatory cascade can adequate prevention and treatment modalities be designed to improve outcome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MEMBRANE TRANSPORT OF NH3 AND NH4+ Principal Investigator & Institution: Nakhoul, Nazih L.; Medicine; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Renal production and excretion of NH3/NH4+ play a vital role in acid/base homeostasis and regulation of systemic pH. The classical model of NH3/NH4+ transport proposes that: 1) NH3 crosses cell membranes solely by nonionic diffusion through the lipid phase of the membrane and 2) NH4+ transport occurs via channels (e.g., K+ channels) or transporters (e.g. Na/K/2CI co-transport or Na-H exchange), mostly as a substitute for K+. Recent studies report new characteristics of NH3/NH4+ transport and regulation that were not previously recognized. A new class of recently cloned membrane proteins, belonging to the Rh antigen family, may function as transporters of NH4+. Other studies indicate that NH3 transport may be facilitated by
Studies
31
the presence of water channels (AQP). In addition, NH3 was reported to act as a signaling molecule and recent studies proposed that the Rh proteins may actually be gas channels for NH3 and even CO2. The main objectives of this proposal are to investigate the characteristics of AQPs and Rh glycoproteins with respect to NH3 and NH4+ transport. Specifically we will address the following aims: 1) Transport of NH3 through carrier proteins and the role of AQPs. 2) Characterization of transport properties of Rh glycoproteins. These studies will involve expression of cloned genes (Rh and AQPs) in oocytes to study their transport characteristics. Measurements of intracellular pH and other ions will be obtained by microelectrodes and pH sensitive dyes. Studies will also be conducted on cells in culture and the isolated perfused tubule preparation. Because of the importance of NH3/NH4+ in regulating pH, these studies have significant physiological implications. The possibility that a gas, such as NH3, could be transported through an AQP or another carrier protein, is unique and suggest that its transport could be regulated. NH4+-specific transporters, as Rh glycoproteins may be, have never been described in mammalian cells before. These are new properties of NH3/NH4+ transport that will help explain the role of NH3 and NH4+ in acidosis and their effect on transport of other ions a well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLIC REGULATION OF MUSCLE BLOOD FLOW Principal Investigator & Institution: Hester, Robert L.; Physiology and Biophysics; University of Mississippi Medical Center 2500 N State St Jackson, Ms 39216 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-MAY-2005 Summary: The blood flow to the peripheral circulation is regulated to maintain a balance between the delivery of nutrients and the metabolic demands of the tissue. Blood flow increases to a metabolically active tissue. This increased blood flow is the result of an increase in arteriolar diameter of terminal arterioles and larger upstream vessels. The terminal arterioles appear to determine distribution of flow while the upstream or "feed" vessels are more important in regulating total tissue flow. With an increase in metabolism there is the release of vasoactive metabolites from the tissue. Although vasoactive metabolites are known to affect the diameters of terminal arterioles the mechanisms by which metabolic factors regulate the diameter of upstream arterioles is uncertain. Recent studies from our lab and others have indicated an important role for the venular-arteriolar diffusion of vasoactive substances. The studies outlined in this proposal will test the following working hypothesis. In response to mismatches in blood flow and tissue metabolism, decreases in PO2 and/or increases in PCO2 and H+ are directly or indirectly sensed by the venular endothelial cells, resulting in the release of vasoactive metabolites of arachidonic acid which regulate the tone of adjacent arterioles. The proposed studies will test this hypothesis utilizing recently developed in situ microcirculatory techniques in which we are able to selectively remove the venular endothelium and assess the impact on blood flow regulation. The proposed studies will test two specific hypotheses: 1) The venular endothelium releases a metabolite of arachidonic acid that diffuses from the venule to the arteriole to cause an arteriolar dilation in response to an increase in tissue metabolic rate. 2) The venular endothelium responds to hypoxia, hypercapnia, and acidosis, directly, or indirectly to initiate the release of one or more vasoactive factors from the venular endothelial cells. These studies should provide new and important information relevant to our understanding the importance of venular-arteriolar diffusion of endothelial derived factors in the regulation of blood flow. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
32
•
Acidosis
Project Title: MICROENVIRONMENT OF THE RETINA Principal Investigator & Institution: Linsenmeier, Robert A.; Professor; Biomedical Engineering; Northwestern University 633 Clark Street Evanston, Il 60208 Timing: Fiscal Year 2002; Project Start 01-JUL-1983; Project End 31-JUL-2007 Summary: (provided by applicant): The long-term objectives of this work are to understand aspects of the retinal microenvironment related to oxygen and pH, and how these relate to energy metabolism and function of the mammalian retina in vivo. While this work will be done in animals, it is particularly relevant to blinding diseases that affect the relationships between the circulation and retinal neurons in humans. During the next project period, our main interests are in diabetic retinopathy, retinal detachment, and retinal arterial occlusive disease. However, the results will also provide fundamental information that may be relevant to other types of retinal dysfunction. The proposed work will be done primarily on intact anesthetized cats, since their retina provides a good model for much of the human retina. The techniques are primarily to use oxygen and pH sensitive microelectrodes to map out retinal oxygen levels, pH and electrical activity (the electroretinogram) with high spatial and temporal resolution, as we have done previously under other experimental conditions. Following the measurements, mathematical modeling of diffusion will be used to extract metabolic parameters that are not apparent from the measurements alone, and to perform simulations of situations that may not be amenable to experimentation. Some measurements of retinal histology will also be made. The project has 5 specific aims. 1) We will study intraretinal oxygenation following photocoagulation, because the mechanism by which photocoagulation blocks neovascularization is still unclear. 2) We will use information about oxygenation after photocoagulation from specific aim 1 to create an appropriate two-dimensional diffusion model of this situation, with the hope of providing a better rationale for the density and size of lesions designed to treat retinopathy. 3) We will study retinal oxygenation in the detached retina in order to understand the basis for the protective effect of hyperoxia in retinal detachment, which has been shown recently in cats. 4) We will study pH after retinal arterial occlusion, to understand the potential role of acidosis in damaging the retina. 5) We will investigate the influence of anesthesia on the metabolic measurements we make, and will study metabolic differences between the cat and primate retinas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MITOCHONDRIAL DNA ANALYSIS IN CYCLIC VOMITING SYNDROME Principal Investigator & Institution: Boles, Richard G.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 900276062 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (from applicants abstract): Cyclic vomiting syndrome (CVS) is a disabling condition characterized by multiple severe and distinct episodes of nausea, vomiting, lethargy and variable other symptoms separated by asymptomatic intervals. Although CVS is generally believed to be a (predominantly) childhood variant of migraine, its etiology and pathogenesis are poorly understood. Several features of CVS, including a maternal bias in inheritance, suggest that mitochondrial DNA (mtDNA) sequence variations/mutations may be involved in its etiology. A significant subset of children with CVS have additional neuromuscular disease manifestations including cognitive dysfunction and epilepsy. Maternal inheritance of migraine and/or various neuromuscular disorders and lactic acidosis are present in ten children with CVS
Studies
33
followed by the investigators, strongly suggesting that mtDNA mutations are involved in at least some cases. An inherited complex mtDNA rearrangement was found in one. Preliminary results using temporal temperature gradient gel electrophoresis (TTGE) found heteroplasmic sequence variations in the mtDNA D-loop in 2 additional CVS cases. TTGE is a novel mutation detection assay which was developed for use with mtDNA by the PI and collaborators. TTGE is sensitive and cost effective relative to other methods and for the first time permits the screening of large groups of patients for mutations throughout the entire mtDNA. Since mtDNA sequence variations are postulated to be more likely involved among CVS sufferers with additional neuromuscular disease manifestations, in the first sub-study 50 of these individuals will be screened by TTGE for all sequence variations throughout the mtDNA. The incidence of CVS cases caused by mtDNA sequence variations will be determined in a second substudy in which the mtDNA in an unbiased group of 100 CVS sufferers will be screened. All sequence variations found in CVS sufferers will be compared against those found upon an identical screening of 100 control individuals, and any of interest will be sequenced. Pathogenicity of suspected mutations will be determined in rho negative cybrids. An extensive amount of clinical and laboratory data will be collected in all patients, allowing for the comparison of CVS sufferers with and without mtDNA mutations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MITOCHONDRIAL DYSFUNCTION IN PEDIATRIC HEAD INJURY Principal Investigator & Institution: Robertson, Courtney L.; Assistant Professor; Pediatrics; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Following traumatic brain injury (TBI), the immature rat brain experiences many secondary insults that lead to delayed cell death. Although considerable evidence indicates that mitochondria are primary mediators of ischemic and excitotoxic neural cell death and survival, relatively little is known regarding mitochondrial involvement in adult TBI, and nothing has been reported for models of pediatric TBI. Limited studies of the immature rat brain have demonstrated vulnerability to many known mediators of mitochondrial injury, including elevated intracellular calcium and oxidative stress. Mitochondrial alterations can also trigger the cascade of caspase activities that mediate apoptosis, a process of programmed cell death that appears particularly important in TBI. The working hypothesis for the proposed study is that the response of brain mitochondria to metabolic acidosis, elevated calcium, oxidative stress, and pro-apoptotic proteins plays an integral role in the neurochemical, histologic, and neurologic outcome following pediatric TBI. We will test the following mechanistic hypotheses using a clinically relevant model of pediatric TBI: 1) Mitochondrial injury early after TBI increases the sensitivity of mitochondria to cellular factors that promote apoptotic or necrotic cell death cascades. 2) Cerebral lactic acidosis after TBI promotes cytochrome c release, mediated by mitochondrial swelling due to activation of the membrane permeability transition. 3) Oxidative stress following TBI contributes to mitochondrial dysfunction, cell death and neurologic injury. This study will help define the molecular mechanisms by which mitochondria are injured after TBI in immature animals. This may identify novel targets for neuroprotection following TBI in infants and children. This proposal is intended to provide for the research experience and career development of the applicant, specifically involving the mechanisms of, and therapeutic strategies for, the treatment of acute brain injury. The Departments of Anesthesiology and Pediatrics, and the Brain Injury and Neuroprotection Research
34
Acidosis
Group at the University of Maryland will provide a rich environment for the study of experimental brain injury, and have a strong commitment to fostering meaningful and contemporary research in this field. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MITOCHONDRIAL METABOLITES
NUCLEOTIDE
CARRIERS
OF
NRTI
Principal Investigator & Institution: Gulick, Tod S.; Asst. Biochemist/Asst. Professor of Medi; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Nucleoside reverse transcriptase inhibitors (NRTI) are critical components of highly active anti-viral therapies. Phosphorylated derivatives (NRTI-P) mimic the cellular dNTP substrates for HIV RT, but produce chain termination, thereby limiting retroviral amplification. NRTIs produce reversible side effects that resemble those of patients with mitochondrial (mito) genetic disorders, including cardiomyopathy, myopathy, neuropathy and lactic acidosis, and these correlate with NRTI-induced loss of mito DNA in various tissues. Toxicity has been attributed to inhibition of DNA polymerase g, interfering with mito DNA maintenance. Alternative or additional mechanisms of mito damage may also be at play. Regardless of mechanism, NRTI toxicity is dependent on import into mito. We have isolated novel human genes and cDNAs that encode orphan members of the mito metabolite carrier family (OMC). Five carry a signature specific to nucleotide (nt) carriers, including a putative adenine nt transporter (ANT), two putative CoA transporters, and a nonspecific exchanger of nucleotides (OMC27). We have shown that purified OMC27 and its yeast ortholog transport NRTI-P's AZT-TP and -DP, ddl-TP, and ddC-TP in proteoliposome radiochemical flux assays. Disruption of the orthologous yeast gene protects against AZT-induced mito dysfunction. This project examines the role of OMC27 in NRTI-mediated toxicity, with goals of understanding mechanisms by which NRTIs gain entry to the matrix, and identifying nucleoside analogs with known antiviral activity that offer potential for improved therapeutic index by virture of mito exclusion and reduced mito toxicity. We will test the hypotheses that OMC27 (and yeast ortholog) are highly affinity transporters of NRTI-P, that this represents the primary pathway for mito uptake of NRTI-P; that OMC27 expression is critical to NRTI-induced mito failure; and that a useful therapeutic index for NRTIs may be evident from the ratio of NRTI anti-viral to MC-mediated uptake activities; using complementary in vitro, yeast and mammalian cell, and in vivo mouse studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF ELECTROGENIC SODIUM BICARBONATE TRANSPORT Principal Investigator & Institution: Kurtz, Ira; Professor; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Sodium bicarbonate cotransporters contribute to intracellular pH (pHi) regulation and the transepithelial transport of sodium and bicarbonate in several tissues. The recent cloning, functional expression, and immunolocalization of electrogenic and electroneutral sodium bicarbonate cotransport (NBC) proteins provides an opportunity to investigate the molecular mechanisms responsible for modulating their function. The electrogenic sodium bicarbonate
Studies
35
cotransporter kNBC1 is the main pathway for proximal tubule basolateral bicarbonate effiux. Loss of function mutations in the NBC1 gene cause a severe form of autosomal recessive proximal renal tubular acidosis. There is currently a paucity of information regarding both the structural motifs responsible for the electrogenicity of kNBC 1, and the biologically important protein interactions that modulate its function. In recent studies, we have demonstrated that PKA-dependent phosphorylation of the C-terminal Ser982 residue altered the electrogenicity of kNBC1 by shifting its HCO3-:Na + stoichiometry from 3:1 to 2:1. In the region adjacent to Ser982, structural analysis reveals a charged region with aspartic acid residues that could potentially play an important role in this regard. We hypothesized that the phosphorylation state of Ser982 determines whether this negatively charged region in the kNBC1 C-terminus will interact electrostatically either with one bicarbonate binding site in the transporter (2:1 mode), or a putative binding protein (3:1 mode). On this basis we screened a human kidney cDNA library in a yeast two-hybrid assay using the C-terminus of kNBC 1 as bait, and isolated the enzyme aspartoacylase. Aspartoacylase has several N-terminal basic residues which could mediate its interaction electrostatically with the C-terminus of kNBC1. Aspartoacylase was localized to the basolateral membrane of proximal tubule cells, and co-immunoprecipitated with kNBC 1 from kidney. PKA-dependent phosphorylation of kNBC1-Ser982 prevented the interaction between the proteins. Furthermore, the function of kNBC1 was significantly greater in cells co-transfected with kNBC 1 and aspartoacylase in the presence of N-acetylaspartate. We will use the mPCT cell line as a model system for achieving the goals of this proposal. Successful completion of this project will enhance our understanding of the mechanisms responsible for regulating H+/base transporters. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR PHYSIOLOGY OF BAND 3 LIKE PROTEINS OF KIDNEY Principal Investigator & Institution: Alper, Seth L.; Professor; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2002; Project Start 15-JAN-1991; Project End 31-MAR-2003 Summary: (Adapted from the Applicant's Abstract): The AE anion exchanger gene family encodes complex polytopic transmembrane polypeptides that contribute to regulation of intracellular pH (pHi), cell [Cl-], and cell volume through their mediation of electroneutral Cl-/HCO3- exchange. AE-mediated Cl-/HCO3- exchange in polarized epithelia also regulates secretion and reabsorption of proton equivalents and of Cl-. AEmediated Cl-/HCO3-exchange is thought to be of widespread physiological importance in many cell types. AE1 deficiencies have been particularly associated with hereditary syndromes of spherocytic anemia and of distal renal tubular acidosis. Deficiencies of AE2 or AE3 activity have yet to be defined. Deficiency of a different Cl-/HCO3exchange activity leads to congenital chloride diarrhea. This competitive continuation grant application proposes to extend past and current experiments by pursuit of the following Specific Aims: 1. Further define structural loci of the regulatory differences among AE isoforms, especially AE1 and AE2. 2. Study natural variants of the AE genes and a different class of anion exchanger for clues about ion translocation pathways and mechanisms. These will include: a. AE1 mutations that cosegregate and likely contribute to heritable distal renal tubular acidosis b. AE polypeptides of genetically related fish that live in river or in soda lake environments c. a more distantly related member of the bicarbonate-transporter superfamily cloned from yeast d. the unrelated sulfate transporter DRA that when mutated results in congenital chloride diarrhea. 3. Further
36
Acidosis
compare and define the mechanisms of electroneutral and electrogenic anion exchange mediated by AE1 E699Q and likely mediated by AE2 E1007Q. 4. Apply directed mutagenesis to define the residues of AE1 and AE2 that contribute to binding and transport of substrate anions and to deduce constraints on secondary and tertiary structure of AE polypeptides. 5. Define aspects of transcriptional and translational regulation of AE gene products in kidney of mutant and parental mouse strains and in cultured kidney cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR PHYSIOLOGY OF RENAL K-CI COTRANSPORTERS Principal Investigator & Institution: Mount, David B.; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-MAY-2000; Project End 30-JUN-2008 Summary: (provided by applicant): Coupled K+-CI- co-transport is mediated by the KCC proteins, encoded by four members of the SLC 12 cation-chloride cotransporter gene family. Genetics, physiology, and the characterization of knockout mice have implicated the KCCs in the pathogenesis of disorders as diverse as hypertension, epilepsy, renal tubular acidosis, neuropathic pain, and sickle cell anemia. In the renal proximal tubule, isotonic swelling induced by apical Na absorption activates basolateral K+ -Cl- cotransport mediated by KCC3 and KCC4, implicating these transporters in proximal re-absorption of filtered Na+-Cl- and other solutes. Indeed, in addition to reduced fluid transport, KCC3-deficient mice exhibit defects in the absorption of bicarbonate, suggesting that loss of KCC3 causes generalized proximal tubular defects. Furthermore, given the demonstrated role of KCC3 in regulatory volume decrease (RVD), the response to oxidant stress, and a severe neurodegenerative syndrome, we propose that KCC3 is required to maintain cellular integrity in response to ischemic volume increase ("IVI"), such that loss of KCC3 predisposes to ischemic tubular necrosis. The role and regulation of K+-Cl - cotransport in the proximal tubule is thus the focus of this competing renewal. We propose in Aim 1 to finish characterizing the renal phenotype of our existing mouse strain with germline deletion of the KCC3 (Slc12a6) gene, in addition to creating and characterizing a mouse strain with KCC3 deletion that is limited to the renal proximal tubule. These animal studies will encompass immunohistochemistry, renal physiology, and assessment of the response to renal ischemia/reperfusion injury. Whereas neuronal-specific KCC2 is unique in mediating constitutive K+-Cl - cotransport, the other three KCCs are quiescent in the absence of cell swelling. Using a chimeric approach, we have localized the molecular determinants of constitutive isotonic activity to a KCC2-specific expansion in the C-terminal cytoplasmic domain. Given t he role o f s welling-activated K +-Cl- cotransport in proximal tubular salt and solute transport we will characterize the molecular determinants of swelling activation, using chimeras between K CC4 and t he s wellinginhibited N a-K-2Cl cotransporter N KCC2. T he effect o f c ell volume o n phosphorylation status and membrane trafficking will also be studied in Aim 2, using KCC4 and several N-terminal variants of KCC3. These studies will begin in Xenopus oocytes but will ultimately be extended to the opossum kidney (OK) cell line and/or other epithelial cell lines. In Aim 3 we will focus on the role of conserved cysteines in the mechanism and regulation of K+-Cl - cotransport, building on data from both activating and inactivating mutations of conserved transmembrane cysteines. Various cysteinedepleted mutants will also be used to distinguish the cytoplasmic and membraneassociated mechanisms in the activation and inactivation of the KCCs by nitric oxide (NO) and related cysteine-reactive compounds.
Studies
37
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MRI AGENTS THAT REPORT THE EXTRACELLULAR PH OF TUMORS Principal Investigator & Institution: Mudigonda, Dhurjati S.; Macrocyclics Suite 120 Dallas, Tx 75252 Timing: Fiscal Year 2003; Project Start 01-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): In this project, we will develop new gadoliniumbased contrast agents that are exquisitely sensitive to pH and establish their feasibility in determining extracellular pH in vivo using a standard clinical MRI protocol. Extracellular pH is clearly an important parameter to know in neoplastic tissues because it has been shown that acidosis can modulate the cytotoxicity of some anticancer drugs, influence thermal radio-sensitization and enhance the killing effects of heat. We recently demonstrated that a simple gadolinium complex containing a single, slowly exchanging, inner-sphere water molecule senses pH via catalytic exchange of bound water protons. This unique chemical feature offers a major advantage over other known gadolinium complexes because proton relaxivity is not limited by molecular exchange of the bound water. This means that complexes with water relaxivity values higher than previously achieved can be made by attaching existing small molecule pH sensitive agent to polymers of increasing size. We have licensed this technology from the University of Texas at Dallas and through the current funding mechanism intend to create even more pH responsive MRI agents, demonstrate their utility in vivo in animal models, and make them commercially to the biomedical research community. PROPOSED COMMERCIAL APPLICATION: Magnetic resonance imaging is widely used to detect tumors in humans, yet little physiological information is gained in a normal MRI exam. We plan to develop new pH sensitive contrast agents that can be safely injected into patients to determine the extracellular pH of tumors using a standard imaging protocol. We believe this could become a standard protopcol in clinical oncology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEONATAL PROXIMAL TUBULE ACIDIFICATION Principal Investigator & Institution: Baum, Michel G.; Professor; Pediatrics; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-FEB-1991; Project End 30-JUN-2006 Summary: (provided by applicant): There are clinically important differences between the neonatal and adult kidney. The neonatal kidney has a lower glomerular filtration rate and immature tubules compared to the adult. Tubular immaturity predisposes neonates to develop fluid and electrolyte disorders. The adult proximal tubule reabsorbs 80 percent of the filtered bicarbonate and 60 percent of the filtered NaCl. Most of proximal tubule acidification in the mature proximal tubule is due to the apical Na+/H+ exchanger (NHE3). The Na+/H+ exchanger in parallel with a Cl-/base exchanger also mediates transcellular NaCl transport. Half of NaCl transport in the mature segment is passive and paracellular. Neonatal proximal tubules have almost an undetectable level of NHE3. This proposal will examine what produces the developmental increase in NHE3 and in proximal tubule NaCl transport. There is a 100-fold increase in corticosterone level and a 10-fold increase in thyroid hormone level during the first three weeks of life in the rat. We have recently demonstrated that this rise in glucocorticoids mediates most, but not all, of the increase in NHE3. The first aim will examine the mechanisms whereby glucocorticoids increase NHE3. The second aim will
38
Acidosis
examine if the maturation of NHE3 is totally prevented in a novel animal model, a hypothyroid glucocorticoid deficient neonatal rat. In addition to the developmental changes in active transport, we have recently demonstrated that there are significant differences in the paracellular pathway in immature tubules, which impact the passive component of NaCl transport. Whereas one half of NaCl transport is paracellular in the adult proximal tubule, there is essentially no passive NaCl transport in the neonatal segment. The third aim will characterize the physiologic and molecular characteristics of the neonatal and adult proximal tubule paracellular pathway to determine why there is no passive NaCl transport in the neonatal proximal tubule. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROLOGIC AIDS RESEARCH CONSORTIUM Principal Investigator & Institution: Clifford, David B.; Professor; Neurology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 01-MAY-1997; Project End 31-JUL-2008 Summary: The Neurologic AIDS Research Consortium (NARC) will maintain an effective collaborative clinical study group dedicated to the study of HIV-associated neurologic disease. Projects are identified by investigators, designed with review by internal and external experts and implemented. This proposal includes completion of currently active studies, and initiation of new areas of investigation relevant to the neurologic complications associated with HIV infection. The specific projects to be undertaken include: 1. Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2. Monitor the incidence, prevalence and natural history of HIV related neuropathy and neuropsychologic disorders and validate brief screens for detection of central and peripheral nervous system dysfunction in the Adult Longitudinal Linked Retroviral Treatment (ALLRT) Cohort of the AIDS Clinical Trial Group; 3. Complete and analyze longitudinal physiologic and morphologic characterization of distal sensory neuropathy in HIV over a one year period of observation; 4. Complete and analyze our study of the virologic, immunologic and pharmacologic manifestations of HIV in CSF compartment during anti-retroviral treatment; 5. Perform a study of Acetyl L-carnitine for treatment of dideoxynucleoside induced painful neuropathy in HIV infection; 6. Develop and implement a study to measure the safety, tolerability and analgesic properties of Prosaptide for HIV-associated painful peripheral neuropathy; and 7. Characterize the newly described acute neuromuscular disorder associated with lactic acidosis seen in treated HIV patients. Major studies will be developed and operated cooperatively with the AIDS Clinical Trial Group (ACTG). The NARC will continue to develop a broad agenda for clinical study of neuroAIDS complications following these studies, directed by the Principal Investigator, Executive Steering committee and the NINDS appointed Data and Safety Monitoring Board (DSMB). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL ASSAY FOR ETHYLENE GLYCOL TOXICITY Principal Investigator & Institution: Kloepfer, Hans G.; Micronix, Inc. 14950 Greyhound Ct, Ste 307 Carmel, in 46032 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-MAY-2003 Summary: (Applicant's abstract) Poisoning from ethylene glycol is a potentially lethal medical emergency but can be treated effectively when recognized early. Conversely, when diagnosis is late, the outcome is usually poor. The major pathogenic factor is
Studies
39
metabolic acidosis from glycolic acid (glycolate). Because laboratory testing for ethylene glycol and glycolate is severely restricted, timely diagnosis depends on comparatively nonspecific physical signs and laboratory tests. Lack of access to specific testing and need for differentiation from conditions featuring similar symptoms constitute a unique medical dilemma. Recognizing these deficiencies we propose to develop novel, specific enzymic assays for ethylene glycol and glycolate. Two product configurations are perceived: 1) aqueous reagents for existing clinical analyzers (serum, quantitative); 2) a dry-chemistry, dual-analyte point-of-care testrip method (whole blood, semiquantitative).The POC method is a dual-analyte test tab device for the simultaneous estimation of ethylene glycol and glycolate from approximately two (2) microliters of whole blood without centrifugation or any other form of sample or reagent handling. To make such a level of miniaturization and simplicity feasible, we have developed a capillary fill sampling technique permitting specimen dosing, plasma separation, and red cell removal in one wholly integrated step. Because of rapid metabolism of (flontoxic) ethylene glycol and the longer half life of (toxic) glycolate, the latter provides better prognostic information and improved clinical sensitivity, especially late postingestion. Thus, rapid and simultaneous availability of test results for both analytes expands the window of diagnostic/therapeutic opportunity. Socioeconomic benefits are: 1) reducing expensive gas chromatographic screening, confirmatory and other testing; 2) averting late or unnecessary treatment; 3) cutting intensive care and hospital stay; 4) abating long term morbidity (renal dialysis). PROPOSED COMMERCIAL APPLICATION: Most current gas chromatographic screening and confirmatory methods for ethylene glycol require derivatization, sample pretreatment and special columns. Direct methods are fraught with analytical problems such as peak overlap and trailing. Cases have been reported where other compounds were identified as ethylene glycol with serious consequences. All methods require specialized equipment unavailable in most laboratories, are technically demanding, time consuming, and relatively insensitive. For these reasons access to timely and reliable testing for ethylene glycol is extremely limited. Testing for the clinically more sensitive and relevant toxic metabolite glycolic acid is essentially non-existant. Not a single routine clinical analyzer currently exists offering either an ethylene glycol or glycolate method. The proposed products would solve these problems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL NON-HEART-BEATING DONOR KIDNEY STORAGE MEDIUM Principal Investigator & Institution: Chen, Sumi C.; Principal Investigator; Chen Laboratories, Inc. 13704 Killarney Court Phoenix, Md 21131 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 31-OCT-2002 Summary: Donor kidney cannot meet current demand for kidney transplantation, the most effective for end stage renal failure. Non-heart-beating (NHB) donor kidneys are under-utilized because current technology does not allow NHB donor organs to withstand unavoidable extended periods of warm and cold ischemia. Chen Medium (CM), a novel physiological preservation solution, is highly effective for human donor cornea storage and preservation. CM contains beta-hydroxybutyrate, a unique nonlactate-generating high-energy metabolite that enables tissues to generate high levels of ATP while suppressing intracellular acidosis. NHB donor organs undergo unique metabolic compromise, many aspects of which could be prevented by nicotinamide. Nicotinamide, an NAD+ precursor that is safe for humans, is idea for MHB donor organ preservation because it scavenges free radicals, preserves NDA+ levels through
40
Acidosis
inhibition of poly(ADP-ribose) polymerase-mediated NAD+ catabolism, and inhibits both inducible nitric oxide synthase and expression of leukocyte-attracting molecules on human endothelial cells after injury. We propose to use physiological, biochemical and histological criteria with the isolated perfused pig kidney model to demonstrate that CM with nicotinamide is superior to UW and EC solutions for NHB donor organ preservation. Our aim is to advance transplant technology to allow effective utilization of under-utilized NHD donor organs. PROPOSED COMMERCIAL APPLICATIONS: The proposed research, if successful, will have potential commercial application. That is, CM will be able to be marked as a non-heart-beating kidney preservation medium. This is an Orphan product with a market size estimated about $20 million a year in the US and about $6-10 million for the foreign markers combined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NRTI-INDUCED MITOCHONDRIAL CARDIOMYOPATHY Principal Investigator & Institution: Wallace, Kendall B.; Professor; Biochem/Mole Biol/Biophysics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Cardiovascular disease is a growing complication of HIV. Although there is an increased incidence associated with the infection itself, it is further complicated by the antiviral therapy prescribed to treat the disease. The cornerstone of the HAART drug regimen for treating HIV are nucleoside analog reverse transcriptase inhibitors (NRTIs), which inhibit viral RNA-dependent DNA polymerases. However, these drugs are also recognized by host cell DNA polymerases including Polg, which is responsible for replicating the mitochondrial genome. As a result, the NRTIs inhibit mtDNA replication and biogenesis leading to mitochondrial depletion, which is manifested as a dose-limiting lactic acidosis and life-threatening cardiomyopathy. Although there is considerable evidence implicating mitochondrial depletion in the pathogenesis of NRTI toxicity, little is known regarding the bioenergetic characteristics responsible for the mitochondrial phenotype. The purpose of this investigation is identify which NRTIs induce mitochondrial cardiomyopathy in animal models at relevant doses and to fully characterize the mitochondrial bioenergetic deficits that underlie the metabolic disorder. We propose that the loss of coordinated expression of the nuclear and mitochondrial genomes leads to the assembly of poorly coupled electron transport chains, resulting in a loss of efficiency of oxidative phosphorylation accompanied by the catalytic liberation of highly reactive oxygen free radicals. Mitochondrial cardiomyopathy likely reflects both bioenergetic failure and increased oxidative damage owing to this interference with mitochondrial biogenesis. The results of this investigation will provide valuable insight into distinguishing which NRTIs are cardiotoxic and identifying the underlying mechanisms in the pathogenesis of cardiac injury. This information will be essential to predicting possible interactions between components of the HAART drug regimen and for developing reliable biomarkers and/or new treatment strategies designed to minimize the cardiomyopathy and thus improve the clinical success of HIV pharmacotherapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OSTEOCLAST ACTIVATION IN UREMIC BONE DISEASE Principal Investigator & Institution: Holliday, Lexie S.; Orthopaedics & Rehabilitation; University of Florida Gainesville, Fl 32611
Studies
41
Timing: Fiscal Year 2002; Project Start 17-SEP-2001; Project End 30-JUN-2006 Summary: (Adapted from the Applicant's Abstract): Vacuolar V-ATPases (V-ATPases) have an essential role in the endocytic pathways of eukaryotic cells. In some cell types, like osteoclasts and certain renal epithelial cells, V-ATPases are expressed at high levels and are required for the specialized functions of the cells. In osteoclasts and renal epithelial cells, V-ATPases are stored in vesicles or tubules in the cytoplasm until the cell encounters an activating signal. V-ATPases are then transported to specialized domains of the plasma membrane. Although this transport is a crucial means by which VATPases are regulated, until recently little was known about the underlying mechanisms. A specific interaction between V-ATPases and filamentous actin (F-actin) has been identified by our lab. This represents the first example of a direct interaction between an ion pump and microfilaments. This grant will test the hypothesis that interaction between V-ATPase and F-actin accounts for the transport of V-ATPases in osteoclasts and other cells. The binding interaction between V-ATPase and F-actin is mediated by the B-subunit of V-ATPase; the B-subunit thus represents a new and unique member of the family of actin binding proteins. The interaction between actin and V-ATPase can be reconstituted using bacterially-expressed fusion proteins representing the N-terminal domains of B-subunits. This grant will continue characterization of the binding interaction between V-ATPase and actin using molecular and biochemical techniques with the goal of understanding the binding interaction in great detail. With this information, mutated molecular constructs of the B-subunit will be created which are able to integrate with other VATPase subunits to support proton pumping activity, but which lack the capacity to bind actin. These constructs will be expressed in an osteoclast cell culture model to test the physiologic importance of the binding interaction between V-ATPase and F-actin. The specific aims are: I. To obtain detailed molecular information about the F-actin binding site on the B-subunit, and generate mutant B subunits that lack actin binding but retain catalytic activity. II. To study effects of V-ATPase-F-actin binding on F-actin organization and V-ATPase enzymatic function. III. To test the importance of the binding interaction in osteoclast cell culture models. Because V-ATPases are crucial enzymes to the lives of all cells, and have been implicated in clinical disorders including osteoporosis and renal tubular acidosis, understanding their regulation will be of great importance for both basic and clinical science. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF RETINOPATHY OF PREMATURITY Principal Investigator & Institution: Holmes, Jonathan M.; Professor and Chairman; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: (Adapted from the applicant's abstract): Retinopathy of prematurity (ROP) is a blinding disease of premature infants resulting from development of abnormal blood vessels in the immature retina. It has been well established that excess oxygen is an important causative factor in the pathogenesis of ROP. Nevertheless, despite the more careful use of oxygen, the incidence of ROP is increasing in the United States. In addition, current treatments for severe ROP fail to prevent blindness in a large proportion of infants. Therefore, further research into the pathogenesis of ROP is critical to increase our understanding of the disease and to develop new methods of prevention and treatment. Infants who never experience hyperoxia (e.g., those with congenital heart disease) may also develop ROP. For these infants in particular, and for premature neonates in general, systemic acidosis has been implicated as a risk factor in the
42
Acidosis
development of ROP. A new neonatal animal model has been developed that allows study of metabolic acidosis and retinal neovascularization. The investigator has confirmed that metabolic acidosis alone leads to preretinal neovascularization in the retina of immature animals, and has termed this model "metabolic acidosis-induced retinopathy" (MAIR). Using this model, the investigator proposes to characterize the effect of acidosis on the immature retina and investigate biochemical and molecular mechanisms. These studies may lead to new avenues of prevention and treatment of ROP. The primary hypothesis for this series of experiments is that: "acidosis is a risk factor for ROP in human neonates." This leads to the following secondary hypotheses that will be tested in the MAIR model, which is that: (1) a dose-response relationship exists between the extent of metabolic acidosis and the severity of retinopathy in the neonatal rat model; (2) neovascularization in the acidotic model is mediated by downregulation followed by up-regulation of one or more growth factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and insulin-like growth factor 1 (IGF-1); and (3) the retinopathy can be prevented by reversal of acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHWAYS OF APOPTOSIS IN HYPOXIC CARDIAC MYOCYTES Principal Investigator & Institution: Webster, Keith A.; Professor; Molecular and Cellular Pharm; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2003; Project Start 01-APR-1990; Project End 31-MAR-2007 Summary: (provided by applicant): C-Jun N-terminal kinase (JNK) is activated by reoxygenation or reperfusion in all models of myocardial ischemia in vitro and in vivo. JNK can exert strong modulation over cell survival and may determine the extent of myocardial cell loss during reperfusion. Controversy has existed over the role of activated JNK in different models of reperfusion with some groups describing proapoptosis and others protection. We present new data demonstrating that JNK functions are metabolically regulated that may resolve this controversy; JNK is protective when intracellular [ATP] is high and pro-apoptotic when [ATP] is low. As such JNK acts as a metabolic sensor in determining cell fate. We hypothesize that the targets that promote survival are different from those that promote death. In aim 1 of this proposal we will use the JNK functional switch as a tool to identify the phospho-proteins that mediate these different effects on hypoxic cardiac myocytes. Hypoxia and acidosis are integral features of ischemic heart disease. This combination is one of the strongest stimuli to activate programmed death of cardiac myocytes in culture. The pathway involves the Bcl-2 family protein BNIP3 that is strongly induced by hypoxia. Hypoxic cardiac myocytes containing induced BNIP3 do not undergo programmed death until the environment becomes acidic. We hypothesize that BNIP3 is induced and activated by hypoxia and acidosis respectively. Experiments are proposed to determine the mechanism and whether there are secondary effects of acidosis on mitochondrial signaling. Because we have established the role of BNIP3 in cultured cardiac myocytes, a major goal is to determine whether the same pathway promotes cell death during ischemia and infarction in vivo. The signals for JNK activation by reoxygenation have not been determined but are thought to involve reactive oxygen species (ROS). Our preliminary data suggest that coupled mitochondrial electron transport and membrane potential, but not ROS are essential components of this signaling pathway. We hypothesize that the pathway involves calcium loading activated by the mitochondrial membrane potential, coupled with myofilament calcium transients. Calcium is proposed to activate the kinase Pyk2 followed by Rac-1 and TAK- 1 and then JNK. Experiments proposed to test this hypothesis include measurements of membrane potential and
Studies
43
intracellular calcium during hypoxia and reoxygenation and relating these to Pyk2 and JNK. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PH CONTROL OF PROTEIN SYNTHESIS Principal Investigator & Institution: Garlick, Peter J.; Professor and Director of Research; Surgery; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2004 Summary: Patients with renal failure, diabetic ketosis, severe trauma or sepsis often become acidotic. Moreover, they are also susceptible to body protein wasting. Experimental acidosis has been shown to result in negative nitrogen balance, and body protein loss in acidotic patients can be alleviated by normalization of pH. Previous work has concentrated on the effects of pH on protein degradation and no systematic studies have been performed on pH and protein synthesis. However, measurements in animals and human volunteers have shown that both metabolic and respiratory acidosis are associated with depressed rates of synthesis of skeletal muscle protein and serum albumin. The purpose of the present proposal is therefore to characterize the relationship between protein synthesis rates in tissues, especially muscle and liver, of rats and humans in relation to changes in intra- and extracellular pH, to confirm the hypotheses: (i) that changes in blood pH, both by metabolic and respiratory means, modify rates of tissue protein synthesis and gene expression and contribute to the protein wasting of patients with acidosis, and (ii) that these effects of pH operate directly via the intracellular pH and do not involve extracellular mediators such as hormones. The studies will employ measurements of rates of protein synthesis in tissues of rats and human volunteers to characterize the responses to changes in intra- and extracellular pH induced by metabolic and respiratory means and to confirm that these effects are rapid, operate over the full range of pH from acidosis to alkalosis and are independent of oxygen supply. In the animals, the responses of gene expression in the liver will be investigated by determining the levels of mRNA for 3 liver proteins. In particular, the treatments studied will produce different changes in the infra- and extracellular pH. Measurements of intracellular pH will be made by nuclear magnetic resonance, to confirm the hypothesis that changes in protein synthesis are determined by the intracellular rather than extracellular pH. A separate set of studies will be performed in isolated tissues and cells, to determine whether responses to changes in pH are direct or act through circulating hormones. The cellular and molecular mechanisms through peptide chain initiation and initiation factors eIF-2 and eIF-4 will also be identified. Finally, the effect of changes in pH on tissue protein synthesis will be measured in human volunteers and hemodialysis patients, to identify the role of pH control of protein synthesis in health and in protein wasting conditions with abnormalities of pH control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PH REGULATION IN HEART CELLS Principal Investigator & Institution: Spitzer, Kenneth W.; Cardiovascular Res & Trng Inst; University of Utah Salt Lake City, Ut 84102 Timing: Fiscal Year 2003; Project Start 01-JUL-1989; Project End 30-JUN-2008 Summary: (provided by applicant): The broad, long-term goal of this work is to establish a comprehensive understanding of the role of pH in cardiac function at the cellular level. Changes in intracellular pH (pHi) and extracellular pH have profound
44
Acidosis
effects on electrical activity, excitation-contraction coupling and contraction in the heart, which accounts in part for the arrhythmias and contractile dysfunction elicited by myocardial ischemia. Compared to the information available for ventricular muscle, much less is known concerning pHi regulation, the effects of pH on Ca 2+ handling, and intra- and intercellular H+ diffusion in cardiac myocytes that lack transverse tubules (Purkinje and atrial). The protocols described in this project focus primarily on these two cell types and are designed to help fill this gap using fluorescence imaging and patch pipette techniques. The specific aims include: 1. Characterize the effect of intracellular acidosis on excitation-contraction coupling in atria/and Purkinje myocytes. The goal here is to determine the effects of acidosis on Ca 2+ current (L and T type), the spatiotemporal profile of the Ca2+ transient, Ca 2+ handling by the sarcoplasmic reticulum and intracellular Ca 2+ diffusion in these cell types. The response of [Ca2+]i to spatially confined changes in pHi will also be studied. 2. Characterize the electrogenic properties of Na-HCO3 cotransport in ventricular, atrial and Purkinje myocytes. The objective here is to test the hypothesis that Na-HCO3 cotransport is electrogenic in these cell types. 3.Characterize the properties of pH_ regulatory systems in cardiac Purkinje myocytes. The objective here is to determine the kinetic properties and pH-dependence of Na-H exchange (NHE), Na-HCO3 cotransport (NBC) and HCO3-CI exchange (AE) in isolated Purkinje myocytes and to test the hypothesis that CI-OH exchange (CHE) is operational in this cell type. 4. Characterize intra- and intercellular H+ diffusion in atrial and Purkinje cells. The goal here is to determine the intracellular H+ diffusion coefficient within single cells and the junctional permeability H+ coefficient between pairs of electrically coupled myocytes and to test the hypothesis that both parameters are modulated by carbonic anhydrase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECEPTOR
PHARMACOGENETICS
OF
THE
HUMAN
PROSTACYCLIN
Principal Investigator & Institution: Hwa, John; Pharmacology and Toxicology; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2008 Summary: (provided by applicant): Prostacyclin (PGI2), a derivative of arachidonic acid, plays an important role promoting vascular smooth muscle relaxation and preventing platelet aggregation. The actions are mediated through a poorly understood seven transmembrane domain spanning G-protein coupled receptor (GPCR), the prostacyclin receptor (IP). The clinical importance of this receptor stems from its involvement in cardiovascular diseases such as myocardial infarction, stroke, atherosclerosis, and hypertension. The potential use of prostacyclin in the treatment of pulmonary hypertension, and cancers (colon, breast and lung), is currently being intensely investigated. We have recently discovered eleven human prostacyclin receptor polymorphisms. Furthermore preliminary in vitro studies have revealed abnormal function in one of these polymorphisms (R212H). This has led to the hypothesis that such polymorphisms may play a critical role in cardiovascular disease. Through three Specific Aims the goal of this proposal is to understand the pharmacogenetic importance of hIP polymorphisms and in so doing to determine distinct features of this receptor, which enable it to bind a 20-carbon fatty acid (eicosanoid) and couple it to signal transduction pathways, leading to cardiovascular disease. Genomic screening and sequencing will be used to comprehensively search for new polymorphisms and assess association with clinical cardiovascular disease (Specific Aim #1). Novel polymorphisms found will be tested in vitro using site-directed mutagenesis, and structure-function
Studies
45
studies (Specific Aim #2). Specific Aim #3 will focus on downstream signal transduction pathways in human vascular smooth muscle cells to determine mechanisms for cardiovascular defects. In addition to this proposed collaboration between the Pharmacology, Medicine (Statistics), Vascular Surgery, Cardiology and Pathology Departments here at Dartmouth, strong groups in protein structure-function and signal transduction, will be critical resources for addressing these Specific Aims. Achievement of these aims, should not only improve our understanding of the molecular genetics and structure-function of the prostacyclin receptor, but may also provide the critical biochemical understanding to explain interindividual differences in progress of cardiovascular disease and variable responses associated with prostacyclin analogue treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSIOLOGICAL ROLE OF CIC-2 CI CHANNELS IN HEART Principal Investigator & Institution: Duan, Dayue; Pharmacology; University of Nevada Reno 204 Ross Hall Mailstop 325 Reno, Nv 89557 Timing: Fiscal Year 2002; Project Start 20-JUL-2002; Project End 30-JUN-2006 Summary: (provided by applicant): Activation of chloride (Cl-) currents in the heart can cause important changes in action potential characteristics, which may increase the dispersion of electrophysiological properties and provide the substrate for the occurrence of arrhythmias. In mammalian myocardial cells the P.I and his colleagues have recently discovered a novel volume-regulated Cl- inward rectifier channel (Cl.ir) (Circulation Research 86:e63-e71, 2000). Distinct from all cardiac Cl- channels described previously, Cl.ir is the only channel that exhibits inwardly rectifying current-voltage relationship. The molecular property and the potential physiological role of Cl.ir in the heart, however, are presently not known. The working hypotheses for this proposal are that 1) Cl.ir may be encoded by ClC-2 gene, a member of the large C1C Cl- channel family, since Cl. ir has many biophysical and pharmacological properties in common to those of CIC-2 channel when expressed in heterologous expression systems, and 2) ClC2 channels are important in the regulation of the electrical activity and cell volume adaptation in the heart. Three specific aims are proposed to address these hypotheses. Aim 1 will determine the molecular localization of ClC-2 and its correlation with functional Cl.ir distribution pattern in different regions in the heart and the cellular and subcellular (sarcolemmal or subsarcolemmal membrane) localization of ClC-2 channel protein. This information will also greatly facilitate our understanding of the physiological role of ClC-2 channels in heart since regulation of cardiac electrical activity is determined by the heterogeneity of ion channel distribution in different regions. Aim 2 will use combined molecular biological, electrophysiological, and pharmacological approaches to identify the molecular identity of cardiac Cl.ir channel. The results from the proposed experiments will determine whether ClC-2 is responsible for native Cl.ir channels and the resulting molecular clones will provide essential tools for the study of the basic features and the regulatory mechanism of native and recombinant ClC-2 channels at molecular, cellular, and single-channel levels. Aim 3 will characterize the contribution of CIC-2 Cl- channels to the modulation of cardiac electrical activity (including resting membrane potential, diastolic membrane potential, action potential duration and repolarization, automaticity, etc.) and the regulation of cell volume in the heart. Since activation of volume- and acidosis-regulated ClC-2 Cl- channels can produce significant effects on action potential duration and automaticity of both conducting and contractile cells, as shown in our new preliminary experimental data, these channels have important clinical significance for several heart diseases, such as
46
Acidosis
arrhythmias, myocardial ischemia, hypertrophy, and congestive heart failure and represent new important targets for the development of new agents against these diseases. This project has significant potential of elucidating the normal physiological and possible pathophysiological role of the newly discovered cardiac ClC-2 channels in the heart. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSIOLOGY OF ELECTROGENIC NA/HCO3 COTRANSPORTERS Principal Investigator & Institution: Boron, Walter F.; Cellular/Molecular Physiology; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-JAN-1982; Project End 30-NOV-2006 Summary: A major task of the kidney tubule is to reabsorb filtered HCO-3 and generate "new" HCO-3, thereby preventing a fatal metabolic acidosis. About 80 percent of HCO-3 reabsorption and generation occurs in the proximal tubule (PT), which secretes H+ into the tubule lumen, titrating HCO-3 to CO2 + H2O. After entering the PT cell, the CO2 + H2O regenerate HCO-3, which exits across the basolateral membrane via the electrogenic Na/HCO3 cotransporter (NBCe1-A). Since the Pl's laboratory reported the expression cloning of this cotransporter nearly 5 yrs ago, both "pancreatic" (NBCe1-B) and "brain" (NBCe1-C) splice variants have been identified. These cotransporters play key roles in HCO-3 transport by other epithelia, and in pHi regulation by many cell types. NBCe1 is part of the Bicarbonate Transporter (BT) superfamily, along with the C1-HCO3 exchangers (AEs), two other Na+ -coupled HCO-3 transporters (the electroneutral NBC and the Na+ -driven C1-HCO3 exchanger), related proteins not yet fully characterized, and at least one new gene (known from human genome sequence). The major goal of this project is to elucidate the molecular physiology of electrogenic NBCs, particularly in the kidney. An ancillary goal is to elucidate the expression of other Na+ -coupled HCO-3 transporters in key renal cell types. The proposed work has three aims: (i) Develop molecular tools. We will obtain the cDNA for a new NBCe-related sequence identified in the genome, extend our panel of type-specific antibodies, and determine the localization of Na+ -coupled HCO-3 transporters in the kidney. (ii) Determine properties of wild- type electrogenic NBCs. Using heterologous expression in oocytes, we will determine the function of two cDNA clones likely to encode electrogenic NBCs. We will also determine the stoichiometry of the electro-genic NBCs; assess their dependence on Na+, HCO-3 and pH; ask whether they transport CO=3; characterize the interaction between NBCe1 and carbonic anhydrase II; and examine the action of PKA on NBCe1 in oocytes. (iii) Analyze structure-function relationships. We will determine the structural requirements for extra- and intracellular DIDS sensitivity, ask whether conserved putative DIDS-reaction motifs are involved in electrostatic trapping of HCO-3, assess naturally occurring human NBCe1 mutations, explore the topology of NBCe1, and-in collaboration with another laboratory-study the biochemistry of the isolated cytoplasmic N termini of NBCe1-A and -B. The proposed work should elucidate the role that the electrogenic Na/HCO3 cotransporter plays in renal function, both in health and disease. The results could have important implications for understanding the normal control of acid-base balance and renal-tubule acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PILOT STUDY--HEPATIC STEATOSIS Principal Investigator & Institution: Tien, Phyllis C.; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747
Studies
47
Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 30-NOV-2007 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT STUDY--REGIONAL BLOOD FLOW IN FRESH WATER TURTLES Principal Investigator & Institution: Crocker, Carlos E.; San Francisco State University 1600 Holloway Ave San Francisco, Ca 941321722 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2006 Summary: The primary goal of this study is to increase understanding of the physiology of diving in North American freshwater turtles. This research will quantify how environmental hypoxia (severe < 50% oxygen saturation), and/or moderate hypoxia (75 - 50% saturation), which leads to hypoxic hypoxia, affects the cardiovascular system. Ischemic hypoxia can cause irreversible damage to tissues; the protection of brain and heart function during long-term submergence is critical to survival. Hypoxic hypoxia produces cardiac insufficiency and alters peripheral vascular resistance, and it is currently hypothesized that it results in significant changes in the regional distribution of cardiac output to the vital organs (e.g. brain, heart, liver), at the expense of non-vital tissues/organs (e.g. skeletal muscle, gastrointestinal tract). To test this hypothesis, experimental animals will be fitted with indwelling catheters and one or more surgically implanted ultrasonic flow probes, for the measurement of blood flow to specific organs/tissues during prolonged aquatic submergence. Periodic sampling from the indwelling arterial cannula will provide blood samples for analysis of physiologically important acid-base relevant ions, plasma stress hormone concentrations (primarily epinephrine and cortisol), blood gases (O2 and CO2) and pH. Overall, this research will show that systemic hypoxia, cold-induced metabolic depression, and the progressive metabolic acidosis associated with prolonged aquatic submergence results in preferential blood distribution that favors the vital organs over the 'less critical' tissue masses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PILOT--REGULATION OF RENAL PYRUVATE DEHYDROGENASE DURING ACIDOSIS Principal Investigator & Institution: Harris, Robert A.; Professor of Pharmacology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: The objective of this work is to establish the importance of regulation of the pyruvate dehydrogenase (PDH) complex in the kidney in maintenance of acid-base balance. Activity of the pyruvate dehydrogenase complex is regulated by covalent modification. Phosphorylation and inactivation of the complex is catalyzed by four pyruvate dehydrogenase kinase (PDK) isoenzymes; dephosphorylation by two pyruvate dehydrogenase phosphatase (PDP) isoenzymes. Unique regulatory properties of these isoenzymes and differences in their levels of expression in different cell types provide tissue specific control of the activity of the pyruvate dehydrogenase complex. The basis for this proposed work is our preliminary data indicating that two of the PDK isoenzymes, PDK2 and PDK4, are increased in the kidney by metabolic acidosis. We propose therefore that increased expression of these PDKs results in inactivation of pyruvate dehydrogenase complex, which promotes generation of new bicarbonate by
48
Acidosis
the kidney. Our working hypothesis is that alterations in the expression of the PDK2 and PDK4 isoenzymes cause hyperphosphorylation and therefore inactivation of pyruvate dehydrogenase complex in kidney during metabolic acidosis. The hypothesis will be tested by: (a) determining the effects of acute and chronic metabolic acidosis and alkalosis on activity state of the PDH complex and the expression levels of its kinases and phosphatases in rat kidney; (b) determining whether the compensatory mechanism for metabolic acidosis is abnormal in the kidney of the PDK4 null mouse; and (c) establish factors and mechanisms that regulate expression of PDK2, PDK4, and PDP2 in the kidney. The findings are expected to provide new insight with respect to an important compensatory mechanism for life threatening metabolic acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEIN NUTRITION IN EXPERIMENTAL UREMIA Principal Investigator & Institution: Mitch, William E.; Professor; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2002; Project Start 01-SEP-1987; Project End 30-NOV-2005 Summary: Uremia is often associated with weight loss, reduced muscle mass and a low serum albumin. Our long-term goal is to identify cellular mechanisms causing protein malnutrition in uremia to improve treatment. In rats with chronic renal failure (CRF), we identified metabolic acidosis as a stimulus for accelerated muscle protein degradation. This proteolytic response was confirmed in patients and is now vigorously treated to improve their nutritional status but the mechanism(s) underlying muscle catabolism is unknown. Factors that we identified as activators of the ubiquitinproteasome (Ub-P'some) Proteolytic pathway in muscle are a low extracellular pH, glucocorticoids and a low insulin level. Important problems to be solved are: first, myofibrillar proteins are not degraded and adding actin blocks myosin degradation by the Ub-P'some system. Our Preliminary Results indicate that the protease, caspase 3, is induced by acidification and plays a role in the early stages of muscle cell proteolysis by degrading myofibrillar proteins and actin to a stage where degradation proceeds via the Ub-P'some pathway. A second problem is how to integrate multiple signals that can activate the Ub-P'some system. We propose that depressed phoshatidylinositol 3-kinase (PI 3-kinase) is a key step as: we find CRF reduces muscle PI 3-kinase activity and insulin (or IGF- 1) blocks caspase 3 activation in muscle cells. A third problem is to understand how signals that initiate muscle proteolysis invariably stimulate transcription of genes encoding components of the Ub-P'some pathway. Since clinical evidence suggests an important role for TNFalpha in causing muscle wasting in CRF, we will examine the opposing actions between glucocorticoids and a TNFalphainducible transcription factor, NF-kB, on transcription of the C3 proteasome subunit to understand the requirement for glucocorticoids in stimulating transcription in many catabolic conditions. Finally, we will examine how TNFalpha influences protein degradation in muscle of CRF rats and in cultured muscle cells. Our results will uncover cellular mechanisms regulating protein turnover in uremia and other catabolic conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REENTRANT WAVEFRONTS IN VENTRICULAR FIBRILLATION Principal Investigator & Institution: Chen, Peng-Shen; Director, Pacemaker and Icd Clinic; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024
Studies
49
Timing: Fiscal Year 2002; Project Start 01-JAN-2002; Project End 31-DEC-2002 Summary: Sudden cardiac death due to ventricular fibrillation (VF) is an important public health problem. However, our understanding of VF is limited. The broad, longterm objective of this research project is to elucidate the mechanisms of the generation and the maintenance of reentrant wavefronts in VF. The applicant has previously reported that the reentrant wavefronts are responsible for the generation VF in the canine model. In this grant application, the applicant proposes to study the reentrant wavefronts in VF both in vivo and in vitro. Computerized mapping studies will be performed in human patients and in dogs to document that reentrant wavefronts are present in Wiggers' stage II VF. Computerized mapping techniques and standard transmembrane microelectrode recording techniques will be used to study a novel in vitro model of sustained reentry. The following hypotheses will be tested: (1) Multiple reentrant wavefronts are present during Wiggers' stage II VF in humans, in normal healthy dogs, and in acutely ischemic dogs. (2) The reentrant wavefront circulates around an area of functional conduction block (the 'core' of reentry) formed by cells undergoing graded responses but not full action potentials. There is no anatomical barrier at the core of reentry. (3) In normal tissue, the cycle length of the reentrant wavefront is longer than the wavelength of the reentrant wavefront. Therefore, an excitable gap is present. (4) The size of the core and the duration of the excitable gap are both important in determining the generation and maintenance of reentry. (5) Perturbations that decrease the size of the core decrease the volume of tissue that is needed to support a reentrant wavefront. Therefore, the smaller the size of the core, the easier to induce multiple reentrant wavefronts and VF. (6) Perturbations that decrease the excitable gap can protect the reentrant wavefronts from termination by competing wavefronts. Therefore, the smaller the excitable gap, the longer the life-span of the reentrant wavefronts, and the easier for VF to sustain itself. (7) The size of the core and the excitable gap of the reentrant wavefronts are both decreased by ischemia, predisposing the heart to ventricular fibrillation in this setting. These studies will further our understanding of the basic mechanisms of the generation and maintenance of VF in humans, and lead to new insights into prevention and treatment of sudden cardiac death. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF KIDNEY MEMBRANE ION CHANNELS Principal Investigator & Institution: Boulpaep, Emile L.; Professor; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: The proposed studies plan to characterize channels, in particular chloride channels, in cell membranes of proximal tubule cells, from kidneys of rabbit, salamander, or CFTR knockout mouse, using a combination of isolated perfused tubules, non-perfused renal tubules, and separated single cells that have preserved their epithelial polarity. Patch-clamp and optical techniques will be used. The specific aims are: 1. To test the hypothesis that the chloride channel in the basolateral membrane of the proximal tubule cells share many of the intrinsic properties of the cystic fibrosis transmembrane conductance regulator CI- channel, we will study the biophysics and kinetics of chloride channels in mammalian proximal tubule and the intracellular signal transduction pathways involved in their regulation. 2. To test whether the gating of the basolateral chloride channel in proximal tubule cells by hydrolytic and non-hydrolytic interactions of ATP is analogous to that of the CFTR CI-channel. 3. To test the hypothesis that the basolateral chloride channel in proximal tubule cells regulates
50
Acidosis
transcellular chloride reabsorption by the proximal tubule, and that alterations of apical chloride uptake indirect modulate the function of the basolateral chloride channel. 4. To explore the alternative pathways for transcellular chloride movement in proximal tubules of a CFTR-knockout mouse. Although the kidney expresses CFTR, there appears to be no impaired ion transport in patients suffering from cystic fibrosis. We will use a CFTR-knockout mouse, in order to establish how chloride channels contribute to transcellular chloride movement, and whether there is a regulatory relationship between CFTR and other chloride pathways. 5. To test the hypothesis that epithelial polarity in dissociated cells is not maintained by intrinsic proteins associated with the tight junction, we will study a model of a proximal tubule cells, that maintains epithelial polarity for us to ten days, and examine the cytoskeletal interactions that are essential for preserving polarity. The overall scope of the project is to understand transepithelial solute movement by the kidney at the single cell membrane and single channel protein level and to contribute to the understanding of clinical disorders such as cystic fibrosis, hypertension, metabolic alkalosis, acidosis, and acute renal failure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RENAL AND SYSTEMIC PH IMAGING BY CONTRAST-ENHANCED MRI Principal Investigator & Institution: Raghunand, Natarajan; Assistant Research Assistant; None; University of Arizona P O Box 3308 Tucson, Az 857223308 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAR-2005 Summary: (provided by applicant): This proposal seeks to develop a contrast-enhanced magnetic resonance imaging (MRI) method for imaging extracellular pH of tissues in vivo, with special emphasis on the kidneys. Perturbations of both renal and systemic pH may accompany diseases of the kidney such as renal tubular acidosis. The ability to image tissue pH, particularly renal pH, would be helpful to assess the extent and severity of such conditions, and also to non-invasively follow response to therapy in the affected tissue(s). GdDOTA-4AmP is a gadolinium-based MRI contrast agent with a pHdependent longitudinal water-proton relaxivity. As with all other Gd-based contrast agents, the enhancement in water-proton relaxation rate produced by GdDOTA-4AmP is also dependent on its local concentration. In order to measure pH in vivo using GdDOTA-4AmP, one needs an independent measure of its pharmacokinetics in the animal being imaged. We propose a dual-contrast-agent strategy to image pH, in which GdDOTA-4AmP and a pH insensitive analogue, GdDOTP, are sequentially injected into the animal 1 h apart, with T1-weighted MRI images being dynamically collected following both injections. In preliminary experiments in mice we have made the assumption that the pharmacokinetics of GdDOTP and GdDOTA-4AmP are identical in a given animal, based on the similar size and charge of the two molecules. We have calculated preliminary pH images of the kidneys and surrounding tissues which distinctly show regions of acid pH corresponding to the collecting ducts, and pH 7.0-7.4 in other regions of the kidneys, in control mice. pH images of an acetazolamide-treated mouse showed an increase of 0.5-1.0 pH units in all renal pixels, with an apparent decrease of pH in extra-renal pixels, as compared to control mice. The goal of this proposal is to refine this dual-contrast-agent strategy for pH imaging using GdDOTA4AmP and GdDOTP, and to characterize and minimize sources of error in the pH measurement. The specific aims of this proposal are three-fold: (i) To optimize the dualcontrast-agent technique for imaging renal pH; (ii) To optimize the dual-contrast-agent technique for imaging pH of non-renal tissues; (iii) To devise a compromise protocol for
Studies
51
optimally imaging pH of renal and non-renal tissues in the same experiment, and apply it to measure dose vs. pH response in mice with acetazolamide-induced acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RENAL CONTRANSPORTER
NET
ACID
SECRETION
AND
THE
NA/K/2C1
Principal Investigator & Institution: Wall, Susan M.; Professor; Internal Medicine; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2002; Project Start 01-APR-1993; Project End 31-JAN-2004 Summary: Two distinct genes (BSC-1 and BSC-2) encode the NA/+-K/+-2CI- cotransporter. BSC-1, or the "absorptive isoform", is kidney-specific and localizes to the apical membrane of the thick ascending limb. BSC-2, the "secretory" isoform, is widely distributed BSC-1 is responsible for the "single effect" of the countercurrent multiplier, and thereby generates an axial gradient in the medullary interstitium for ammonium and other solutes, facilitating net acid secretion and urinary concentration. In the thick ascending limb, NH/4 uptake by the Na/+-K/+-2CI-co-transporter (BSC-1) is highly regulated. Since BSC-2 localizes to the basolateral membrane of the rat alpha intercalated cell and since it is both an NH/4 amd a CO/transporter, it likely mediates net acid secretion. However, regulation of BSC-2 in the kidney and its role in net acid secretion are untested. Regulation of net CI- and H/+ secretion by the collecting duct requires transport of these ions to be regulated in parallel across the apical and the basolateral membrane of the collecting duct cell. With perturbations in acid-base balance such as chronic metabolic acidosis an increase in apical proton secretion is observed which results from up- regulation of the apical H/+-ATPase in parallel with the basolateral CI- HCO/3-exchanger. However, in the rat contribution of CI-/HCO/3exchange to transepithelial net acid and CI-secretion has not been established. Thus, another mechanism for net H/+ and/or CI-uptake across the basolateral membrane may be important in mediating or modulating transepithelial net acid secretion. We will determine the contribution of BSC-2 to transepithelial net acid and net CI-secretion. Moreover, we will determine if activity of the co-transporter is modulated in a fashion appropriate for correction of perturbations in acid-base balance. With the recent cloning of both isoforms of the co-transporter, the published structure has been exploited to raise antibodies against co-transporter peptides. These antibodies can be used to study the long term regulation of the co-transporter. Changes in protein immunoreactivity and mRNA can be correlated with changes in transport activity to determine the role of the co-transporter in acid-base homeostasis. Specific Aims are to determine the following in the rat OMCD: 1. If BSC-2 modulates net acid secretion through direct NH/4+ uptake. 2. If BSC-2 is a major contributor to transepithelial net CI- secretion. 4. To determine the mechanism of BSC-2 transport regulation. To answer these questions, isolated renal tubules perfused in vitro will be studied. Transport will be studied with microfluorimetry as well as pH sensitive fluorescent probes. Transporter immunoreactivity and message abundance will be studied using immunoblots, immunocytochemistry and RT PCR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESTORATION REHABILITATION
OF
MUSCLE
FUNCTION
DURING
Principal Investigator & Institution: Vandenborne, Krista H.; Chair and Associate Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104
52
Acidosis
Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2003 Summary: The purpose of this study is to investigate the spatial distribution of brain lactate in children with lactic acidosis using 1H spectroscopic imaging. Brain lactic acidosis may occur in a number of very different conditions. Inborn errors of metabolism affecting the lactate-pyruvate metabolism or those leading to secondary lactic acid accumulation represent some of them. Data are acquired using either a hybrid of 1D, 4th order, transverse Hadamard Spectroscopic Imaging (HSI) and a 2D Chemical Shift Imaging (CSI) or a 2D CSI. With the hybrid technique multiple slices can be obtained, covering a greater volume of the brain. The volume of interest usually is 7x7x4 cm3. We apply this technique into the clinical setting. The patient population consists of children with the diagnosis of an inborn error of for instance the lactate metabolism, mitochondrial encephalopathies, primary lactic acidosis of unknown etiology. Data obtained in several patient studies revealed regional differences of brain lactate accumulation. The pattern of spatial distribution of lactate may identify different subsets of mitochondria which can be affected separately by different metabolic diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE EXCHANGERS
AND
REGULATION
OF
INTESTINAL
SODIUM/H+
Principal Investigator & Institution: Chang, Eugene B,.; Martin Boyer Professor of Medicine; Medicine; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2002; Project Start 01-JUL-1986; Project End 31-MAR-2003 Summary: Intestinal epithelial cell Na-H exchanger (NHE) isoforms have very specialized functions, regulatory systems, cellular distribution, and regional patterns of expression which are inherently important in adapting to acute and chronic metabolic demands and changes in liminal Na load. Until now, the regulation of NHE isoforms has largely been studied in mutant, NHE-deficient, non-epithelial cells where some findings, particularly with the epithelial-specific NHE-2 and NHE-3 isoforms, substantially differ from NHE function and regulation in intact enterocytes. These isoforms are believed to be the major route for non-nutrient dependent Na absorption by the gut. Therefore, the goal of this proposal is to test the hypothesis that the role and regulation of intestinal epithelial NHE isoforms are unique and best studied in intestinal epithelial cells in vivo and in vitro. The first Specific Aim is to characterize the role of intestinal epithelial NHEs in mediating the adaptation of intestinal Na absorption following massive small bowel resection and chronic metabolic acidosis in the rat. Preliminary studies show striking isoform-, region-, and cell-specific changes in NHE function and expression in response to these conditions. Additional studies will be performed to define the cellular and molecular bases for these adaptive responses. Potential determinants of the adaptive changes in the NHE expression, i.e. alterations in Na luminal load or metabolic/hormonal perturbations, will be experimentally assessed. In Specific Aim #2, Caco-2/C2BBE (C2) intestinal epithelial cell monolayers will be used to examine specific mechanisms of NHE function, regulation, and expression in response to extracellular metabolic perturbations and stimuli. C2 cells spontaneously differentiate in culture, have endogenous NHE-1, but little apical NHE expression, and, when transfected with NHE-2 or NHE-3, demonstrate correct sorting and functional and regulatory characteristics of these proteins that correlate with observations made in native enterocytes. NHE isoform activities expressed in C2 cells can also be separately measured. The roles of protein phosphorylation, membrane recycling, post-translational modifications, and potential regulatory roles of NHE binding proteins in mediating NHE responses to hormonal stimuli, luminal Na load, metabolic acidosis, and states of
Studies
53
cellular differentiation will be examined. These studies will provide important insights into the gut-specific cellular and molecular mechanisms for regulation of intestinal epithelial NHEs and into physiologically-relevant mechanisms mediating the Na absorptive response of the gut to acute and chronic metabolic perturbations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF ACID-SENSING ION CHANNELS IN GLAUCOMA Principal Investigator & Institution: Saugstad, Julie A.; Emanuel Hospital and Health Center Portland, or 972083950 Timing: Fiscal Year 2004; Project Start 01-DEC-2003; Project End 30-NOV-2006 Summary: (provided by applicant): Glaucoma comprises a group of ocular disorders that exhibit characteristic optic nerve degeneration (glaucomatous optic neuropathy, GON), associated with concomitant visual field loss, and often, increased intraocular pressure (lOP). In many individuals, reduction of lOP ameliorates vision loss, but many others continue to lose vision despite pressure lowering. There are no therapies that directly target and prevent GON. While the exact underlying mechanisms of GON are being elucidated, specific patho-physiological changes (such as mechanical trauma and ischemia) ultimately lead to the death of retinal ganglion cells and their axons. We have directed our attention to a newly discovered family of proteins; acid-sensing ion channels (ASICs), which appear to be significant in brain injury. The ASICs are protonactivated sodium selective cation channels comprised of six subtypes that are expressed throughout the nervous system. They respond to acidic and mechanical stimuli activating in response to acidosis and swelling, notable features of ischemic brain injury. Recent studies reveal that rabbit retinal neurons and gila express ASIC messenger RNA. Thus ASICs could respond to mechanical stimulation in the eye from increased intraocular pressure and/or ischemic changes within the retina and optic nerve, two mechanisms commonly implicated in the pathogenesis of GON. These findings make retinal ASICs attractive cellular mediators for investigation. Our preliminary studies support a role of ASICs in the retina: immunoblot analysis of the ASIC2a subtype reveals a dramatic increase in expression in the retina and optic nerve of glaucomatous human tissue relative to age-matched controls. Upregulation of brain ASIC2a may be important for cell survival as cells expressing ASIC2a are less responsive to injury. Our laboratory has shown that neurons that survive an ischemic insult have increased levels of ASIC2a protein, suggesting a neuroprotective role for ASIC2a. This prediction is supported by the observation that ASIC2a alters the ion channel activation properties when it is complexed with ASICla, a subtype that is implicated in cell injury. Cells expressing homomeric ASICla channels are injured by low pH and modeled ischemia, while heteromeric ASICla/2a channels are less vulnerable to injury. Physiological studies lend insight into this finding; the pH of half-maximal activation (pHo.s) for ASIC2a channels is 4.35, for ASICla channels is 6.2, whereas ASICla/ASIC2a heteromeric channels is 4.8. This could be significant in the context of injury, where intracellular calcium overload has been implicated as a primary mechanism of neuronal injury. The goal of these studies is to characterize fully the expression of ASIC2a in the retina and optic nerve of normal and glaucomatous tissue, and to determine whether ASIC2a enhances cell survival in response to injury and could potentially serve as a therapeutic target for the treatment or prevention of glaucoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
54
•
Acidosis
Project Title: SENSITIZATION TO THERMORADIOTHERAPY IN HUMAN XENOGRAFTS Principal Investigator & Institution: Leeper, Dennis B.; Professor; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 31-MAR-2007 Summary: Project 1 serves the program by testing the hypothesis that acute acidification by lactic acidosis will enhance thermosensitization and selectively sensitize melanoma xenografts to radiotherapy. Protocols were established for acute acidification to less than or equal too pH3 6.3 and oxygenation of melanoma has uniquely high activity of H+ linked monocarboxylate transporters (MCT, a.k.a. lactate symport) that are the major membrane proton exchange. Although thermosensitization by acidification was demonstrated, radiation must be combined with hyperthermia to achieve local control. Five specific aims will test the hypothesis and investigate mechanisms of melanoma acidification. Aim 1 will investigate inhibition of mitochondrial respiration by metaiobenzylguanidine (MIBG) on melanoma acidification and oxygenation for sensitization to thermoradiotherapy. Variation in glycolytic/respiratory ratio among frozen melanoma biopsy cell suspensions will indicate relative susceptibility to MIBG. Aim 2 will investigate inhibition of the MCT either by alpha-cyano-4-hydroxy-cinnamic acid (CNCn) or by Ionidamine on acidification of melanoma and sensitization to thermoradiotherapy. The activity of the plasma membrane MCT among stored melanoma biopsy cell suspensions will indicate relative susceptibility to CNCn or Ionidamine. Aim 3 will identify the utility of combining MIBG and CNCn as a cocktail to acidify and oxygenate all melanomas. Melanomas with high rates of respiration will be sensitive to MIBG, and those with high rates of glycolysis sensitive to CNCn. In each protocol excess glucose must be combined with inhibitors to fuel lactate production. Two different F2 melanomas xenografts in nude mice will be studied that differ in vascularity, radiation sensitivity and expression of heat shock proteins. Tumor growth delay will be compared with tibial bone marrow toxicity to establish therapeutic gain. Cellular radiation response parameters in vitro will be determined in Project 3. Project 1 provides mice with melanoma xenografts to Project 2, so that together with Core A, biological endpoints can be investigated to predict response of melanomas and normal tissues to treatment pH9, pHi, 23Nai, pO2, oxygen consumption, bioenergetics and blood flow. Aim 4 supports Project 3 to determine the effect of acute acidification on apoptosis and the relationship with hyperthermia-induced upregulation of hsp70 in DB1 xenografts grown up from cell stably transfected with the gene for enhanced green fluorescent protein (egfp) under control of the hsp70 promoter. Aim 5 with Project 3 supports Project 4 to confirm whether nucleolin translocation is a determinant of heat response in vivo by measuring nucleolin movement from the nucleolus into the nucleoplasm in DB-1 xenografts as a function of acidification during hyperthermia. Acute tumor acidification will have the clinical effect of increased tumor temperature with additional benefit from increased tumor oxygenation. These results will help direct a Phase I/II trial conducted by Dr. Douglas Fraker, Univ. of Penn. To demonstrate the effects of acidification of melanoma response to limb perfusion with melphalan at 42 degrees Centigrade. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
55
Project Title: SEVERE MALARIA IN AFRICAN CHILDREN: A CLINICAL NETWORK Principal Investigator & Institution: Taylor, Terrie E.; Distinguished University Professor; Internal Medicine; Michigan State University 301 Administration Bldg East Lansing, Mi 48824 Timing: Fiscal Year 2002; Project Start 30-SEP-1999; Project End 31-JUL-2004 Summary: Malaria remains a major scourge in sub-Saharan Africa, killing 1-2 million children each year. Major advances in our understanding of disease pathogenesis have occurred, along with the emergence of drugs which kill the malaria parasite twice as rapidly quinine, the current drug of choice--- but the mortality rate for severe malaria has not changed. Between 15-40% of children with cerebral malaria, malaria-associated acidosis and/or severe anemia will die, and half of those deaths occur within 12 hours of arriving at a hospital. Five clinical centers with much experience of severe malaria in African children have joined together to form a clinical trials network (SMAC). Individually frustrated by our own attempts to demonstrate any impact of promising interventions on malaria mortality, we have decided that our fundamental goal, to lower the death rate associated with severe malaria in African children, would be best realized by conducting mortality-based multi-center studies. This approach is necessary because there are no surrogate markers for outcome deaths in any one site are rare We are proposing to evaluate fluid resuscitation in children with malaria complicated by acidosis, and pentoxifvrnne (PTX) as adjunct therapy in children with cerebral malaria. Both of these require pilot studies (1 year) prior to the larger clinical trials. Our network is also well-positioned to evaluate "disease associations" which may illuminate pathogenetic processes or reveal potential new targets. Because it is simple to assess and because there are plausible biological and parasitological implications, we would like to determine the predictive value of intraleukocvtic DiQment in children with P. falciparum infections. This study will be part of an ongoing network activity, describing the malaria experience in each site using standardized information collected prospectively and archived in a database. The statistical and administrative "cores" will facilitate the efforts of the network. Data will be entered at each site and transmitted to a central facility (at one of the five sites) for analysis. There will be an annual SMAC meeting, and the intervals between meetings will be punctuated by frequent visits between sites so that young investigators can standardize their observations and experience other settings. This capacity to conduct multi-center trials in severe pediatric malaria has not existed before. The statistical power of a large group can unearth even a small decrease in mortality associated with a particular intervention. Given the enormous toll of malaria, this could re resent a significant decline in the death rate across sub-Saharan Africa. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRUCTURE AND FUNCTION OF MITOCHONDRIAL PROTEIN KINASE Principal Investigator & Institution: Chuang, David T.; Associate Professor; Biochemistry; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2003; Project Start 15-FEB-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The long-term goal of this project is to understand the structure and function of a novel family of mitochondrial protein kinases (mPKs). The mPK members consist of branched-chain alpha-ketoacid dehydrogenase kinase (BCK) and the four isoforms of pyruvate dehydrogenase kinase. They are molecular
56
Acidosis
switches that down-regulate the oxidation of alpha-ketoacids and pyruvate. Elevated levels of these metabolites are implicated in disease states such as insulin-resistant Type II diabetes, branched-chain ketoaciduria, and primary lactic acidosis. BCK is a component of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. This macromolecular multi-enzyme complex is organized about a 24-meric transacylase (E2b) scaffold, to which a decarboxylase (Elb), a dehydrogenase (E3), the BCK and the BCKD phosphatase are attached through ionic interactions. The P.I.'s laboratory has recently determined the structure of the rat BCK. The BCK structure features a characteristic nucleotide-binding domain and a four-helix bundle domain. These two domains are reminiscent of modules found in protein histidine kinases (PHKs), which are involved in two-component signal transduction systems. In this application, the P.I. proposes: 1) to identify and characterize the domains/regions in BCK, which interact with Elb (the substrate) and E2b (the regulator) components of the BCKD complex; 2) to decipher the functional significance of nucleotide-induced domain communication in BCK; 3) to elucidate the reaction mechanisms for the BCK-catalyzed ATP hydrolysis and phosphotransfer in BCK. The information derived from the proposed studies will provide mechanistic insights into the regulation of alpha-ketoacid dehydrogenase complexes by reversible phosphorylation. This knowledge will have wide implications for understanding conservation in the reaction mechanism for protein kinases involved in signal transduction as well as how this mechanism is perturbed in human diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SUBUNIT STRUCTURE AND FUNCTION IN VACUOLAR H+ATPASE Principal Investigator & Institution: Kane, Patricia M.; Professor; Biochem and Molecular Biology; Upstate Medical University Research Administration Syracuse, Ny 13210 Timing: Fiscal Year 2003; Project Start 01-MAR-1994; Project End 31-MAY-2007 Summary: (provided by applicant): Vacuolar proton-translocating ATPases (V-ATPases) couple hydrolysis of cytosolic ATP to proton transport into organelles of all eukaryotic cells and across the plasma membrane of some cell types. Organelle acidification, the major constitutive function of V-ATPases, is essntial for many physiological processes, but is also linked to a number of disease states. For example, acidification of phagosomes is essential for killing invading bacteria, but many viruses and toxins exploit the acidic environment generated by V-ATPases to facilitate their escape from organelles into the cytoplasm where they become biologically active. Plasma membrane V-ATPases are involved in renal acid secretion and osteoclast bone dissolution; mutations in tissue-specific V-ATPase subunit isoforms necessary for these processes result in genetic diseases characterized by metabolic acidosis and osteoporosis. The long-term goal of the lab is to understand the structure, function, assembly and regulation of V-ATPases by studying the yeast V-ATPase, which has proven to be an excellent model for all eukaryotic V-ATPases. All V-ATPases are composed of two multisubunit domains, a peripheral membrane complex involved in ATP hydrolysis and an integral membrane complex required for proton transport. In this proposal, we focus on the "stalk" subunits that structurally and functionally bridge these two domains. These subunits are responsible for transmission of conformational changes resulting from ATP hydrolysis to the proton pore, and are also key players in regulated disassembly of V-ATPases, an important regulatory mechanism. The aims of this proposal are: 1) to position the stalk subunits in the yeast V-ATPase, by a combination of
Studies
57
electron microscopy, hydrodynamic studies of subcomplexes, mutagenesis, and crosslinking experiments, 2) to elucidate the roles of the C and H subunits, particularly in the functionally important conformational change accompanying release of the peripheral sector from the membrane sector, 3) to examine protein-protein interactions with two isoforms of the "a" subunit and test their importance in regulated disassembly, and 4) to follow V-ATPase assembly and disassembly in vivo using GFP-tagged VATPase subunits. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THEORY OF SOLUTE AND WATER TRANSPORT ACROSS EPITHELIA Principal Investigator & Institution: Weinstein, Alan M.; Professor of Medicine and Physiology; Physiology and Biophysics; Weill Medical College of Cornell Univ New York, Ny 10021 Timing: Fiscal Year 2003; Project Start 01-AUG-1981; Project End 31-JAN-2006 Summary: A mathematical model of the mammalian distal nephron will be developed, comprised of cellular models of ascending Henle limb, distal tubule, and collecting duct. The model will represent sodium, potassium, and acid/base transport under normal and pathological conditions, and will predict renal excretion from distal delivery. The project begins with models of the three collecting duct segments; it will require development of two distal tubule segments plus an ascending limb, and then concatenation of all segments into a distal nephron. The segmental models will incorporate representations of specific membrane transporters: in distal tubule, the NaCI cotransporter, and in ascending limb, the luminal Na-K-2CI and peritubular K-CI cotransporters. Segment-specific issues, as well as segmental interactions will be considered. For the collecting duct, proposed lesions underlying distal renal tubular acidosis (ATPase failure, base-exit defects, or paracellular leak) will be examined, and clinical tests for identifying these lesions will be simulated. In this, the objective is to examine the rationalization for the clinical taxonomy of distal tubular acidosis. The distal tubule model will be used to examine flow- dependence of potassium secretion, to estimate the component attributable to luminal gradient attenuation. This will be preliminary to quantifying the alkalinizing and potassium-wasting effect of thiazide diuretics, which act on distal tubule. In the ascending limb, an important focus will be identifying the modulated transporters responsible for cellular homeostasis, specifically, mechanisms used to accommodate large reabsorptive fluxes of sodium and ammonium, while preserving cell volume and pH. In ascending limb, the three different transport defects which all present as Bartter's syndrome will be simulated, to understand the potassium depletion alkalosis common to all three. The full distal nephron model will be required to critically examine the proposal that medullary interstitial potassium concentration modulates overall renal potassium and acid excretion: namely, that by blunting ascending limb sodium reabsorption, peritubular potassium sends more sodium to distal tubule and collecting duct where potassium secretion and base reabsorption depend on sodium delivery. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TISSUE SPECIFIC NUTRITIONAL ADAPTATIONS IN RENAL FAILURE Principal Investigator & Institution: Price, S Russ.; Associate Professor; Medicine; Emory University 1784 North Decatur Road Atlanta, Ga 30322
58
Acidosis
Timing: Fiscal Year 2002; Project Start 01-AUG-1996; Project End 31-MAY-2004 Summary: The essential branched-chain amino acids (BCAA) play critical roles in maintaining normal protein homeostasis and they influence critical intracellular signaling pathways that regulate metabolic functions. In normal individuals, nutritional adaptations to a reduced dietary protein intake (e.g., fasting, a low protein diet prescription) decrease the irreversible degradation of BCAA. Catabolic conditions like chronic renal failure (CRF) or acute diabetes impair these adaptive responses that preserve protein mass, thus contributing to the loss of lean body mass. The goals of Dr. Price and colleagues are to understand the mechanisms that regulate the activity of branched-chain alpha-ketoacid dehydrogenase (BCKAD), the rate-limiting enzyme in BCAA degradation, in the major tissues where BCAA are catabolized, and to determine if there are common signals in different catabolic states that regulate BCKAD activity, and hence, BCAA levels. To address these goals, the investigators will evaluate three hypotheses: 1) Acidification and glucocorticoids influence transcription of BCKAD subunit genes through specific cis-acting response elements. The investigators will identify specific DNA promoter elements in the BCKAD E2 gene that confer responses to acidification and glucocorticoids. 2) Abnormalities in BCAA utilization in rats with CRF result from tissue-specific alterations in BCKAD activity at both genetic and biochemical levels. The investigators will define how CRF influences the activities of BCKAD and BCKAD kinase, a unique kinase that inhibits BCKAD activity, in muscle, liver and kidney in a well-established rat model. They will measure BCKAD activity, BCKAD subunit and kinase proteins and amounts of subunit and kinase mRNAs 3) Insulin modulates BCKAD and/or BCKAD activities in different tissues by a mechanism requiring the critical signaling enzyme phosphatidylinositol 3-kinase. The investigators will determine the biochemical mechanism(s) that increase BCKAD activity in rat muscle, liver and kidney in response to acute diabetes mellitus (i.e., insulin insufficiency) and then examine the signaling mechanisms by which insulin regulates BCKAD and BCKAD kinase in cultured L6 muscle cells. The investigators findings will define cellular mechanisms regulating BCAA degradation in uremia, acute diabetes and other catabolic conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS Principal Investigator & Institution: Burge, Mark R.; Assistant Professor; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TROPONIN AND HEART FUNCTION IN HEALTH AND DISEASE Principal Investigator & Institution: Metzger, Joseph M.; Professor; Molecular and Integrative Physiology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 08-DEC-1997; Project End 31-AUG-2006 Summary: (provided by applicant): This grant is focused on cardiac troponin I (cTnl), an essential protein of the cardiac sarcomere. Transgenic mouse studies have given conflicting results as to whether Tnl phosphorylation plays any role in the increased rate of myocardial relaxation during adrenergic stimulation. In addition, a major theme of this proposal is that heart function differs markedly between rodents and higher
Studies
59
mammals due to key differences in contractile isoforms and calcium handling. Consequently, results obtained from transgenic experiments may not necessarily translate to cardiac myocytes that have more "human-like" functional properties. The working hypothesis of this proposal is that cTnl phosphorylation status has an important role in the relaxation rate of canine myocytes that more closely resemble the functional properties of human cardiac muscle. Additionally, the acidosis accrued in myocardial infarction depresses cardiac function in part by altering Tnl function. The working hypothesis is that a charged amino-acid motif in the C-terminus of cTnl defines the critical switch domain responsible for acidic pH-induced alterations in Tnl function in myocytes from both small and large mammals. We have developed and optimized a gene transfer/primary culture system that takes advantage of the broad j species tropism of adenoviral vectors to accomplish rapid and efficient replacement of Tnl in living adult cardiac myocytes isolated from functionally divergent mammals. This technology is unique in the field as it allows rapid genetic engineering of TnI in living cardiac myocytes with "human-like" contractile function. The Specific Aims are: Aim 1. To compare in adult cardiac myocytes from small and large mammals the direct effects of b-adrenergic-mediated Tnl phosphorylation on contractile performance. Aim 2. To compare transgenesis versus gene transfer, focusing on the functional effects of phospho-mimetic Tnls in adult cardiac myocytes. Hypothesis: In comparison to wildtype rodent cardiac myocytes, myocytes expressing a phosphorylation mimetic cTnI (Ser23/24Asp) obtained by transgenesis or gene transfer will exhibit desensitization of calcium-activated isometric tension and enhanced relaxation kinetics. Aim 3. To establish in a range of mammalian myocytes, the molecular basis for Tnl-isoform dependent altered calcium sensitivity of tension under normal and acidic pH conditions. Hypothesis: A highly charged and isoform variable motif in the C-terminus of Tnl defines the acidic pH-mediated decrease in tension in all mammalian species. Collectively, these studies will provide new information about Tnl function in cardiac myocytes from large versus small mammals, and will help identify new potential therapies for enhanced myofilament function in diseased myocardium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: UTILIZING ETHYL NITRATE GAS IN LAPAROSCOPIC SURGERY Principal Investigator & Institution: Reynolds, James D.; Anesthesiology; Duke University Durham, Nc 27710 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: The principal goal of this project is to evaluate the ability of ethyl nitrate to attenuate the reduced tissue perfusion and respiratory acidosis produced during carbon dioxide pneumoperitoneum. The studies will use a novel method of drug delivery: inclusion of ethyl nitrate in the insufflating gas. Laparoseopy has rapidly become the method of choice for surgical intervention to correct abdominal pathologies. However, pneumoperiteneum, the act of insufflating the peritoneal cavity with gas, is not without physiologic consequence: pulmonary function is impaired and organ blood flows altered. In addition, due to its plasma solubility, insufflation with CO2 will increase pCOz and decrease blood pH, actions that can produce respiratory acidosis, tachycardia, and arrhythmia. The overall effects can become profound in the presence of underlying vascular disease, in[ the elderly, if the patient is pregnant, and/or when the duration of surgery is extended. In all situations, tissue ischemia and fetal ischemia (where applicable) can produce significant morbidity. To control this, it is a logical supposition that administration of a vasoactive agent to increase tissue blood flow and gas exchange would be beneficial. For the purposes of this study, we propose to
60
Acidosis
introduce a nitric oxide donator (ethyl nitrate; E-NO) into the insufflating gas. As the released nitric oxide can act locally (i.e. within the peritoneum) as well as entering the systemic circulation and, in the case of the gravid patient, the fetal circulation (either by diffusion or maternal-fetal exchange), this would appear to be an ideal methodology to abate the CO2 pnenmoperiteneum-mediated changes in physiologic status. Such abatement is expected to be of long-term benefit to all laparoscopic patients including the parturient and her fetus. To evaluate this novel therapy, we will test two research hypotheses: 1. In the non-gravida, inclusion of E-NO in the insufflating gas attenuates the tissue perfusion changes produced by CO2 pneumoperitoneum; and 2. In the parturient, inclusion of E-NO during maternal pneumoperitoneum stabilizes fetal physiologic status. Studies will utilize adult swine and pregnant sheep. Completion of this investigation will produce clinically-relevant information that will be of significant interest to surgeons With patients in need of laparoscopic surgery and to obstetricians who are presented with parturients in abdominal distress. It is expected that the results of these studies will be used to further develop and refine standards of care for human laparoscopy and will lead to a novel therapy for controlling the blood flow changes produced during pneumoperitoneum. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VASCULAR KATP CHANNEL MODULATION IN HYPERCAPNIC ACIDOSIS Principal Investigator & Institution: Jiang, Chun; Associate Professor; Biology; Georgia State University University Plaza Atlanta, Ga 30303 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): ATP-sensitive K+ channels (KATP) couple the intermediary metabolism to cellular excitability, and play an important role in reactive hyperemia. It is known that hyperemia underlies the cardio-protective effect of ischemic preconditioning and the activity-dependent auto-regulation of cerebral circulation, and involves sensing of O2, CO2 and pH. Our recent studies indicate that KATP channels are indeed activated with high COz / low pH. The regulation of KATP by protons is significant, because a drop in pH levels often accompanies various metabolic stresses and is more frequently seen than sole energy depletion. Such regulation may enable cells to change their membrane excitability in response to a wide variety of physiologic and pathophysiologic conditions. However, previous studies on the pH sensitivity were rather controversial: proton was shown to stimulate cell-endogenous KATP in some studies but inhibit it in others. The inconsistence is further complicated by the indirect effect of ATP, ADP and Mg ++ on channel activity. Thereby, it is unclear how the KATP is modulated during hypercapnia and acidosis, whether these channels are inherently pH-sensitive, and what the molecular mechanisms underlying the modulation are. The cloned KATP channels are ideal for addressing these questions, which allow a fine dissection of the modulatory mechanisms and elaborate manipulations of PCO2 and pH in the expression system. Thereby, we have been studying the pH sensitivity of the cloned KATP over the past 3 years. Our preliminary data have clearly shown that proton is a potent activator of the KATP. TO further these observations, we have proposed studies aimed at 1) elucidating the modulation of KATP by hypercapnia and acidosis, 2) demonstrating the sensing mechanisms in the channel proteins, 3) determining factors and their interactions with protons in regulating the pH sensitivity, and 4) identifying the pH-sensitive KATP isoforms in vascular smooth muscles. This information should have profound impacts not only on cardiovascular physiology but
Studies
61
also on the design of therapeutical modalities by manipulating the pH-sensing mechanisms to control cellular activity in stroke, epilepsy and coronary heart disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VENTILATOR-INDUCED CONSEQUENCES
LUNG
INJURY:MECHANISMS
&
Principal Investigator & Institution: Sinclair, Scott E.; Medicine; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-AUG-2002 Summary: Mechanical ventilation is an important tool in the management of respiratory failure. However, the ventilation strategy can initiate or exacerbate lung injury. Several mechanisms have been implicated in ventilator-induced lung injury (VILI), particularly cyclical airway collapse and reopening. Inferential data supports cyclical airway collapse as an important factor in the genesis of VILI, but it has never been definitively documented. Strategies minimizing alveolar over distension and cyclical airway closure decrease mortality in ARDS patients but are confounded by hypercapnic acidosis, itself a potential modulator of lung injury. Establishing the presence of cyclical airway collapse, its abolition with palliative interventions, and correlation with severity and distribution of injury is vital to understanding VILI and developing relevant strategies to prevent it. This proposal will evaluate mechanisms by which mechanical ventilation induces lung injury and initiates inflammation in a rabbit model of VILI caused solely by mechanical forces. I will address the following questions: 1) Is cyclical airway collapse and reopening a stimulus for inflammation? 2) Where in the lung and on which cell types do mechanical forces exert their effects? 3) Can we definitively document cyclical airway closure? 4) If so, can we accurately predict ventilatory conditions that prevent it? 5) Do non- mechanical forces (hypercapnia) play a protective role in VILI? Methods: Spatial inflammation distribution measured with monoclonal antibody ELISA and immunohistochemistry. Spatial injury measured by extravascular albumin accumulation and gravimetrics. Regional V and Q measured with aerosolized and perfused fluorescent microspheres. Global gas exchange measured with the multiple inert gas elimination technique. Ventilation heterogeneity measured with multiple breath nitrogen washout. Aim 1A: Examine how posture change and PEEP effect severity and distribution of injury and inflammation. Aim 1B: Determine the anatomical location and cell type(s) responsible inflammation in VILI. Aim 2A : Measure effects of hypercapnia on lung injury and inflammation during VILI. Aim 2B: Examine how hypercapnia alters hypoxic pulmonary vasoconstriction and reduces VILI. Aim 2C : Examine how hypercapnia effects ventilation heterogeneity and reduces VILI. Aim 3A: Document cyclical airway collapse and reopening via changes in regional ventilation distribution. Aim 3B: Validate a method to estimate appropriate PEEP level to prevent cyclical airway collapse. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ZINC NEUROTOXICITY IN TRAUMATIC BRAIN INJURY Principal Investigator & Institution: Prough, Donald S.; Chairman; Anesthesiology; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2002; Project Start 15-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): After traumatic brain injury (TBI), systemic hypotension causes secondary ischemic brain injury that markedly worsens mortality and neurologic outcome. We will test the hypothesis that, as a consequence of TBI and
62
Acidosis
posttraumatic hemorrhagic hypotension, neurotoxic concentrations of Zn2+ are released from presynaptic glutamatergic vesicles in association with glutamate, enter postsynaptic neurons through receptor-associated calcium channels (especially AMPA/kainite receptors) and voltage-operated calcium channels, and worsen outcome by accumulating in postsynaptic neurons. Specific aim 1: In rats subjected to TBI with our without hypotension, we will test the hypothesis that neuronal Zn2+ accumulation is related to Zn2+ release, which is proportional to the severity of TBI and hypotension and the interval between TBI and hypotension. Methodologies: microdialysis (Zn2+ and glutamate); staining with the Zn2+-specific dye TSQ (intracellular Zn2+ accumulation); vanadium acid fuchsin (VAF) staining (acute cell injury); staining for DNA fragmentation (TUNEL); ribonuclease protection assays (apoptosis); neuronal counts (histopathologic outcome), and beam walking, beam balance and the Morris water maze (neurobehavioral outcome). Specific aim 2: In rats subjected to moderate TBI with or without hypotension, we will address the hypothesis that after TBI, Zn2+ enters neurons through receptor-associated calcium channels and voltage-operated calcium channels (VOCCs) and that entry through (VOCCs) is enhanced by posttraumatic brain tissue acidosis. Interventions: the NMDA receptor antagonist MK-801, the AMPA/kainite receptor antagonist LY300164, the L-type calcium channel antagonist nimodipine, and increases and decreases in extracellular pH. Methodologies: microdialysis, TSQ staining, and VAF staining. Specific aim 3: In rats subjected to moderate TBI and hypotension, we will address the hypothesis that after, TBI and hypotension, modifying extracellular Zn2+ concentrations will modify neurobehavioral and histopathologic injury. We will test this hypothesis by using intracerebroventricular (icv) injection of Zn2+ and by icv injection of the specific Zn2+-binding apoenzyme of carbonic anhydrase. Methodologies: identical to specific aim 1 plus monitoring for signs of neurologic zinc deficiency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “acidosis” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for acidosis in the PubMed Central database: •
3 4
A Comparison of the Effects of Glucose Ingestion and NH4Cl Acidosis on Urinary Calcium and Magnesium Excretion in Man. by Lennon EJ, Piering WF.; 1970 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322619
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
63
•
A Point Mutation of the Na+/H+ Exchanger Gene (NHE1) and Amplification of the Mutated Allele Confer Amiloride Resistance Upon Chronic Acidosis. by Counillon L, Franchi A, Pouyssegur J.; 1993 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46541
•
Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat. by Bichara M, Mercier O, Borensztein P, Paillard M.; 1990 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296745
•
Acute Reversal of Experimental Diabetic Ketoacidosis in the Rat with (+)Decanoylcarnitine. by McGarry JD, Foster DW.; 1973 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302335
•
An Experimental Renal Acidification Defect in Patients with Hereditary Fructose Intolerance. I. ITS RESEMBLANCE TO RENAL TUBULAR ACIDOSIS. by Morris RC Jr.; 1968 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297294
•
An Experimental Renal Acidification Defect in Patients with Hereditary Fructose Intolerance. II. ITS DISTINCTION FROM CLASSIC RENAL TUBULAR ACIDOSIS; ITS RESEMBLANCE TO THE RENAL ACIDIFICATION DEFECT ASSOCIATED WITH THE FANCONI SYNDROME OF CHILDREN WITH CYSTINOSIS. by Morris RC Jr.; 1968 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297322
•
An Inherited Defect Affecting the Tricarboxylic Acid Cycle in a Patient with Congenital Lactic Acidosis. by Blass JP, Schulman JD, Young DS, Hom E.; 1972 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292332
•
Attainment and Maintenance of Normal Stature with Alkali Therapy in Infants and Children with Classic Renal Tubular Acidosis. by McSherry E, Morris RC Jr.; 1978 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=372562
•
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. by Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE.; 1983 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=393906
•
Changes in Bone Sodium and Carbonate in Metabolic Acidosis and Alkalosis in the Dog. by Burnell JM.; 1971 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=291928
•
Conventional or physicochemical approach in intensive care unit patients with metabolic acidosis. by Moviat MA, van Haren FM, van der Hoeven JG.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=270679
64
Acidosis
•
Cytoplasmic acidosis as a determinant of flooding intolerance in plants. by Roberts JK, Callis J, Jardetzky O, Walbot V, Freeling M.; 1984 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=391852
•
Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. by King MP, Koga Y, Davidson M, Schon EA.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=364194
•
Deficiency in ubiquinone cytochrome c reductase in a patient with mitochondrial myopathy and lactic acidosis. by Darley-Usmar VM, Kennaway NG, Buist NR, Capaldi RA.; 1983 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=384197
•
Delivery dependence of early proximal bicarbonate reabsorption in the rat in respiratory acidosis and alkalosis. by Santella RN, Maddox DA, Gennari FJ.; 1991 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296353
•
Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. by Chiasson JL, Aris-Jilwan N, Belanger R, Bertrand S, Beauregard H, Ekoe JM, Fournier H, Havrankova J.; 2003 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151994
•
Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. by Blomqvist SR, Vidarsson H, Fitzgerald S, Johansson BR, Ollerstam A, Brown R, Persson AE, Bergstrom G, Enerback S.; 2004 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=419486
•
Drug points: Fatal lactic acidosis associated with tenofovir. by Rivas P, Polo J, de Gorgolas M, Fernandez-Guerrero ML.; 2003 Sep 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=200801
•
Effect of Acute Hypoxia and Hypercapnic Acidosis on the Development of Acetylstrophanthidin-Induced Arrhythmias. by Williams JF Jr, Boyd DL, Border JF.; 1968 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297349
•
EFFECT OF ACUTE METABOLIC ACIDOSIS AND ALKALOSIS ON ACETATE AND CITRATE METABOLISM IN THE RAT. by Gordon EE.; 1963 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=289262
•
Effects of the ionophores monensin and tetronasin on simulated development of ruminal lactic acidosis in vitro. by Newbold CJ, Wallace RJ.; 1988 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204415
•
Endothelin-1/endothelin-B receptor --mediated increases in NHE3 activity in chronic metabolic acidosis. by Laghmani K, Preisig PA, Moe OW, Yanagisawa M, Alpern RJ.; 2001 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=200190
Studies
65
•
Enzymatically Inactive Red Cell Carbonic Anhydrase B in a Family with Renal Tubular Acidosis. by Shapira E, Ben-Yoseph Y, Eyal FG, Russell A.; 1974 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301438
•
Exercise intolerance, lactic acidosis, and abnormal cardiopulmonary regulation in exercise associated with adult skeletal muscle cytochrome c oxidase deficiency. by Haller RG, Lewis SF, Estabrook RW, DiMauro S, Servidei S, Foster DW.; 1989 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303965
•
Experimental Metabolic Acidosis: The Enzymatic Basis of Ammonia Production by the Dog Kidney. by Pollak VE, Mattenheimer H, DeBruin H, Weinman KJ.; 1965 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292466
•
Expression of rat renal Na/H antiporter mRNA levels in response to respiratory and metabolic acidosis. by Krapf R, Pearce D, Lynch C, Xi XP, Reudelhuber TL, Pouyssegur J, Rector FC Jr.; 1991 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296370
•
Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. by Chinn RY, Diamond RD.; 1982 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=347866
•
Glucose Utilization and Production by the Dog Kidney In Vivo in Metabolic Acidosis and Alkalosis. by Costello J, Scott JM, Wilson P, Bourke E.; 1973 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302299
•
Glutamine Transport in Rat Kidney Mitochondria in Metabolic Acidosis. by Adam W, Simpson DP.; 1974 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301536
•
Hepatic Fructose-1,6-Diphosphatase Deficiency. A CAUSE OF LACTIC ACIDOSIS AND HYPOGLYCEMIA IN INFANCY. by Pagliara AS, Karl IE, Keating JP, Brown BI, Kipnis DM.; 1972 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292368
•
Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. by Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA.; 2002 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130544
•
Inactive form of erythrocyte carbonic anhydrase B in patients with primary renal tubular acidosis. by Kondo T, Taniguchi N, Taniguchi K, Matsuda I, Murao M.; 1978 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371806
66
Acidosis
•
Intracellular pH during "chemical hypoxia" in cultured rat hepatocytes. Protection by intracellular acidosis against the onset of cell death. by Gores GJ, Nieminen AL, Wray BE, Herman B, Lemasters JJ.; 1989 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303693
•
Lactic Acidosis as a Result of Iron Deficiency. by Finch CA, Gollnick PD, Hlastala MP, Miller LR, Dillmann E, Mackler B.; 1979 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=372098
•
Low Temperature-Induced Cytoplasmic Acidosis in Cultured Mung Bean (Vigna radiata [L.] Wilczek) Cells. by Yoshida S.; 1994 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=159273
•
Management of acidosis: the role of buffer agents. by Weil MH, Tang W.; 1997; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137219
•
Mechanisms of adaptation to chronic respiratory acidosis in the rabbit proximal tubule. by Krapf R.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303763
•
Metabolic Acidosis Suppresses 25-Hydroxyvitamin D3-1[alpha]-Hydroxylase in the Rat Kidney DISTINCT SITE AND MECHANISM OF ACTION. by Kawashima H, Kraut JA, Kurokawa K.; 1982 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370235
•
Metabolism of Glutamine by the Intact Functioning Kidney of the Dog STUDIES IN METABOLIC ACIDOSIS AND ALKALOSIS. by Pitts RF, Pilkington LA, MacLeod MB, Leal-Pinto E.; 1972 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302161
•
Molecular basis of ocular abnormalities associated with proximal renal tubular acidosis. by Usui T, Hara M, Satoh H, Moriyama N, Kagaya H, Amano S, Oshika T, Ishii Y, Ibaraki N, Hara C, Kunimi M, Noiri E, Tsukamoto K, Inatomi J, Kawakami H, Endou H, Igarashi T, Goto A, Fujita T, Araie M, Seki G.; 2001 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=209339
•
Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. by Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, di Pietro A, Walker WG, Lifton RP.; 1998 May 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27686
•
Na+-H+ exchange activity in renal brush border membrane vesicles in response to metabolic acidosis: The role of glucocorticoids. by Kinsella J, Cujdik T, Sacktor B.; 1984 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=344733
Studies
67
•
On the Mechanism of Renal Potassium Wasting in Renal Tubular Acidosis Associated with the Fanconi Syndrome (Type 2 RTA). by Sebastian A, McSherry E, Morris RC Jr.; 1971 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=291912
•
Pathways of Glutamine and Organic Acid Metabolism in Renal Cortex in Chronic Metabolic Acidosis. by Simpson DP.; 1972 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292353
•
Pediatric diabetic ketoacidosis. by Lawrence S, Pacaud D, Dean H, Lawson M, Daneman D.; 2003 Aug 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=180639
•
Phosphorus-31 magnetic resonance spectra reveal prolonged intracellular acidosis in the brain following subarachnoid hemorrhage. by Brooke NS, Ouwerkerk R, Adams CB, Radda GK, Ledingham JG, Rajagopalan B.; 1994 Mar 1; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=43272
•
Production, Excretion, and Net Balance of Fixed Acid in Patients with Renal Acidosis. by Goodman AD, Lemann J Jr, Lennon EJ, Relman AS.; 1965 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292514
•
Regulatory Mechanisms of Hemoglobin Oxygen Affinity in Acidosis and Alkalosis. by Bellingham AJ, Detter JC, Lenfant C.; 1971 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=291978
•
Renal ammoniagenesis in an early stage of metabolic acidosis in man. by Tizianello A, Deferrari G, Garibotto G, Robaudo C, Acquarone N, Ghiggeri GM.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371188
•
Renal gluconeogenesis in acidosis, alkalosis, and potassium deficiency: its possible role in regulation of renal ammonia production. by Goodman AD, Fuisz RE, Cahill GF Jr.; 1966 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292735
•
Renal Metabolic Response to Acid-Base Changes. II. THE EARLY EFFECTS OF METABOLIC ACIDOSIS ON RENAL METABOLISM IN THE RAT. by Alleyne GA.; 1970 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322557
•
Renal Potassium Wasting in Renal Tubular Acidosis (RTA). ITS OCCURRENCE IN TYPES 1 AND 2 RTA DESPITE SUSTAINED CORRECTION OF SYSTEMIC ACIDOSIS. by Sebastian A, McSherry E, Morris RC Jr.; 1971 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=291975
68
Acidosis
•
Renal Tubular Acidosis in Infants: the Several Kinds, Including BicarbonateWasting, Classic Renal Tubular Acidosis. by McSherry E, Sebastian A, Morris RC Jr.; 1972 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302155
•
Role of increased cytosolic free calcium in the pathogenesis of rabbit proximal tubule cell injury and protection by glycine or acidosis. by Weinberg JM, Davis JA, Roeser NF, Venkatachalam MA.; 1991 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296346
•
Skeletal Troponin C Reduces Contractile Sensitivity to Acidosis in Cardiac Myocytes from Transgenic Mice. by Metzger JM, Parmacek MS, Barr E, Pasyk K, Lin W, Cochrane KL, Field LJ, Leiden JM.; 1993 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47496
•
Studies of the Mechanism by Which Chronic Metabolic Acidosis Augments Urinary Calcium Excretion in Man. by Lemann J Jr, Litzow JR, Lennon EJ.; 1967 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297133
•
Studies on the Pathogenesis of Type I (Distal) Renal Tubular Acidosis as Revealed by the Urinary Pco2 Tensions. by Halperin ML, Goldstein MB, Haig A, Johnson MD, Stinebaugh BJ.; 1974 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=333046
•
Succinyl-CoA: 3-Ketoacid CoA-Transferase Deficiency. A CAUSE FOR KETOACIDOSIS IN INFANCY. by Tildon JT, Cornblath M.; 1972 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302154
•
The Effect of Steroids and Ammonium Chloride Acidosis on Phosphoenolpyruvate Carboxykinase in Rat Kidney Cortex II. THE KINETICS OF ENZYME INDUCTION. by Longshaw ID, Alleyne GA, Pogson CI.; 1972 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292393
•
The Effect of Steroids and Ammonium Chloride Acidosis on Phosphoenolpyruvate Carboxykinase in Rat Kidney Cortex. I. DIFFERENTIATION OF THE INDUCTIVE PROCESSES AND CHARACTERIZATION OF ENZYME ACTIVITIES. by Longshaw ID, Pogson CI.; 1972 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292392
•
The Effect of Treatment of Acidosis on Calcium Balance in Patients with Chronic Azotemic Renal Disease. by Litzow JR, Lemann J Jr, Lennon EJ.; 1967 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297046
•
The Effects of Acidosis and Alkalosis on the Metabolism of Glutamine and Glutamate in Renal Cortex Slices. by Kamm DE, Strope GL.; 1972 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292257
Studies
69
•
The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. by Lemann J Jr, Litzow JR, Lennon EJ.; 1966 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=292842
•
The Maladaptive Renal Response to Secondary Hypocapnia during Chronic HCl Acidosis in the Dog. by Madias NE, Schwartz WB, Cohen JJ.; 1977 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=372497
•
The Mechanism of Acidosis Produced by Hyperosmotic Infusions. by Winters RW, Scaglione PR, Nahas GG, Verosky M.; 1964 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=289542
•
Treatment of Lactic Acidosis with Dichloroacetate in Dogs. by Park R, Arieff AI, Leach W, Lazarowitz VC.; 1982 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370294
•
Water, Acidosis, and Experimental Pyelonephritis. by Andriole VT.; 1970 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322440
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with acidosis, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “acidosis” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for acidosis (hyperlinks lead to article summaries): •
6
A 52-year-old acyanotic man with severe hypoxia and profound metabolic acidosis following an industry chemical exposure. Author(s): Zavotsky KE, Mentler P, Gronczewski C, Torres P. Source: Journal of Emergency Nursing: Jen : Official Publication of the Emergency Department Nurses Association. 2004 April; 30(2): 113-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15039666
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
70
Acidosis
•
A case of lactic acidosis caused by stavudine in an AIDS patient. Author(s): Cho BC, Han SH, Choi SH, Choi JY, Chang KH, Song YG, Kim JM. Source: Korean J Intern Med. 2004 March; 19(1): 66-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15053048
•
A case of PDH-E1 alpha mosaicism in a male patient with severe metabolic lactic acidosis. Author(s): Seyda A, Chun K, Packman S, Robinson BH. Source: Journal of Inherited Metabolic Disease. 2001 October; 24(5): 551-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11757583
•
A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Author(s): Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 July 15; 37(2): 315-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12856228
•
A novel missense mutation in AE1 causing autosomal dominant distal renal tubular acidosis retains normal transport function but is mistargeted in polarized epithelial cells. Author(s): Rungroj N, Devonald MA, Cuthbert AW, Reimann F, Akkarapatumwong V, Yenchitsomanus PT, Bennett WM, Karet FE. Source: The Journal of Biological Chemistry. 2004 April 2; 279(14): 13833-8. Epub 2004 January 20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14734552
•
A novel mutation in the anion exchanger 1 gene is associated with familial distal renal tubular acidosis and nephrocalcinosis. Author(s): Cheidde L, Vieira TC, Lima PR, Saad ST, Heilberg IP. Source: Pediatrics. 2003 December; 112(6 Pt 1): 1361-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14654610
•
Abdominal pain and lactic acidosis with ethylene glycol poisoning. Author(s): Singh M, Murtaza M, D'souza N, Gnanasekaran I. Source: The American Journal of Emergency Medicine. 2001 October; 19(6): 529-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11593483
Studies
71
•
Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes. Author(s): Zaidi FH, Kinnear PE. Source: The British Journal of Ophthalmology. 2004 May; 88(5): 714-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15090429
•
Acidosis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate peritoneal dialysis solution. Author(s): Carrasco AM, Rubio MA, Sanchez Tommero JA, Fernandez Giron F, Gonzalez Rico M, del Peso Gilsanz G, Fernandez Perpen A, Ramon RG, Bueno IF, Tranaeus A, Faict D, Hopwood A. Source: Perit Dial Int. 2001 November-December; 21(6): 546-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11783762
•
Acidosis following aortic cross-clamping: is it the acid or carbon dioxide? Author(s): Tobias JD, Johnson JO, Lemoine K, Lawson NW. Source: Journal of Cardiothoracic and Vascular Anesthesia. 2002 February; 16(1): 73-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11854883
•
Acidosis-induced apoptosis in human and porcine heart. Author(s): Thatte HS, Rhee JH, Zagarins SE, Treanor PR, Birjiniuk V, Crittenden MD, Khuri SF. Source: The Annals of Thoracic Surgery. 2004 April; 77(4): 1376-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15063270
•
Acute correction of metabolic acidosis increases serum procollagen type I carboxyterminal propeptide in patients with chronic renal failure. Author(s): Chu P, Lu KC, Lin YF. Source: J Formos Med Assoc. 2001 November; 100(11): 748-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11802533
•
Acute lymphoblastic leukemia presenting with lactic acidosis and renal tubular dysfunction. Author(s): Hayek M, Srinivasan A. Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology. 2003 June; 25(6): 488-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12794529
72
Acidosis
•
Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans. Author(s): Kleger GR, Turgay M, Imoberdorf R, McNurlan MA, Garlick PJ, Ballmer PE. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2001 December; 38(6): 1199-207. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11728951
•
Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Author(s): Sarner L, Fakoya A. Source: Sexually Transmitted Infections. 2002 February; 78(1): 58-9. Erratum In: Sex Transm Infect. 2003 October; 79(5): 429. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11872862
•
Acute respiratory and metabolic acidosis induced by excessive muscle contraction during spinal evoked stimulation. Author(s): Tohdoh Y, Sumita S, Kawamata T, Omote K, Kawana S, Namiki A. Source: British Journal of Anaesthesia. 2001 April; 86(4): 589-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11573641
•
Albuterol-induced lactic acidosis. Author(s): Liem EB, Mnookin SC, Mahla ME. Source: Anesthesiology. 2003 August; 99(2): 505-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12883427
•
An 11-month-old girl with arrested psychomotor development and lactic acidosis. Author(s): Mizuguchi M, Itoh M, Ozawa H. Source: Neuropathology : Official Journal of the Japanese Society of Neuropathology. 2004 March; 24(1): 103-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15068179
•
Anaesthesia for an adolescent with mitochondrial encephalomyopathy-lactic acidosisstroke-like episodes syndrome. Author(s): Bolton P, Peutrell J, Zuberi S, Robinson P. Source: Paediatric Anaesthesia. 2003 June; 13(5): 453-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12791122
Studies
73
•
Anion exchanger 1 mutations associated with distal renal tubular acidosis in the Thai population. Author(s): Yenchitsomanus PT, Sawasdee N, Paemanee A, Keskanokwong T, Vasuvattakul S, Bejrachandra S, Kunachiwa W, Fucharoen S, Jittphakdee P, Yindee W, Promwong C. Source: Journal of Human Genetics. 2003; 48(9): 451-6. Epub 2003 August 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12938018
•
Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Author(s): Wrong O, Bruce LJ, Unwin RJ, Toye AM, Tanner MJ. Source: Kidney International. 2002 July; 62(1): 10-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12081559
•
Band 3 mutations, renal tubular acidosis and South-East Asian ovalocytosis in Malaysia and Papua New Guinea: loss of up to 95% band 3 transport in red cells. Author(s): Bruce LJ, Wrong O, Toye AM, Young MT, Ogle G, Ismail Z, Sinha AK, McMaster P, Hwaihwanje I, Nash GB, Hart S, Lavu E, Palmer R, Othman A, Unwin RJ, Tanner MJ. Source: The Biochemical Journal. 2000 August 15; 350 Pt 1: 41-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10926824
•
Band 3 Walton, a C-terminal deletion associated with distal renal tubular acidosis, is expressed in the red cell membrane but retained internally in kidney cells. Author(s): Toye AM, Bruce LJ, Unwin RJ, Wrong O, Tanner MJ. Source: Blood. 2002 January 1; 99(1): 342-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11756190
•
Base deficit does not predict mortality when secondary to hyperchloremic acidosis. Author(s): Brill SA, Stewart TR, Brundage SI, Schreiber MA. Source: Shock (Augusta, Ga.). 2002 June; 17(6): 459-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12069180
•
Base deficit is superior to pH in evaluating clearance of acidosis after traumatic shock. Author(s): Davis JW, Kaups KL, Parks SN. Source: The Journal of Trauma. 1998 January; 44(1): 114-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9464758
74
Acidosis
•
Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Author(s): Claessens YE, Chiche JD, Mira JP, Cariou A. Source: Critical Care (London, England). 2003 June; 7(3): 226-32. Epub 2003 February 28. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12793872
•
Benign methylmalonic acidemia in a sibship with distal renal tubular acidosis. Author(s): Dudley J, Allen J, Tizard J, McGraw M. Source: Pediatric Nephrology (Berlin, Germany). 1998 September; 12(7): 564-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9761355
•
Better correction of metabolic acidosis, blood pressure control, and phagocytosis with bicarbonate compared to lactate solution in acute peritoneal dialysis. Author(s): Thongboonkerd V, Lumlertgul D, Supajatura V. Source: Artificial Organs. 2001 February; 25(2): 99-108. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11251475
•
Bicarbonate administration is potentially harmful in patients with moderate acidosis. Author(s): Soto R. Source: Anesthesia and Analgesia. 2002 July; 95(1): 256; Author Reply 256. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12088990
•
Bicarbonate therapy and intracellular acidosis. Author(s): Goldsmith DJ, Forni LG, Hilton PJ. Source: Clinical Science (London, England : 1979). 1997 December; 93(6): 593-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9497798
•
Bicarbonate therapy of metabolic acidosis. Author(s): Kaehny WD, Anderson RJ. Source: Critical Care Medicine. 1994 October; 22(10): 1525-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7924360
•
Bicarbonate-based haemofiltration in the management of acute renal failure with lactic acidosis. Author(s): Hilton PJ, Taylor J, Forni LG, Treacher DF. Source: Qjm : Monthly Journal of the Association of Physicians. 1998 April; 91(4): 279-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9666950
Studies
75
•
Biochemical and genetic advances in distal renal tubular acidosis. Author(s): Sabatini S, Kurtzman NA. Source: Semin Nephrol. 2001 March; 21(2): 94-106. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11245773
•
Blood glucose threshold and the metabolic responses to incremental exercise tests with and without prior lactic acidosis induction. Author(s): Simoes HG, Campbell CS, Kushnick MR, Nakamura A, Katsanos CS, Baldissera V, Moffatt RJ. Source: European Journal of Applied Physiology. 2003 August; 89(6): 603-11. Epub 2003 May 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12759761
•
Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Author(s): Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V, Stitchantrakul W, Leeprasert V, Ongphiphadhanakul B, Radinahamed P, Rajatanavin R. Source: Kidney International. 2002 December; 62(6): 2160-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12427141
•
Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Author(s): Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Source: Clinical Transplantation. 2000 October; 14(5): 457-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11048990
•
Bone mineral density and histology in distal renal tubular acidosis. Author(s): Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, Sirikulchayanonta V, Ongphiphadhanakul B, Radinahamed P, Karnsombut P, Kunkitti N, Ruang-raksa C, Rajatanavin R. Source: Kidney International. 2001 March; 59(3): 1086-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11231364
•
Breath-hold training of humans reduces oxidative stress and blood acidosis after static and dynamic apnea. Author(s): Joulia F, Steinberg JG, Faucher M, Jamin T, Ulmer C, Kipson N, Jammes Y. Source: Respiratory Physiology & Neurobiology. 2003 August 14; 137(1): 19-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12871674
•
Broadsheet number 40: the diagnosis of renal tubular acidosis. Author(s): Clague A, Krause H. Source: Pathology. 1997 February; 29(1): 34-40. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9094175
76
Acidosis
•
Butoxyethanol ingestion with prolonged hyperchloremic metabolic acidosis treated with ethanol therapy. Author(s): McKinney PE, Palmer RB, Blackwell W, Benson BE. Source: Journal of Toxicology. Clinical Toxicology. 2000; 38(7): 787-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11192467
•
Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Author(s): Iida S, Matsuoka K, Inoue M, Tomiyasu K, Noda S. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 2003 January; 10(1): 56-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12534929
•
Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. Author(s): Mandelbrot L, Kermarrec N, Marcollet A, Lafanechere A, Longuet P, Chosidow D, Saada M. Source: Aids (London, England). 2003 January 24; 17(2): 272-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12545093
•
Case study: metformin-associated lactic acidosis: could orlistat be relevant? Author(s): Dawson D, Conlon C. Source: Diabetes Care. 2003 August; 26(8): 2471-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882884
•
Catabolism in uremia: the impact of metabolic acidosis. Author(s): Franch HA, Mitch WE. Source: Journal of the American Society of Nephrology : Jasn. 1998 December; 9(12 Suppl): S78-81. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11443773
•
Cerebrovascular response to acute metabolic acidosis in humans. Author(s): van de Ven M, Colier WN, Kersten BT, Oeseburg B, Folgering H. Source: Advances in Experimental Medicine and Biology. 2003; 530: 707-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14562769
•
Changes in serum leptin levels in chronic renal failure patients with metabolic acidosis. Author(s): Zheng F, Qiu X, Yin S, Li Y. Source: Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation. 2001 October; 11(4): 207-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11680001
Studies
77
•
Child abuse by intentional iron poisoning presenting as shock and persistent acidosis. Author(s): Black J, Zenel JA. Source: Pediatrics. 2003 January; 111(1): 197-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12509576
•
Childhood onset mitochondrial myopathy and lactic acidosis caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene. Author(s): Horvath R, Scharfe C, Hoeltzenbein M, Do BH, Schroder C, Warzok R, Vogelgesang S, Lochmuller H, Muller-Hocker J, Gerbitz KD, Oefner PJ, Jaksch M. Source: Journal of Medical Genetics. 2002 November; 39(11): 812-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12414820
•
Citric acid ingestion: a life-threatening cause of metabolic acidosis. Author(s): DeMars CS, Hollister K, Tomassoni A, Himmelfarb J, Halperin ML. Source: Annals of Emergency Medicine. 2001 November; 38(5): 588-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11679874
•
Clinical pharmacology physiology conference: metformin and lactic acidosis (LA). Author(s): Alkhalil C, Zavros G, Bailony F, Lowenthal DT. Source: International Urology and Nephrology. 2002; 34(3): 419-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12899240
•
Clinical predictors of acute respiratory acidosis during exacerbation of asthma and chronic obstructive pulmonary disease. Author(s): Cham GW, Tan WP, Earnest A, Soh CH. Source: European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine. 2002 September; 9(3): 225-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12394618
•
Coagulopathy, hypothermia and acidosis in trauma patients: the rationale for damage control surgery. Author(s): De Waele JJ, Vermassen FE. Source: Acta Chir Belg. 2002 October; 102(5): 313-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12471762
•
Cochlear implantation in a patient with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome. Author(s): Yasumura S, Aso S, Fujisaka M, Watanabe Y. Source: Acta Oto-Laryngologica. 2003 January; 123(1): 55-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12625574
78
Acidosis
•
Comparison of lactate or BE during out-of-hospital cardiac arrest to determine metabolic acidosis. Author(s): Prause G, Ratzenhofer-Comenda B, Smolle-Juttner F, Heydar-Fadai J, Wildner G, Spernbauer P, Smolle J, Hetz H. Source: Resuscitation. 2001 December; 51(3): 297-300. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11738782
•
Confirmation of the ATP6B1 gene as responsible for distal renal tubular acidosis. Author(s): Ruf R, Rensing C, Topaloglu R, Guay-Woodford L, Klein C, Vollmer M, Otto E, Beekmann F, Haller M, Wiedensohler A, Leumann E, Antignac C, Rizzoni G, Filler G, Brandis M, Weber JL, Hildebrandt F. Source: Pediatric Nephrology (Berlin, Germany). 2003 February; 18(2): 105-9. Epub 2002 December 18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12579397
•
Continuous pH monitoring using the Paratrend 7 inserted into a peripheral vein in a patient with shock and congenital lactic acidosis. Author(s): Easley RB, Johnson TR, Tobias JD. Source: Clinical Pediatrics. 2002 June; 41(5): 351-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12086201
•
Contribution of respiratory acidosis to diaphragmatic fatigue at exercise. Author(s): Jonville S, Delpech N, Denjean A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 June; 19(6): 1079-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12108860
•
Conventional or physicochemical approach in intensive care unit patients with metabolic acidosis. Author(s): Moviat M, van Haren F, van der Hoeven H. Source: Critical Care (London, England). 2003 June; 7(3): R41-5. Epub 2003 May 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12793889
•
Correction of acidosis by hemodialysis: proposal of a correlation with urea kinetics. Author(s): Leite M Jr, Leal E, Cardoso LR. Source: Blood Purification. 2002; 20(6): 551-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12566671
•
Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant echinacea. Author(s): Logan JL, Ahmed J. Source: Clinical Rheumatology. 2003 May; 22(2): 158-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12740687
Studies
79
•
Design and use of a peptide nucleic acid for detection of the heteroplasmic lowfrequency mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) mutation in human mitochondrial DNA. Author(s): Hancock DK, Schwarz FP, Song F, Wong LJ, Levin BC. Source: Clinical Chemistry. 2002 December; 48(12): 2155-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12446471
•
Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Author(s): Claessens YE, Cariou A, Monchi M, Soufir L, Azoulay E, Rouges P, Goldgran-Toledano D, Branche F, Dhainaut JF. Source: Critical Care Medicine. 2003 April; 31(4): 1042-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12682470
•
Diagnosing the cause of a hyperosmolar anion-gap metabolic acidosis. Author(s): Markowitz DH. Source: Journal of Intensive Care Medicine. 2003 May-June; 18(3): 160-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14984636
•
Dichloroacetate treatment for severe refractory metabolic acidosis during neonatal sepsis. Author(s): Arnon S, Litmanovits I, Regev R, Elpeleg O, Dolfin T. Source: The Pediatric Infectious Disease Journal. 2001 February; 20(2): 218-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11224847
•
Dilutional acidosis: an endless story of confusion. Author(s): Doberer D, Funk GC, Schneeweiss B. Source: Critical Care Medicine. 2003 January; 31(1): 337-8; Author Reply 338. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12545056
•
Dimercaptosuccinic acid distribution in renal tubular acidosis. Author(s): Green DA, Davies SG. Source: The British Journal of Radiology. 1997 December; 70(840): 1291-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9505851
•
Direct activation of cloned K(atp) channels by intracellular acidosis. Author(s): Xu H, Cui N, Yang Z, Wu J, Giwa LR, Abdulkadir L, Sharma P, Jiang C. Source: The Journal of Biological Chemistry. 2001 April 20; 276(16): 12898-902. Epub 2001 January 25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11278532
80
Acidosis
•
Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. Author(s): Movilli E, Zani R, Carli O, Sangalli L, Pola A, Camerini C, Scolari F, Cancarini GC, Maiorca R. Source: Nephron. 2001 March; 87(3): 257-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11287761
•
Discordance between cerebral oxygen and glucose metabolism, and hemodynamics in a mitochondrial encephalomyopathy, lactic acidosis, and strokelike episode patient. Author(s): Nariai T, Ohno K, Ohta Y, Hirakawa K, Ishii K, Senda M. Source: Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 2001 July; 11(3): 325-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11462305
•
Distal renal tubular acidosis associated with hypercalcemia and nephrocalcinosis in an infant. Author(s): Maruyama K, Shinohara M, Hatakeyama S, Onigata K. Source: Pediatric Nephrology (Berlin, Germany). 2002 November; 17(11): 977-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12506914
•
Distal renal tubular acidosis with severe bony deformities and multiple fractures. Author(s): Bagga A, Bajpai A, Gulati S, Singh A. Source: Indian Pediatrics. 2001 November; 38(11): 1301-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11721074
•
D-lactic acidosis in a diabetic patient with a short bowel. Author(s): Azhar SS, Beach RE. Source: The Journal of the American Board of Family Practice / American Board of Family Practice. 2002 July-August; 15(4): 316-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12150467
•
D-lactic acidosis in a patient after subtotal colectomy. Author(s): Kamar M, Raziel A, Susmallian S, Kyzer S, Charuzi I. Source: Isr Med Assoc J. 2003 December; 5(12): 891-2. No Abstract Available. Erratum In: Isr Med Assoc J. 2004 February; 6(2): 123. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14689763
•
D-lactic acidosis secondary to short bowel syndrome. Author(s): Zhang DL, Jiang ZW, Jiang J, Cao B, Li JS. Source: Postgraduate Medical Journal. 2003 February; 79(928): 110-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12612331
Studies
81
•
D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Author(s): Uribarri J, Oh MS, Carroll HJ. Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics. 1998 March; 77(2): 73-82. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9556700
•
D-lactic acidosis: pathologic consequence of saprophytism. Author(s): Vella A, Farrugia G. Source: Mayo Clinic Proceedings. 1998 May; 73(5): 451-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9581587
•
Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Author(s): Domrongkitchaiporn S, Khositseth S, Stitchantrakul W, Tapaneya-olarn W, Radinahamed P. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2002 February; 39(2): 383-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11840381
•
Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. Author(s): Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. Source: The Journal of Biological Chemistry. 1998 May 22; 273(21): 12817-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9582309
•
Drug points: Fatal lactic acidosis